NOTE 10 – PROPERTY AND EQUIPMENT
\r\r\r\r
At December 31, 2019 and 2018, property\rand equipment consisted of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Land | \r\r | $ | \r3,887,710 | \r\r | \r | $ | \r3,392,710 | \r|
| Buildings and building improvements | \r\r | \r | 27,063,235 | \r\r | \r | \r | 13,566,144 | \r|
| Tenant improvements | \r\r | \r | 7,762,991 | \r\r | \r | \r | 5,348,882 | \r|
| Furniture and fixtures | \r\r | \r | 299,645 | \r\r | \r | \r | 114,160 | \r|
| Machinery and equipment | \r\r | \r | 4,086,691 | \r\r | \r | \r | 1,632,351 | \r|
| Construction in progress | \r\r | \r | 2,827,940 | \r\r | \r | \r | 12,205,447 | \r|
| \r | \r | \r | 45,928,212 | \r\r | \r | \r | 36,259,694 | \r|
| Less: accumulated depreciation | \r\r | \r | (3,135,843 | \r) | \r\r | \r | (2,159,830 | \r) |
| Property and equipment, net | \r\r | $ | \r42,792,369 | \r\r | \r | $ | \r34,099,864 | \r
\r\r
During the years ended December 31, 2019\rand 2018, additions to property and equipment were approximately $9.7 million and $8.9 million, respectively.
\r\r\r\r
The 2018 additions were primarily comprised\rof (i) the buildout of properties in Hagerstown, MD, New Bedford, MA, and Middleborough, MA, and (ii) improvements to the Wilmington, DE\rfacility.
\r\r\r\r
The 2019 additions consisted primarily of (i)\rthe commencement of construction in Milford, DE and Annapolis, MD, (ii) the continued buildout of properties in Hagerstown,\rMD, New Bedford, MA, and Middleborough, MA, and (ii) improvements to the Wilmington, DE and Las Vegas, NV properties.
\r\r\r\r
The 2018 construction in progress balance of\rapproximately $12.2 million was primarily comprised of (i) New Bedford, MA building, improvements and machinery of approximately\r$9.8 million and (ii) Middleborough, MA building, improvements and fixtures of approximately $2.4 million. All of this construction\rin progress was placed into service in 2019.
\r\r\r\r
The 2019 construction in progress balance\rof approximately $2.8 million consisted of the commencement of construction of properties in Milford, DE and\rAnnapolis, MD.
\r\r\r\r
Depreciation expense for the year ended\rDecember 31, 2019 and 2018 was approximately $999,000 and $658,000, respectively.
"}]},{"name":"rpt:f-86","factDimensions":{"xbrl:concept":"us-gaap:RelatedPartyTransactionsDisclosureTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 19 – RELATED PARTY\rTRANSACTIONS
\r\r\r\r
During 2019, the Company entered into several\rhemp seed sale transactions with GenCanna, a related party, whereby the Company acquired large quantities of top-grade feminized\rhemp seeds at volume discounts that it sold to GenCanna at market rates as previously disclosed in Note 1 –\rOrganization and Description of Business.
\r\r\r\r
As disclosed in Note 11 – Debt,\rthe Company’s two mortgages with Bank of New England are personally guaranteed by the Company’s CEO and CFO.
\r\r\r\r
In 2019, the Company granted five-year options\rto purchase 100,000 shares of common stock to each of the Company’s three independent board members at an exercise price\rof $0.99. The aggregate fair value of these options of approximately $191,000 is being amortized over the vesting period, of which\rapproximately $189,000 was amortized at December 31, 2019. In 2018, the Company granted options to\rpurchase 1.45 million shares of common stock to the Company’s board members at exercise prices ranging from $0.14 to $0.77\rand expiring between December 2020 and December 2022. The aggregate fair value of these options of approximately $480,000 was fully\ramortized by June 30, 2018.
\r\r\r\r
In 2019, options to purchase 200,000\rand 132,499 shares of common stock were exercised by the Company’s CEO and an independent board member,\rrespectively, at weighted average exercise prices of $0.11 and $0.08 per share, respectively. The independent board member’s\roptions were exercised on a cashless basis with the exercise prices paid via the surrender of 3,108 shares\rof common stock. At December 31, 2019, the shares of common stock associated with the exercise by the Company’s CEO\rwere not issued and reflected in Common Stock Subscribed But Not Issued on the balance sheet. In 2018, options\rto purchase 400,000 shares of common stock were exercised by an independent board member at exercise prices of $0.08 to $0.63 per\rshare on a cashless basis with the exercise prices paid via the surrender of 98,000 shares of common stock.
\r\r\r\r
In 2019 and 2018, options to purchase 117,501\rand 200,000 shares of common stock, respectively, were forfeited by board\rmembers.
\r\r\r\r
The Company’s current corporate offices\rare leased from a company owned by a related party under a 10-year lease that commenced August 2018 and contains a five-year extension\roption. Previous to this lease, the Company’s former corporate offices were also leased from a company owned by a related\rparty. For the year ended December 31, 2019 and 2018, expenses incurred under these leases approximated $156,000 and $78,000, respectively.
\r\r\r\r
The balance of Due To Related\rParties at December 31, 2019 and 2018 of approximately $1,455,000 and $276,000, respectively, were\rcomprised of amounts owed of approximately (i) $420,000 and $81,000, respectively, to the Company’s CEO and CFO,\r(ii) $975,000 and $135,000, respectively, to two companies partially owned by these officers, and (iii) $60,000 in both\rperiods to two stockholders of the Company. Such amounts owed are not subject to repayment schedules.
\r\r\r\r
The balance of Due From Related\rParties at December 31, 2018 of approximately $120,000 was comprised of an advance to an entity partially owned\rby the Company’s CEO and CFO. This amount was entirely offset by payments made to the Company from the related entity. At December\r31, 2019, there were no amounts due from related parties.
"}]},{"name":"rpt:f-87","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rStock options outstanding and exercisable as\rof December 31, 2019 were:
\r\r\r\r
| Exercise Price | \r\r | \r | Shares Under Option | \r\r | \r | Remaining | \r||||||||
| per Share | \r\r | \r | Outstanding | \r\r | \r | Exercisable | \r\r | \r | Life in Years | \r|||||
| $ | \r0.130 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 0.50 | \r|
| $ | \r0.140 | \r\r | \r | \r | 550,000 | \r\r | \r | \r | 550,000 | \r\r | \r | \r | 1.00 | \r|
| $ | \r0.330 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 1.19 | \r|
| $ | \r0.417 | \r\r | \r | \r | 900,000 | \r\r | \r | \r | - | \r\r | \r | \r | 4.99 | \r|
| $ | \r0.450 | \r\r | \r | \r | 125,000 | \r\r | \r | \r | 125,000 | \r\r | \r | \r | 1.76 | \r|
| $ | \r0.590 | \r\r | \r | \r | 15,000 | \r\r | \r | \r | - | \r\r | \r | \r | 4.94 | \r|
| $ | \r0.630 | \r\r | \r | \r | 300,000 | \r\r | \r | \r | 300,000 | \r\r | \r | \r | 2.00 | \r|
| $ | \r0.770 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 3.00 | \r|
| $ | \r0.900 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 3.37 | \r|
| $ | \r0.910 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 2.81 | \r|
| $ | \r0.950 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 30,000 | \r\r | \r | \r | 3.00 | \r|
| $ | \r0.992 | \r\r | \r | \r | 300,000 | \r\r | \r | \r | - | \r\r | \r | \r | 4.74 | \r|
| $ | \r1.000 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 15,000 | \r\r | \r | \r | 4.84 | \r|
| $ | \r1.350 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | - | \r\r | \r | \r | 3.58 | \r|
| $ | \r1.950 | \r\r | \r | \r | 500,000 | \r\r | \r | \r | 125,000 | \r\r | \r | \r | 3.50 | \r|
| $ | \r2.320 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 3.70 | \r|
| $ | \r2.450 | \r\r | \r | \r | 2,000,000 | \r\r | \r | \r | 2,000,000 | \r\r | \r | \r | 2.98 | \r|
| $ | \r2.500 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 3.66 | \r|
| $ | \r2.650 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 150,000 | \r\r | \r | \r | 3.73 | \r|
| $ | \r2.850 | \r\r | \r | \r | 56,250 | \r\r | \r | \r | 37,500 | \r\r | \r | \r | 2.95 | \r|
| $ | \r2.850 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 3.95 | \r|
| $ | \r3.000 | \r\r | \r | \r | 25,000 | \r\r | \r | \r | 12,500 | \r\r | \r | \r | 3.96 | \r|
| $ | \r3.725 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 3.94 | \r|
| \r | \r | \r | \r | \r | 6,271,250 | \r\r | \r | \r | 4,207,500 | \r\r | \r | \r | \r |
NOTE 11 – DEBT
\r\r\r\r
Mortgages Payable
\r\r\r\r
At December 31, 2019 and 2018, mortgage balances,\rincluding accrued but unpaid interest, were comprised of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Bank of New England – Massachusetts property | \r\r | $ | \r4,825,226 | \r\r | \r | $ | \r4,895,000 | \r|
| Bank of New England – Delaware property | \r\r | \r | 1,682,275 | \r\r | \r | \r | 1,791,736 | \r|
| DuQuoin State Bank – Illinois properties | \r\r | \r | 829,229 | \r\r | \r | \r | 850,076 | \r|
| Total mortgages payable | \r\r | \r | 7,336,730 | \r\r | \r | \r | 7,536,812 | \r|
| Mortgages payable, current portion | \r\r | \r | (223,889 | \r) | \r\r | \r | (188,231 | \r) |
| Mortgages payable, less current portion | \r\r | $ | \r7,112,842 | \r\r | \r | $ | \r7,348,581 | \r
\r\r
In November 2017, the Company entered into\ra 10-year mortgage agreement with Bank of New England for the purchase of a 138,000 square foot industrial property in New Bedford,\rMassachusetts, within which the Company has built a 70,000 square foot cannabis cultivation and processing facility. This mortgage\rwas personally guaranteed by the Company’s CEO and CFO. From the mortgage date through May 2019, the Company was required\rto make monthly payments of interest-only at a rate equal to the prime rate plus 2%, with a floor of 6.25% per annum. From May\r2019 to May 2024, the Company is required to make principal and interest payments at a rate equal to the prime rate on May 2, 2019\rplus 2%, with a floor of 6.25% per annum. Principal and interest payments shall continue from May 2024 through the end of the lease\rat a rate equal to the prime rate on May 2, 2024 plus 2%, with a floor of 6.25% per annum. The outstanding principal balance on\rthis mortgage was approximately $4,825,000 and $4,895,000 on December 31, 2019 and 2018, respectively, of which approximately $94,000\rand $63,000, respectively, was current.
\r\r\r\r
The Company maintains a second mortgage with\rBank of New England, also personally guaranteed by the Company’s CEO and CFO, for the 2016 purchase of a 45,070 square foot\rbuilding in Wilmington, Delaware which was developed into a cannabis seed-to-sale facility and is currently leased to the Company’s\rcannabis-licensed client in that state. The mortgage matures in 2031 with monthly principal and interest payments at a rate of\r5.25% per annum through September 2021, and thereafter the rate adjusting every five years to the then prime rate plus 1.5% with\ra floor of 5.25% per annum. At December 31, 2019 and 2018, the outstanding principal balance on this mortgage was approximately\r$1,682,000 and $1,792,000, respectively, of which approximately $105,000 and $102,000, respectively, was current.
\r\r\r\r
In May 2016, the Company entered into a mortgage\ragreement with DuQuoin State Bank (“DSB”) for the purchase of two properties which the Company developed into two 3,400\rsquare foot free-standing retail dispensaries in Illinois. On May 5th of each year, this mortgage is due to be repaid\runless it is renewed for another year at a rate determined at the discretion of DSB’s executive committee. The mortgage was\rrenewed in May 2019 at a rate of 8.5% per annum. At December 31, 2019 and 2018, the outstanding principal balance on this mortgage\rwas approximately $829,000 and $850,000, respectively, of which approximately $24,000 and $23,000, respectively, was current.
\r\r\r\r
Notes Payable
\r\r\r\r
In June 2019, the Company and MariMed Hemp,\rits wholly-owned subsidiary, issued a secured promissory note in the principal amount of $10 million to an unaffiliated party (the\r“$10M Note”). The proceeds from the $10M Note were used to finance a portion of the purchases of hemp seed inventory\rpreviously discussed in Note 1 – Organization and Description of Business. The $10M Note provided for the repayment\rof principal plus a payment of $1.5 million on January 31, 2020. At December 31, 2019, the pro-rata portion of such payment, based\ron the term of the $10M Note, approximated $1,307,000 and was charged to interest expense. The $10M Note imposes certain covenants\ron the borrowers, all of which were complied with as of December 31, 2019.
\r\r\r\r
In February 2020, the Company entered into\ran amendment agreement with the holder of the $10M Note, whereby the Company and MariMed Hemp issued an amended and restated promissory\rnote in the principal amount of $11,500,000 (the “$11.5M Note”), bearing interest at a rate of 15% per annum, due on\rJune 15, 2020, and with monthly interest payments and minimum amortization payments of $3,000,000 in the aggregate due on or before\rApril 30, 2020, of which the Company has already paid $2,300,000. The $11.5M Note is secured by a first priority security interest\rin the assets of certain of the Company’s subsidiaries and brands, and a pledge of the Company’s ownership interest\rin certain of its subsidiaries. The $11.5M Note imposes certain covenants on the borrowers effective on the date of the amendment\ragreement.
\r\r\r\r
As part of the $10M Note transaction, the Company\rissued three-year warrants to purchase 375,000 shares of common stock at an exercise price of $4.50 per share to the holder of\rthe $10M Note. The fair value of these warrants on the issuance date of approximately $601,000 was recorded as a discount to the\r$10M Note. Approximately $523,000 of the warrant discount was amortized to interest expense in 2019. Accordingly, the carrying\rvalue of the $10M Note approximated $9.92 million at December 31, 2019.
\r\r\r\r
In April 2019, MariMed Hemp issued a secured\rpromissory note in the principal amount of $1,000,000 to an unaffiliated party. The proceeds of the note were used to finance a\rportion of the purchases of hemp seed inventory previously discussed in Note 1 – Organization and Description of Business.\rThe note is secured by the collateral assignment of certain receivables from GenCanna (the “Secured Receivables”) and\rcertain obligations of GenCanna to MariMed Hemp. The principal balance plus a payment of $180,000, initially due on December 31,\r2019, was extended to March 31, 2020 in accordance with the terms of the note, requiring an additional payment of $30,000 payable\ron the extended due date. MariMed Hemp can elect to repay the note in whole or in part without penalty, provided the noteholder\ris given proper notice and MariMed Hemp is not in default of the note agreement. Upon such election, the entire payment of $180,000\rand additional payment of $30,000 shall be deemed earned by and due to the noteholder.
\r\r\r\r
In March 2019, the Company raised $6 million\rthrough the issuance of a secured promissory note to an unaffiliated party bearing interest at a rate of 13% per annum and a service\rfee of $900,000 (the “$6M Note”). The proceeds of the note were used to finance a portion of the purchases of hemp\rseed inventory previously discussed in Note 1 – Organization and Description of Business. The note is secured by the\rcollateral assignment of certain receivables from and obligations of GenCanna to MariMed Hemp. The note’s initial maturity\rdate of December 31, 2019 was extended to April 30, 2020 in accordance with the terms of the note, with the Company paying an extension\rfee in December 2019 of $300,000 which was charged to interest expense. At December 31, 2019, accrued interest payable on the note\rapproximated $635,000.
\r\r\r\r
In September 2018, the Company raised $3 million\rfrom the issuance of a secured promissory note to the same unaffiliated party of the $6M Note, bearing interest at a rate of 10%\rper annum, with interest payable monthly through an initial maturity date of March 31, 2020 (the “$3M Note”). The Company\rmay elect to prepay the $3M Note in whole or part at any time after December 17, 2018 without premium or penalty provided the noteholder\ris given proper notice and the Company is not in default of the note agreement. The $3M Note was extended for an additional six\rmonths in accordance with its terms, with the interest rate increasing to 12% per annum during the extension period. The $3M Note\ris secured by the Company’s property in Maryland.
\r\r\r\r
As part of $3M Note transaction, the Company\rissued three-year warrants to the lender’s designees to purchase 750,000 shares of the Company’s common stock at an\rexercise price of $1.80 per share. The Company recorded a discount on the $3M Note of approximately $1,511,000 from the allocation\rof note proceeds to the warrants based on the fair value of such warrants on the issuance date. Approximately $882,000 of the warrant\rdiscount was amortized to interest expense during 2018, and the remaining $629,000 was amortized during 2019. At December 31, 2019\rand 2018, the carrying value of the $3M Note was $3 million and approximately $2.37 million (principal less the remaining warrant\rdiscount of $629,000), respectively.
\r\r\r\r
In addition to the above transactions, the\rCompany raised $2,760,000 in 2019 from the issuance of promissory notes to individuals and accredited investors bearing interest\rat rates of 10% to 18% per annum, and maturing in 2020 and 2021. No additional promissory notes were issued in 2018 than those\rpreviously described above.
\r\r\r\r
Note Settlements
\r\r\r\r
During 2018, holders of previously issued promissory\rnotes with principal balances of $1,075,000 converted such promissory notes into 1,568,375 shares of common stock at conversion\rprices ranging from $0.65 to $0.90 per share. The conversions resulted in the recording of non-cash losses of approximately $829,000\rin the aggregate based on the fair value of the common stock on the dates of conversion. No conversions of promissory notes occurred\rduring 2019.
\r\r\r\r
During 2019 and 2018, the Company issued 2,435,116\rshares and 3,827,373 shares of its common stock, respectively, and subscriptions on zero and 79,136 shares of its common stock,\rrespectively to retire promissory notes (principal and accrued interest) of approximately $1,047,000 and $7,590,000, respectively.\rThe Company recorded non-cash losses of approximately $2.5 million in 2018 based on the fair value of the common stock on the retirement\rdates. No such losses were incurred in 2019.
\r\r\r\r
During 2018, the Company repaid $700,000 of\rpromissory notes. No repayments of promissory notes occurred during 2019.
\r\r\r\r
Debt Maturities
\r\r\r\r
As of December 31, 2019, the aggregate scheduled\rmaturities of the Company’s total debt outstanding, inclusive of the promissory notes and mortgages described within this\rNote 11 – Debt, and the convertible debentures described in the following Note 12 – Debentures Payable, were:
\r\r\r\r
| 2020 | \r\r | $ | \r21,433,484 | \r|
| 2021 | \r\r | \r | 11,262,710 | \r|
| 2022 | \r\r | \r | 280,830 | \r|
| 2023 | \r\r | \r | 300,248 | \r|
| 2024 | \r\r | \r | 320,702 | \r|
| Thereafter | \r\r | \r | 5,822,397 | \r|
| Total | \r\r | \r | 39,420,370 | \r|
| Less discounts | \r\r | \r | (3,135,686 | \r) |
| \r | \r | $ | \r36,284,684 | \r
At December 31, 2019 and 2018, property\rand equipment consisted of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Land | \r\r | $ | \r3,887,710 | \r\r | \r | $ | \r3,392,710 | \r|
| Buildings and building improvements | \r\r | \r | 27,063,235 | \r\r | \r | \r | 13,566,144 | \r|
| Tenant improvements | \r\r | \r | 7,762,991 | \r\r | \r | \r | 5,348,882 | \r|
| Furniture and fixtures | \r\r | \r | 299,645 | \r\r | \r | \r | 114,160 | \r|
| Machinery and equipment | \r\r | \r | 4,086,691 | \r\r | \r | \r | 1,632,351 | \r|
| Construction in progress | \r\r | \r | 2,827,940 | \r\r | \r | \r | 12,205,447 | \r|
| \r | \r | \r | 45,928,212 | \r\r | \r | \r | 36,259,694 | \r|
| Less: accumulated depreciation | \r\r | \r | (3,135,843 | \r) | \r\r | \r | (2,159,830 | \r) |
| Property and equipment, net | \r\r | $ | \r42,792,369 | \r\r | \r | $ | \r34,099,864 | \r
NOTE 3 – ACQUISITIONS
\r\r\r\r
ARL Healthcare Inc.
\r\r\r\r
In October 2018, the Company’s cannabis-licensed\rclient in Massachusetts, ARL Healthcare Inc. (“ARL”), filed a plan of entity conversion with the state to convert from\ra non-profit entity to a for-profit corporation, with the Company as the sole shareholder of the for-profit corporation. ARL holds\rthree cannabis licenses from the state of Massachusetts for the cultivation, production and dispensing of cannabis.
\r\r\r\r
On November 30, 2018, the conversion plan was\rapproved by the Massachusetts Secretary of State, and effective December 1, 2018, ARL was consolidated into the Company as a wholly-owned\rsubsidiary.
\r\r\r\r
The acquisition was accounted for in accordance\rwith ASC 805, Business Combinations. The following table summarizes the allocation of the purchase price to the fair value\rof the assets acquired and liabilities assumed on the acquisition date:
\r\r\r\r
| Equipment | \r\r | $ | \r21,000 | \r|
| Cannabis licenses | \r\r | \r | 185,000 | \r|
| Accounts payable | \r\r | \r | (120,689 | \r) |
| Due to related parties | \r\r | \r | (92,765 | \r) |
| Total identifiable net assets | \r\r | \r | (7,454 | \r) |
| Goodwill | \r\r | \r | 731,902 | \r|
| Total fair value of consideration | \r\r | $ | \r724,448 | \r
\r\r
The total consideration paid by the Company\rwas equal to the forgiveness of amounts owed to the Company by ARL. Accordingly, the transaction gave rise to goodwill of approximately\r$732,000, which the Company wrote off in 2018. The balance of acquired cannabis licenses was included in Intangibles within\rthe asset section of the Company’s balance sheet at December 31, 2018. This intangible asset was fully amortized by December\r2019.
\r\r\r\r
In 2019, the Company paid for the annual renewal\rARL’s cannabis license. At December 31, 2019, the carrying value less amortization was approximately $138,000.
\r\r\r\r
KPG of Anna LLC and KPG of Harrisburg\rLLC
\r\r\r\r
In October 2018, the Company entered into a\rpurchase agreement to acquire 100% of the ownership interests of KPG of Anna LLC and KPG of Harrisburg LLC, the Company’s\rtwo cannabis-licensed clients that operate medical marijuana dispensaries in the state of Illinois (both entities collectively,\rthe “KPGs”), from the current ownership group of the KPGs (the “Sellers”). As part of this transaction,\rthe Company also acquired the Sellers’ ownership interests of Mari Holdings IL LLC, the Company’s subsidiary which\rowns the real estate in which the KPGs’ dispensaries are located (“Mari-IL”).
\r\r\r\r
In October 2019, the transaction was approved\rby the Illinois Department of Financial & Professional Regulation, and 1,000,000 shares of the Company’s common stock,\rrepresenting the entire purchase price, were issued to the Sellers. Effective October 1, 2019, the KPGs and Mari-IL became wholly-owned\rsubsidiaries of the Company with 100% of the operations of these entities consolidated into the Company’s financial statements\ras of that date. The KPGs contributed revenues of approximately $1.3 million and pretax income of approximately $79,000 since the\rdate of acquisition.
\r\r\r\r
The acquisition was accounted for in accordance\rwith ASC 805. The following table summarizes the allocation of the purchase price to the fair value of the assets acquired and\rliabilities assumed on the acquisition date:
\r\r\r\r
| Cash and cash equivalents | \r\r | $ | \r443,980 | \r|
| Inventory | \r\r | \r | 113,825 | \r|
| Intangibles | \r\r | \r | 2,067,727 | \r|
| Minority interests | \r\r | \r | 138,356 | \r|
| Accounts payable | \r\r | \r | (642,033 | \r) |
| Accrued expenses | \r\r | \r | (186,005 | \r) |
| Due to third parties | \r\r | \r | (1,020,850 | \r) |
| Total fair value of consideration | \r\r | $ | \r915,000 | \r
\r\r
Consolidated unaudited pro forma results of\roperations for the Company are presented below assuming this 2019 acquisition had occurred at January 1, 2018, the beginning of\rthe reporting period of these financial statements.
\r\r\r\r
| \r | \r | Year Ended December 31, | \r||||||
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Total revenues | \r\r | $ | \r48,444,052 | \r\r | \r | $ | \r14,417,923 | \r|
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Net income (loss) | \r\r | $ | \r(81,705,403 | \r) | \r\r | $ | \r(13,514,832 | \r) |
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Net income (loss) per share | \r\r | $ | \r(0.39 | \r) | \r\r | $ | \r(0.07 | \r) |
\r\r
Pro forma financial information is not necessarily\rindicative of the Company’s actual results if the transaction had been completed during the periods reflected above, nor\ris it necessarily an indication of future operating results. Amounts do not include any operating efficiencies or costs savings\rthat the Company would have been able to achieve.
\r\r\r\r
The Harvest Foundation LLC
\r\r\r\r
In November 2018, the Company issued a letter\rof intent to acquire 100% of the ownership interests of The Harvest Foundation LLC (“Harvest”), the Company’s\rcannabis-licensed client in the state of Nevada. In August 2019, the parties entered into a purchase agreement governing the transaction.\rThe acquisition is conditioned upon legislative approval of the transaction, which is expected to occur by the end of 2020. Upon\rconsummation, the operations of Harvest will be consolidated into the Company’s financial statements.
\r\r\r\r
The purchase price is comprised of the issuance\rof (i) 1,000,000 shares of the Company’s common stock, in the aggregate, to two owners of Harvest, which as a good faith\rdeposit, were issued upon execution of the purchase agreement, (ii) $1.2 million of the Company’s common stock at closing,\rbased on the closing price of the common stock on the day prior to legislative approval of the transaction, and (iii) warrants\rto purchase 400,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s\rcommon stock on the day prior to legislative approval of the transaction. These shares are restricted and will be returned to the\rCompany in the event the transaction does not close by a date certain. As the transaction has not been consummated, the issued\rshares were recorded at par value within the Stockholders’ Equity section of the balance sheet at December 31, 2019.
\r\r\r\r
Kind Therapeutics USA Inc.
\r\r\r\r
In December 2018, the Company entered into\ra memorandum of understanding (“MOU”) to acquire Kind Therapeutics USA Inc. (“Kind”), its client in Maryland\rthat holds licenses for the cultivation, production, and dispensing of medical cannabis. The MOU provides for a total purchase\rprice of $6.3 million in cash, 2,500,000 shares of the Company’s common stock, and other consideration. The acquisition is\rsubject to the approval by the Maryland Medical Cannabis Commission, which approval is not expected prior to October 2020.
\r\r\r\r
Also in December 2018, MariMed Advisors Inc,\rthe Company’s wholly owned subsidiary, and Kind entered into a management agreement pursuant to which the Company provides\rcomprehensive management services in connection with the business and operations of Kind, and Mari Holdings MD LLC, the Company’s\rmajority-owned subsidiary, entered into a 20-year lease with Kind for its utilization of the Company’s 180,000 square foot\rcultivation and production facility in Hagerstown, MD. Additionally, in October 2019, Mari Holdings MD LLC purchased a 9,000 square\rfoot building in Anne Arundel County, MD for the development of a dispensary which would be leased to Kind.
\r\r\r\r
Recently, the sellers of Kind have attempted\rto renegotiate the terms of the MOU. Even though the MOU contains all the definitive material terms with respect to the acquisition\rtransaction and confirms the management and lease agreements, the selling parties now allege that the MOU is not an enforceable\ragreement. The Company engaged with the sellers in good faith in an attempt to reach updated terms acceptable to both parties,\rhowever the sellers failed to reciprocate in good faith, resulting in an impasse, resulting in both parties commencing legal proceedings.\rFor further information, see Part II, Item 1. Legal Proceedings in this report.
\r\r\r\r
MediTaurus LLC
\r\r\r\r
In May 2019, the Company entered into a purchase\ragreement to acquire MediTaurus LLC (“MediTaurus”), a company formed and owned by Jokubas Ziburkas PhD, a neuroscientist\rand leading authority on CBD and its interactions with the brain and endocannabinoid system. MediTaurus currently operates in the\rUnited States and Europe and has developed proprietary CBD formulations sold under its Florance™ brand.
\r\r\r\r
Pursuant to the purchase agreement, the Company\racquired 70% of MediTaurus on June 1, 2019, and will acquire the remaining 30% of MediTaurus on June 1, 2020. The purchase price\rfor the initial 70% was $2.8 million, comprised of cash payments totaling $720,000 and 520,000 shares of the Company’s common\rstock valued at $2,080,000. The purchase price of the remaining 30%, payable in cash or stock at the Company’s option, shall\rbe equal to a defined percentage of the Company’s receipts from the licensing of certain MediTaurus technology and products\rthat existed on June 1, 2019 (all such technology and products, the “MT Property”). For a period of ten years following\rJune 1, 2020, certain former members of MediTaurus shall be paid a royalty on the Company’s receipts from the licensing of\rMT Property, with the royalty percentage commencing at 10% and decreasing to 2% over time.
\r\r\r\r
The acquisition was accounted for in accordance\rwith ASC 10. The following table summarizes the allocation, adjusted in September 2019, of the purchase price to the fair value\rof the assets acquired and liabilities assumed on the acquisition date:
\r\r\r\r
| Cash and cash equivalents | \r\r | $ | \r64,196 | \r|
| Accounts receivable | \r\r | \r | 5,362 | \r|
| Inventory | \r\r | \r | 519,750 | \r|
| Goodwill | \r\r | \r | 2,662,669 | \r|
| Accounts payable | \r\r | \r | (777 | \r) |
| Total value of MediTaurus | \r\r | \r | 3,251,200 | \r|
| Noncontrolling interests in MediTaurus | \r\r | \r | (975,360 | \r) |
| Total fair value of consideration | \r\r | $ | \r2,275,840 | \r
\r\r
Based on a valuation of MediTaurus in late\r2019, the goodwill on the transaction was adjusted to approximately $2.7 million, which was written off in expectation of the impact\rof the coronavirus pandemic on MediTaurus’ business.
\r\r\r\r
As part of the transaction, the Company hired\rDr. Ziburkas as the Company’s Chief Innovation Officer, as well as other members of the MediTaurus executive team.
\r\r\r\r
iRollie LLC
\r\r\r\r
Effective April 2018, the Company entered into\ra purchase agreement whereby 264,317 shares of the Company’s common stock were exchanged for 100% of the ownership interests\rof iRollie LLC (“iRollie”), a manufacturer of branded cannabis products and accessories for consumers, and custom product\rand packaging for companies in the cannabis industry. The Company acquired, among other assets, iRollie’s entire product\rline, service offerings, client list, and intellectual property, and hired its two co-founders.
\r\r\r\r
The acquisition was accounted for in accordance\rwith ASC 10. The shares of Company common stock, valued at approximately $280,000, were issued to iRollie’s former owners\rin December 2018, at which time the Company adjusted the total goodwill generated by the transaction. The following table summarizes\rthe allocation of the purchase price to the fair value of the assets acquired:
\r\r\r\r
| Cash and cash equivalents | \r\r | $ | \r13,494 | \r|
| Goodwill | \r\r | \r | 266,682 | \r|
| Total fair value of consideration | \r\r | $ | \r280,176 | \r
\r\r
Prior to the acquisition, iRollie had not been generating positive\rcash flow as a stand-alone entity, and in conformity with relevant accounting guidance, the goodwill was written off.
\r\r\r\r
AgriMed Industries of PA LLC
\r\r\r\r
In July 2018, the Company entered into a purchase\ragreement to acquire 100% of the ownership interests of AgriMed Industries of PA LLC (“AgriMed”), an entity that holds\ra license from the state of Pennsylvania for the cultivation of cannabis. The purchase price was comprised of $8 million, payable\rin stock and cash, and the assumption of certain liabilities of AgriMed. In February 2019, the Company commenced legal proceedings\ragainst AgriMed seeking specific performance of the purchase agreement.
\r\r\r\r
In May 2019, the dispute between the parties\rwas resolved through the cash payment to the Company of $3.1 million and other good and valuable consideration, in exchange for\rthe Company relinquishing its rights under the purchase agreement and releasing its claims against AgriMed. The net amount of\rapproximately $2,949,000, representing the cash payment less legal fees and write-offs of assets and supplies, was recorded in\rOther Non-Operating Income in the Company’s consolidated statement of operations for the year ended December 31,\r2019.
"}]},{"name":"rpt:f-230","factDimensions":{"xbrl:concept":"us-gaap:InvestmentHoldingsTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 4 – INVESTMENTS
\r\r\r\r
At December 31, 2019 and 2018, the\rCompany’s investments were comprised of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Current investments: | \r\r | \r | \r | \r | \r | \r | \r | |
| Terrace Inc. | \r\r | $ | \r1,449,144 | \r\r | \r | $ | \r- | \r|
| Total current investments | \r\r | $ | \r1,449,144 | \r\r | \r | $ | \r- | \r|
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Non-current investments: | \r\r | \r | \r | \r | \r | \r | \r | |
| GenCanna Global Inc. | \r\r | \r | - | \r\r | \r | \r | - | \r|
| CVP Worldwide LLC | \r\r | \r | 1,066,975 | \r\r | \r | \r | 1,172,163 | \r|
| Iconic Ventures Inc. | \r\r | \r | - | \r\r | \r | \r | 500,000 | \r|
| Chooze Corp. | \r\r | \r | 257,686 | \r\r | \r | \r | - | \r|
| Total non-current investments | \r\r | \r | 1,324,661 | \r\r | \r | \r | 1,672,163 | \r|
| Total investments | \r\r | $ | \r2,773,805 | \r\r | \r | $ | \r1,672,163 | \r
\r\r
Terrace Inc.
\r\r\r\r
In May 2019, the Company issued 500,000 shares\rof its common stock, valued at $1.59 million on the date of issuance, to purchase an 8.95% interest in Terrace Inc. (“Terrace”),\ra Canadian entity that develops and acquires international cannabis assets. The Company has no board representation, nor does it\rhave the ability to exert operational or financial control over the entity.
\r\r\r\r
In November 2019, the common stock of Terrace\rcommenced public trading on the Toronto Stock Venture Exchange. In accordance with ASC 321, Investments – Equity\rSecurities, this investment is carried at fair value, with changes to fair value recognized in net income. Prior to Terrace\rbecoming publicly traded, the Company had elected the measurement alternative to value this equity investment without a readily\rdeterminable fair value.
\r\r\r\r
At December 31, 2019, the carrying amount of\rthis investment declined to approximately $1.45 million, based on its fair value on such date, and the Company recorded a charge\rto net income of approximately $141,000.
\r\r\r\r
GenCanna Global Inc.
\r\r\r\r
During 2018, in a series of transactions, the\rCompany purchased $30 million of subordinated secured convertible debentures (the “GC Debentures”) of GenCanna. In\rFebruary 2019, the Company converted the GC Debentures, plus unpaid accrued interest of approximately $229,000 through the conversion\rdate, into common stock of GenCanna equal to a 33.5% ownership interest in GenCanna on a fully diluted basis. Concurrent with\rthe conversion, Company’s CEO was appointed to GenCanna’s board and the Company was granted certain rights, including\rthe rights of inspection, financial information, and participation in future security offerings of GenCanna.
\r\r\r\r
Since the conversion date, this investment\rhad been accounted for under the equity method. However, as previously discussed in Note 1 – Organization and Description\rof Business, GenCanna filed for voluntary reorganization under Chapter 11 in February 2020 with the U.S. Bankruptcy Court in\rthe Eastern District of Kentucky. As a result, the Company recorded a charge to net income of approximately $30.23 million, classified\runder Loss on Equity Investments on the statement of operations for the year ended December 31, 2019, which reduced\rthe carrying value of this investment to zero.
\r\r\r\r
CVP Worldwide LLC
\r\r\r\r
In August 2018, the Company invested $300,000,\rof a total contracted cash investment of $500,000, and issued 378,259 shares of its common stock, valued at approximately $915,000,\rin exchange for a 23% ownership in CVP Worldwide LLC (“CVP”). CVP has developed a customer relationship management\rand marketing platform, branded under the name Sprout, which is specifically designed for companies in the cannabis industry.
\r\r\r\r
The Company shall assist in the ongoing development\rand design of Sprout, and in marketing Sprout to companies within the cannabis industry. The Company shall earn a percentage share\rof Sprout’s revenues generated from sales (i) to the Company’s clients, and (ii) by the Company to third parties. As\rof December 31, 2019, no revenue was earned by the Company.
\r\r\r\r
The investment is accounted under\rthe equity method. In 2018, the Company recorded a charge to net income of approximately $43,000 based on its equity in CVP’s\rnet loss during the period of the Company’s ownership. Such amount reduced the carrying value of the investment to approximately\r$1,172,000 at December 31, 2018. In 2019, the Company recorded a charge of approximately $105,000 representing\rthe Company’s equity in CVP’s net loss during year, further reducing the carrying value of the investment\rto approximately $1,067,000 at December 31, 2019.
\r\r\r\r
Iconic Ventures Inc.
\r\r\r\r
In December 2018, the Company purchased 2,500,000\rshares of common stock of Iconic Ventures Inc. (“Iconic”) for an aggregate cash payment of $500,000. Iconic has developed\rDabTabs™, a unique solution for cannabinoid vaporization via a convenient portable tablet that provides precisely measured\rdosing and acts as a storage system for full spectrum extracts, concentrates and distillates.
\r\r\r\r
The Company’s investment equates to a\rcurrent ownership interest in Iconic of approximately 10%. The Company has no board representation, nor does\rit have the ability to exert operational or financial control over the entity. In accordance with ASC 321, the Company elected\rthe measurement alternative to value this equity investment without a readily determinable fair value. Under this alternative\rmeasurement election, the investment is recorded at its cost minus impairment, if any, plus or minus changes resulting from observable\rprice changes in orderly transactions for the identical or a similar investment in Iconic.
\r\r\r\r
In 2019, the Company wrote off the investment\rafter an impairment review that considered the viability of the entity in light of the current economic climate. Accordingly,\rthis investment was carried at zero and $500,000 on December 31, 2019 and 2018, respectively.
\r\r\r\r
Chooze Corp.
\r\r\r\r
In January 2019, the entire principal and accrued\rinterest balance of a note receivable from Chooze Corp. of approximately $258,000 was converted into a 2.7% equity interest in\rChooze. In accordance with ASC 321, the Company elected the measurement alternative to value this equity investment without a readily\rdeterminable fair value. Following the Company’s purchase, there has been no impairment to this investment, nor any observable\rprice changes to investments in the entity. Accordingly, this investment was carried at approximately $258,000 at December\r31, 2019.
\r\r\r\r
The Company will continue to apply the alternative\rmeasurement guidance until this investment does not qualify to be so measured. The Company may subsequently elect to measure this\rinvestment at fair value, and if so, shall measure all identical or similar investments in Chooze at fair value. Any subsequent\rchanges in fair value shall be recognized in net income.
\r\r\r\r
Binske®
\r\r\r\r
In July 2019, the Company entered into a licensing\ragreement for the exclusive manufacturing and distribution in seven eastern U.S. states of the Binske® portfolio\rof products, a brand known for utilizing best-in-class proprietary strains and craft ingredients in its edibles, concentrates,\rvaporizers, and topicals. In consideration for the license and other rights, the Company agreed to pay a royalty of 10.0% to 12.5%\rof gross revenue, as defined, derived from the sale of Binske® products, subject to an annual minimum royalty.\rNo gross revenue was generated as of December 31, 2019.
\r\r\r\r
Vitiprints
\r\r\r\r
In August 2019, the Company terminated the\rlicense agreement it had entered into in August 2018 for the use of a patented technology to produce and distribute cannabis products\rwith precise dosing and at increased economies (“Vitiprints”). The licensing agreement had an initial term of five\ryears, and required the Company to make a non-refundable payment of $250,000 which the Company charged to Cost of Revenues in\rAugust 2018.
"}]},{"name":"rpt:f-231","factDimensions":{"xbrl:concept":"us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 7 – NOTES RECEIVABLE
\r\r\r\r
At December 31, 2019 and 2018, notes receivable\rwere comprised of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| First State Compassion Center | \r\r | $ | \r527,261 | \r\r | \r | $ | \r578,722 | \r|
| Healer LLC | \r\r | \r | 846,985 | \r\r | \r | \r | 307,429 | \r|
| Atalo Holdings Inc. | \r\r | \r | - | \r\r | \r | \r | - | \r|
| Maryland Health & Wellness Center Inc. | \r\r | \r | 323,526 | \r\r | \r | \r | - | \r|
| High Fidelity Inc. | \r\r | \r | 252,873 | \r\r | \r | \r | - | \r|
| Chooze Corp. | \r\r | \r | - | \r\r | \r | \r | 257,687 | \r|
| Total notes receivable | \r\r | \r | 1,950,645 | \r\r | \r | \r | 1,143,838 | \r|
| Notes receivable, current portion | \r\r | \r | 311,149 | \r\r | \r | \r | 51,462 | \r|
| Notes receivable, less current portion | \r\r | $ | \r1,639,496 | \r\r | \r | $ | \r1,092,376 | \r
\r\r
The Company loaned approximately $700,000 to\rFirst State Compassion Center, its Delaware cannabis-licensee client, during the period from October 2015 to April 2016. In May\r2016, this client issued a 10-year promissory note, as subsequently amended, to the Company bearing interest at a rate of 12.5%\rper annum. The monthly payments of approximately $10,100 will continue through April 2026, at which time the note will become due.\rAt December 31, 2019 and 2018, the current portion of this note was approximately $58,000 and $51,000, respectively, and is included\rin Notes Receivable, Current Portion on the respective balance sheets.
\r\r\r\r
In 2018, the Company loaned an aggregate of\r$300,000 to Healer LLC (“Healer”), an entity that provides cannabis education, dosage programs, and products developed\rby Dr. Dustin Sulak, an integrative medicine physician and nationally renowned cannabis practitioner. In 2019, the Company loaned\rHealer an additional aggregate amount of $500,000. The loans bear interest at 6% per annum, with principal and interest payable\ron the maturity dates which are three years from the respective loan dates.
\r\r\r\r
In 2019, the Company extended loans aggregating\r$980,000 to Atalo Holdings Inc. (“Atalo”), an agriculture and biotechnology firm specializing in research, development,\rand production of industrial hemp and hemp-based CBD products. The loans bear interest at 6% per annum, with principal and interest\rpayable on the earlier of April 3, 2020 or the date on which the Company acquires at least 25% of Atalo’s outstanding capital\rstock, in which case the principal and interest due shall be credited toward Company’s purchase price for such capital stock.\rIn December 2019, the Company wrote off the entire carrying value of the Atalo note receivable balance based on the expectation\rthat the operations of Atalo would be negatively impacted by the coronavirus pandemic.
\r\r\r\r
In January 2019, the Company entered into an\ragreement with Maryland Health & Wellness Center Inc. (“MHWC”), an entity that has been pre-approved by the state\rof Maryland for a cannabis dispensing license, to provide MHWC with a $300,000 construction loan in connection with the buildout\rof MHWC’s proposed dispensary. The Company also entered into a consulting services agreement to provide MHWC with advisory\rand oversight services over a three-year period relating to the development, administration, operation, and management of MHWC’s\rproposed dispensary in Maryland. The construction loan bears interest at 8% per annum, with principal and interest payable in May\r2022, the two-year anniversary of final state approval of MHWC’s dispensing license, provided however, that the Company shall\rhave the right, that extends through such two-year anniversary and which is subject to state approval, to convert the promissory\rnote underlying the construction loan into a 20% ownership interest of MHWC. This conversion right of the Company shall terminate\rif the consulting services agreement is terminated.
\r\r\r\r
In August 2019, the Company loaned $250,000\rto High Fidelity Inc., a company that owns and operates two seed-to sale medical marijuana facilities in the state of Vermont\rand produces its own line of CBD products. The loan bears interest at a rate of 10% per annum, with interest-only monthly payments\rthrough its extended maturity in August 2020.
\r\r\r\r
During the period from May to October 2018,\rthe Company loaned $250,000 to Chooze Corp. bearing interest at 8% per annum and maturing in 2021. In January 2019, the entire\rprincipal and accrued interest balance of approximately $258,000 was converted into a 2.7% ownership interest in Chooze, as previously\rdiscussed in Note 4 – Investments.
\r\r\r\r
In January 2019, KPG of Anna LLC and KPG of\rHarrisburg LLC each issued a promissory note to the Company in the approximate amount of $451,000 and $405,000, respectively,\rrepresenting the advances made by the Company to these entities through December 31, 2018. The notes bore interest at 12% per\rannum, with monthly principal and interest payments due through December 2038. With the acquisition of the KPGs as disclosed in\rNote 3 – Acquisitions, these notes were eliminated upon the consolidation of the KPGs in October 2019.
"}]},{"name":"rpt:f-232","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3307839","decimals":0}]},{"name":"rpt:f-233","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"643","decimals":0}]},{"name":"rpt:f-234","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"1194917","decimals":0}]},{"name":"rpt:f-235","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1195560","decimals":0}]},{"name":"rpt:f-236","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2018-07-01T00:00:00/2018-08-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:AgriMedIndustriesOfPALLCMember","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember"},"factValues":[{"value":"8000000","decimals":0}]},{"name":"rpt:f-237","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"2520","decimals":0}]},{"name":"rpt:f-238","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"}},{"name":"rpt:f-239","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"2468317","decimals":0}]},{"name":"rpt:f-240","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:RetainedEarningsMember"}},{"name":"rpt:f-241","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:NoncontrollingInterestMember"},"factValues":[{"value":"837002","decimals":0}]},{"name":"rpt:f-242","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueAcquisitions","xbrl:period":"2019-05-29T00:00:00/2019-06-02T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"2080000","decimals":0}]},{"name":"rpt:f-243","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2750000","decimals":0}]},{"name":"rpt:f-244","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"8500000","decimals":0}]},{"name":"rpt:f-245","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"31821001","decimals":0}]},{"name":"rpt:f-246","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"2750000","decimals":0}]},{"name":"rpt:f-247","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:EmployeesMember"},"factValues":[{"value":"223000","decimals":0}]},{"name":"rpt:f-248","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 13 – EQUITY
\r\r\r\r
Preferred Stock
\r\r\r\r
In January 2018, all 500,000 shares of subscribed\rSeries A convertible preferred stock then outstanding were converted into 970,988 shares of common stock at a conversion price\rof $0.55 per share. The Company recorded a non-cash loss on conversion of approximately $34,000 based on the market value of the\rcommon stock on the conversion date. At December 31, 2019 and 2018, no shares of Series A convertible preferred stock were\rissued or outstanding.
\r\r\r\r
In February 2020, the Company filed a certificate\rof elimination to return all shares of the Series A convertible preferred stock to the status of authorized and unissued shares\rof undesignated preferred stock. Concurrent with this filing, the Company also filed a certificate of designation to designate\rthe rights and preferences of newly authorized Series B convertible preferred stock, shares of which were issued in February 2020\ras further discussed in Note 21 – Subsequent Events.
\r\r\r\r
Common Stock
\r\r\r\r
During 2019, the Company sold 1,014,995 shares\rof common stock at prices of $0.70 and $3.25 per share, resulting in total proceeds of $2,750,000. During\r2018, the Company sold 10,111,578 shares of common stock, at prices ranging from $0.50 to $1.30 per share, resulting in total proceeds\rof approximately $8.5 million.
\r\r\r\r
During 2019 and 2018, the Company issued 97,136\rand 1,000,000 common shares, respectively, associated with previously issued subscriptions on common stock with a value of approximately\r$169,000 and $370,000, respectively.
\r\r\r\r
During 2019 and 2018, the Company issued 172,663\rand 3,420,526 common shares, respectively, in exchange for services rendered by third-parties or to otherwise settle outstanding\robligations. Based on the market value of the common stock on the dates of issuance, the Company recorded non-cash losses on these\rsettlements of approximately $5,000 in 2019 and $1,024,000 in 2018.
\r\r\r\r
In 2019, the Company granted 141,546 shares\rof common stock to employees at an aggregate value of approximately $223,000. Of these granted shares, 32,726 were not issued\ras of December 31, 2019 and were reflected in Common Stock Subscribed But Not Issued on the balance sheet. No\rcommon stock was granted in 2018.
\r\r\r\r
As previously disclosed in Note 3 –\rAcquisitions, the Company issued (i) 264,317 shares of common stock in connection with the acquisition of iRollie in 2018,\r(ii) 1,000,000 shares of common stock in connection with the acquisition of the KPGs and Mari-IL in 2019, (iii) 1,000,000\rshares of stock as a good faith deposit in 2019 on the Harvest acquisition, and (iv) 520,000 shares of commons stock\rin connection with the acquisition of MediTaurus in 2019.
\r\r\r\r
As previously disclosed in Note 4 –\rInvestments, the Company issued 500,000 shares of common stock in 2019 to purchase a minority interest in Terrace in\r2019, and 378,259 shares of its common stock in 2018 to purchase a minority interest in CVP.
\r\r\r\r
As previously disclosed in Note 11 – Debt,\rthe Company issued (i) 1,568,375 shares of common stock in 2018 to former noteholders who converted promissory notes with principal\rbalances of $1,075,000, and (ii) 2,435,116 shares in 2019 and 3,827,373 shares in 2018 of common stock to retire promissory notes\r(principal and accrued interest) of approximately $1,047,000 in 2019 and $7,590,000 in 2018.
\r\r\r\r
As previously disclosed in Note 12 – Debentures\rPayable, the holder of the $20M Debentures converted (i) in 2018, approximately $1,436,000 of principal and\rinterest into 524,360 shares of common stock, and (ii) in 2019, approximately $8,976,000 of principal\rand interest into 6,798,339 shares of common stock and subscriptions on 3,004,131 shares of common stock.
\r\r\r\r
As further disclosed in Note 14 –\rStock Options, during 2019 and 2018, 3,261,808 and 760,000 shares of common stock, respectively, were issued in connection\rwith the exercise of stock options.
\r\r\r\r
As further disclosed in Note 15 –\rWarrants, during 2019 and 2018, warrants to purchase 686,104 and 2,300,237 shares of common stock, respectively, were\rexercised.
\r\r\r\r
Common Stock Issuance Obligations
\r\r\r\r
At December 31, 2019, the Company\rwas obligated to issue (i) 32,726 shares of common stock, valued at approximately $29,000, in connection with\rthe stock grants disclosed earlier in this Note 13 – Equity, (ii) 3,004,131 shares of common\rstock, valued at approximately $1,117,000, with respect to the December 2019 conversion of a portion of the\r$20M Debentures as previously disclosed in Note 12 – Debentures Payable, and (iii) 200,000 shares of\rcommon stock associated with exercise of stock options by the Company’s CEO as further disclosed in Note 19 – Related\rParty Transactions. These shares were issued in the first quarter of 2020.
\r\r\r\r
At December 31, 2018, the Company was obligated\rto issue: (a) 79,136 shares of common stock, valued at approximately $95,000, related to the settlement of a previously issued\rpromissory note with a principal balance of $50,000 and accrued interest of $1,454; and (b) 18,000 shares of common stock, valued\rat approximately $74,000, for the payment of rent for a leased property in Massachusetts for the months of September 2018 through\rJanuary 2019. Such shares were subsequently issued in the first quarter of 2019.
\r\r\r\r
Membership Interests
\r\r\r\r
In August 2018, an individual member of Mari\rHoldings MD LLC, a majority owned subsidiary of the Company (“Mari-MD”), exchanged his 0.5% membership interest in\rsuch subsidiary for 222,222 shares of the Company’s common stock. In December 2018, a subscriptions receivable balance of\r$25,000 related to a member’s interest in a majority-owned subsidiary was written off, with a corresponding reduction of\rsuch member’s capital contribution account.
\r\r\r\r
Amended and Restated 2018 Stock Award\rand Incentive Plan
\r\r\r\r
In August 2019, the Company’s board of\rdirectors approved the Amended and Restated 2018 Stock Award and Incentive Plan (the “Incentive Plan”), based on the\rboard’s belief that awards authorized under the Incentive Plan provide incentives for the achievement of important performance\robjectives and promote the long-term success of the Company. In September 2019, the Incentive Plan was approved by the stockholders\rat the Company’s annual stock-holders meeting.
\r\r\r\r
The Incentive Plan is an omnibus\rplan, authorizing a variety of equity award types as well as cash and long-term incentive awards. The Incentive Plan amends and\rrestates the Company’s 2018 Stock Award and Incentive Plan (the “Previous Plan”), which was approved\rby the board of directors in July 2018 but never presented to stockholders for approval. Any grants made under the Previous Plan\rprior to the approval date of the Incentive Plan shall continue to be governed by the terms of the Previous Plan.
\r\r\r\r
The Incentive Plan authorizes a broad range\rof awards, including stock options, stock appreciation rights, restricted stock, deferred stock, dividend equivalents, performance\rshares, cash-based performance awards, and other stock-based awards. Such awards can be granted to employees, non-employee directors\rand other persons who provide substantial services to the Company and its affiliates. Nothing in the Incentive Plan precludes the\rpayment of other compensation to officers and employees, including bonuses based upon performance, outside of the Incentive Plan.
\r\r\r\r
An aggregate of 40,000,000 shares are reserved\rfor delivery to participants, and may be used for any type of award under the Incentive Plan. Shares actually delivered in connection\rwith an award will be counted against such number of reserved shares. Shares will remain available for new awards if an award under\rthe Incentive Plan expires, is forfeited, canceled, or otherwise terminated without delivery of shares or is settled in cash. Each\raward under the Incentive Plan is subject to the Company’s claw back policy in effect at the time of grant of the award.
\r\r\r\r
The board of directors may amend, suspend,\rdiscontinue, or terminate the Incentive Plan or the authority to grant awards thereunder without stockholder approval, except\ras required by law or regulation or under rules of the stock exchange, if any, on which the Company’s stock may then be\rlisted. Unless earlier terminated, grants under the Incentive Plan will terminate ten years after stockholder approval of the\rIncentive Plan, and the Incentive Plan will terminate when no shares remain available and the Company has no further obligation\rwith respect to any outstanding award.
"}]},{"name":"rpt:f-249","factDimensions":{"xbrl:concept":"MRMD:DebenturePayableTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 12 – DEBENTURES PAYABLE
\r\r\r\r
In October and November 2018, pursuant to a\rsecurities purchase agreement (the “SPA”), the Company sold an aggregate of $10,000,000 of convertible debentures to\ran accredited investor bearing interest at the rate of 6% per annum that mature two years from issuance, with a 1% issuance discount,\rresulting in net proceeds to the Company of $9,900,000 (the “$10M Debentures”).
\r\r\r\r
The holder of the $10M Debentures (the “Holder”)\rhas the right at any time to convert all or a portion of the $10M Debenture, along with accrued and unpaid interest, into the Company’s\rcommon stock at conversion prices equal to 80% of a calculated average, as determined in accordance with the terms of the $10M\rDebentures, of the daily volume-weighted price during the ten consecutive trading days preceding the date of conversion. Notwithstanding\rthis conversion right, the Holder shall limit conversions in any given month to certain agreed-upon amounts based on\rthe conversion price, and the Holder shall also be limited from beneficially owning more than 4.99% of the Company’s outstanding\rcommon stock (potentially further limiting the Holder’s conversion right).
\r\r\r\r
The Company shall have the right to redeem\rall or a portion of the $10M Debentures, along with accrued and unpaid interest, at a 10% premium, provided that the Company first deliver advance\rwritten notice to the Holder of its intention to make a redemption, with the Holder allowed to effect certain conversions\rof the $10M Debentures during such notice period.
\r\r\r\r
Upon a change in control transaction, as defined\rin the $10M Debentures, the Holder may require the Company to redeem all or a portion of the $10M Debentures at a price equal to\r110% of the outstanding principal amount of the $10M Debentures, plus all accrued and unpaid interest thereon. So long as the $10M\rDebentures are outstanding, in the event the Company enters into a Variable Rate Transaction (“VRT”), as defined in\rthe SPA, the Holder may cause the Company to revise the terms of the $10M Debentures to match the terms of the convertible security\rissued in such VRT.
\r\r\r\r
In conjunction with the issuance of the $10M\rDebentures, the Company issued two warrants to the Holder to purchase 142,857 and 181,818 shares of the Company’s common\rstock at exercise prices of $3.50 and $5.50 per share, respectively, and expiring three years from issuance (the “Initial\rWarrants”). The fair value of the Initial Warrants of approximately $1,058,000 was recorded as a discount to the\rcarrying amount of the $10M Debentures.
\r\r\r\r
Pursuant to the terms of a registration rights\ragreement with the Holder, entered into concurrently with the SPA and the $10M Debentures, the Company agreed to provide the Holder\rwith certain registration rights with respect to any potential shares issued pursuant to the terms of the SPA, the $10M Debentures,\rand the Initial Warrants.
\r\r\r\r
Subsequent to entering into the SPA and related\ragreements, the Company and the Holder executed an addendum to the SPA whereby the Holder agreed to that it would not undertake\ra conversion of all or a portion of the $10M Debentures that would require the Company to issue more shares than the amount of\ravailable authorized shares at the time of conversion, which amount of authorized shares shall not be less than the current authorized\rnumber of 500 million shares of common stock. Such addendum eliminated the requirement to bifurcate and account for the conversion\rfeature of the $10M Debentures as a derivative.
\r\r\r\r
Based on the conversion prices of the $10M\rDebentures in relation to the market value of the Company’s common stock, the $10M Debentures provided the Holder with a\rbeneficial conversion feature, as the embedded conversion option was in-the-money on the commitment date. The intrinsic value of\rthe beneficial conversion feature of approximately $5,570,000 was recorded as a discount to the carrying amount of the $10M Debentures,\rwith an offset to additional paid-in-capital.
\r\r\r\r
In May 2019, the Company sold to the Holder\ran additional $5,000,000 convertible debenture bearing interest at the rate of 6% per annum that matures two years from\rissuance, with a 1% issuance discount, resulting in net proceeds to the Company of $4,950,000 (the “$5M Debentures”).\rIn each of June and August 2019, the Company sold to the Holder an additional $2,500,000 of convertible debentures, totaling $5,000,000,\rthat mature two years from issuance, with a 7% issuance discount, resulting in aggregate net proceeds to the Company\rof $4,650,000 (the “Two $2.5M Debentures,” and together with the $5M Debentures, the “Additional $10M Debentures”).
\r\r\r\r
The terms of the Additional $10M Debentures\rare consistent with the terms of the $10M Debentures, except that (i) no interest shall accrue on the Two $2.5M Debentures, (ii)\rthe issuance discount on the Two $2.5M Debentures is 7%, compared to 1% on the $10M Debentures and the $5M Debentures,\rand (iii) other small variations, most notably a cap on the conversion price. The SPA, registration rights agreement, and addendum\rto the SPA were all amended and restated to incorporate the Additional $10M Debentures.
\r\r\r\r
As part of issuance of the Additional $10M\rDebentures, the Company issued three-year warrants to the Holder to purchase 550,000 and 300,000 shares of common stock at exercise\rprices of $3.00 and $5.00 per share, respectively (the “Additional Warrants”). The fair value of the Additional Warrants\rof approximately $1,148,000 was recorded as a discount to the carrying amount of the Additional $10M Debentures.
\r\r\r\r
Based on the conversion prices of the Additional\r$10M Debentures in relation to the market value of the Company’s common stock, the Additional $10M Debentures provided the\rHolder with a beneficial conversion feature, as the embedded conversion option was in-the-money on the commitment date. The aggregate\rintrinsic value of the beneficial conversion feature of approximately $4,235,000 was recorded as a discount to the carrying amount\rof the Additional $10M Debentures, with an offset to additional paid-in-capital.
\r\r\r\r
In November and December 2018, the Holder converted,\rin two separate transactions, an aggregate of $1,400,000 of principal and approximately $36,000 of accrued interest into 524,360\rshares of common stock at conversion prices of $2.23 and $3.04 per share.
\r\r\r\r
In January 2019, the Holder converted, in three\rseparate transactions, an aggregate of $600,000 of principal and approximately $97,000 of accrued interest into 233,194 shares\rof common stock at conversion prices ranging from $2.90 to $3.06 per share. In April and June 2019, the Holder converted, in four\rseparate transactions, an aggregate of $1,750,000 of principal and approximately $181,000 of accrued interest into 923,185 shares\rof common stock at conversion prices ranging from $1.74 to $2.74 per share. In July, the Holder converted, in two separate transactions,\ran aggregate of $2,750,000 of principal and approximately $17,000 of accrued interest into 2,435,144 shares of common stock at\rconversion prices of $1.08 and $1.70 per share. In September 2019, the Holder converted $2,400,000 of principal and approximately\r$64,000 of accrued interest into 3,206,816 shares of common stock at a conversion price of $0.77 per share. In December 2019,\rthe Holder converted $1,100,000 of principal and approximately $17,000 of accrued interest into subscriptions on 3,004,131 shares\rof common stock at a conversion price of $0.37 per share.
\r\r\r\r
All of the aforementioned conversions were\rperformed in accordance with the terms of their respective convertible debenture agreements, and therefore the Company was not\rrequired to record a gain or loss on such conversions.
\r\r\r\r
During 2019 and 2018, amortization\rof the beneficial conversion features, after adjustment for the conversions, approximated $5,242,000 and $1,522,000, respectively; amortization\rof the discounts from the Initial Warrants and Additional Warrants (together, the “Total Warrants”) approximated $1,298,000\rand $91,000 respectively; and the amortization of original issue discounts approximated $107,000 and $9,000, respectively. This\ramortization was charged to interest expense. Additionally, accrued interest expense for such periods approximated $513,000\rin 2019 and $98,000 in 2018.
\r\r\r\r
At December 31, 2019, the aggregate\routstanding principal balance on the $10M Debentures and the Additional $10M Debentures (together, the “$20M Debentures”)\rwas $10,000,000. Also on such date, the unamortized balances of the beneficial conversion feature, the Total Warrants\rdiscount, and original issue discounts were approximately $3,041,000, $817,000, and $307,000, respectively.\rAccordingly, at December 31, 2019, the carrying value of the $20M Debentures was approximately $5,835,000.
\r\r\r\r
At December 31, 2018, the outstanding principal\rbalance on the $10M Debentures was $8,600,000. Also on such date, the unamortized balances of the beneficial conversion feature,\rInitial Warrants discount, and original issue discounts were approximately $4,048,000, $966,000, and $91,000, respectively, and\raccrued and unpaid interest was approximately $62,000. Accordingly, at December 31, 2018, the carrying value of the $10M Debentures\rwas approximately $3,557,000.
"}]},{"name":"rpt:f-250","factDimensions":{"xbrl:concept":"us-gaap:DueFromRelatedPartiesNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"119781","decimals":0}]},{"name":"rpt:f-251","factDimensions":{"xbrl:concept":"us-gaap:DueFromRelatedPartiesNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-252","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"16575395","decimals":0}]},{"name":"rpt:f-253","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"11851915","decimals":0}]},{"name":"rpt:f-254","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","xbrl:period":"2019-12-29T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:BinskeMember","us-gaap:TypeOfArrangementAxis":"MRMD:LicensingAgreementMember"}},{"name":"rpt:f-255","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:GenCannaMember","us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis":"us-gaap:BilledRevenuesMember"},"factValues":[{"value":"33200000","decimals":0}]},{"name":"rpt:f-256","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax","xbrl:period":"2019-10-01T00:00:00/2019-11-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember"},"factValues":[{"value":"1300000","decimals":0}]},{"name":"rpt:f-257","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rAs of December 31, 2019, the aggregate\rscheduled maturities of the Company’s total debt outstanding, inclusive of the promissory notes and mortgages described within\rthis Note 11 – Debt, and the convertible debentures described in the following Note 12 – Debentures\rPayable, were:
\r\r\r\r
| 2020 | \r\r | $ | \r21,433,484 | \r|
| 2021 | \r\r | \r | 11,262,710 | \r|
| 2022 | \r\r | \r | 280,830 | \r|
| 2023 | \r\r | \r | 300,248 | \r|
| 2024 | \r\r | \r | 320,702 | \r|
| Thereafter | \r\r | \r | 5,822,397 | \r|
| Total | \r\r | \r | 39,420,370 | \r|
| Less discounts | \r\r | \r | (3,135,686 | \r) |
| \r | \r | $ | \r36,284,684 | \r
For the years ended December 31, 2019\rand 2018, the Company’s revenues were comprised of the following major categories:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Real estate | \r\r | $ | \r6,836,316 | \r\r | \r | $ | \r6,441,160 | \r|
| Management | \r\r | \r | 2,798,738 | \r\r | \r | \r | 1,581,548 | \r|
| Supply procurement | \r\r | \r | 3,555,555 | \r\r | \r | \r | 3,015,745 | \r|
| Licensing | \r\r | \r | 1,794,161 | \r\r | \r | \r | 700,173 | \r|
| Product sales | \r\r | \r | 1,542,037 | \r\r | \r | \r | - | \r|
| Product sales to related party | \r\r | \r | 29,029,249 | \r\r | \r | \r | - | \r|
| Other | \r\r | \r | 48,589 | \r\r | \r | \r | 113,289 | \r|
| Total revenues | \r\r | $ | \r45,604,644 | \r\r | \r | $ | \r11,851,915 | \r
The following table summarizes the range of\rinputs used by the Company during the prior two fiscal years:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Life of instrument | \r\r | \r | 1.5 to 4.0 years | \r\r | \r | \r | 0.5 to 5.0 years | \r|
| Volatility factors | \r\r | \r | 1.039 to 1.106 | \r\r | \r | \r | 1.019 to 2.086 | \r|
| Risk-free interest rates | \r\r | \r | 1.42% to 2.28% | \r\r | \r | \r | 1.65% to 3.07% | \r|
| Dividend yield | \r\r | \r | 0% | \r\r | \r | \r | 0% | \r
NOTE 6 – DUE FROM THIRD PARTIES
\r\r\r\r
At December 31, 2019 and 2018, the following\rtable reflects amounts that were advanced by the Company to its cannabis-licensed clients primarily for working capital purposes,\rand the carrying amount of such advances after write-offs:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Kind Therapeutics USA Inc. (Maryland licensee) | \r\r | $ | \r1,475,675 | \r\r | \r | $ | \r2,679,496 | \r|
| Harvest Foundation LLC (Nevada licensee) | \r\r | \r | 1,938,787 | \r\r | \r | \r | 248,796 | \r|
| KPG of Anna LLC (Illinois licensee acquired Oct. 2019) | \r\r | \r | - | \r\r | \r | \r | 482,700 | \r|
| KPG of Harrisburg LLC (Illinois licensee acquired Oct. 2019) | \r\r | \r | - | \r\r | \r | \r | 449,385 | \r|
| Total working capital advances to third parties | \r\r | \r | 3,414,462 | \r\r | \r | \r | 3,860,377 | \r|
| Reserves against working capital advances | \r\r | \r | (3,414,462 | \r) | \r\r | \r | - | \r|
| Due from third parties, net | \r\r | $ | \r- | \r\r | \r | $ | \r3,860,377 | \r
\r\r
When a client is able to organically fund its\rongoing operations, such client will issue a promissory note to the Company for the cumulative advances made up to that point,\rwhich will then be paid down monthly over a specified period of time. The Company has successfully employed this strategy in the\rpast, and accordingly, in January 2019, KPG of Anna LLC and KPG of Harrisburg LLC issued promissory notes to the Company as further\rdescribed in Note 7 – Notes Receivable.
\r\r\r\r
In December 2019, the Company recorded bad\rdebt reserves against the working capital advance balances due from (i) Kind of approximately $1.5 million in light of the ongoing\rlitigation between the Company and Kind, and (ii) Harvest of approximately $1.9 million because of the anticipated effect on Harvest’s\roperations from a weakened local economy due to the coronavirus pandemic.
"}]},{"name":"rpt:f-265","factDimensions":{"xbrl:concept":"MRMD:ScheduleOfMajorityOwnedSubsidiariesTableTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rThe accompanying condensed consolidated financial\rstatements include the accounts of MariMed Inc. and the following majority-owned subsidiaries:
\r\r\r\r
| Subsidiary: | \r\r | Percentage \rOwned | \r ||
| MariMed Advisors Inc. | \r\r | \r | 100.0 | \r% |
| Mia Development LLC | \r\r | \r | 89.5 | \r% |
| Mari Holdings IL LLC | \r\r | \r | 100.0 | \r% |
| Mari Holdings MD LLC | \r\r | \r | 97.4 | \r% |
| Mari Holdings NV LLC | \r\r | \r | 100.0 | \r% |
| Hartwell Realty Holdings LLC | \r\r | \r | 100.0 | \r% |
| iRollie LLC | \r\r | \r | 100.0 | \r% |
| ARL Healthcare Inc. | \r\r | \r | 100.0 | \r% |
| KPG of Anna LLC | \r\r | \r | 100.0 | \r% |
| KPG of Harrisburg LLC | \r\r | \r | 100.0 | \r% |
| MariMed Hemp Inc. | \r\r | \r | 100.0 | \r% |
| MediTaurus LLC | \r\r | \r | 70.0 | \r% |
The following table summarizes the allocation\rof the purchase price to the fair value of the assets acquired and liabilities assumed on the acquisition date:
\r\r\r\r
| Equipment | \r\r | $ | \r21,000 | \r|
| Cannabis licenses | \r\r | \r | 185,000 | \r|
| Accounts payable | \r\r | \r | (120,689 | \r) |
| Due to related parties | \r\r | \r | (92,765 | \r) |
| Total identifiable net assets | \r\r | \r | (7,454 | \r) |
| Goodwill | \r\r | \r | 731,902 | \r|
| Total fair value of consideration | \r\r | $ | \r724,448 | \r
The following table summarizes the allocation\rof the purchase price to the fair value of the assets acquired:
\r\r\r\r
| Cash and cash equivalents | \r\r | $ | \r13,494 | \r|
| Goodwill | \r\r | \r | 266,682 | \r|
| Total fair value of consideration | \r\r | $ | \r280,176 | \r
The following table summarizes the allocation,\radjusted in September 2019, of the purchase price to the fair value of the assets acquired and liabilities assumed on the acquisition\rdate:
\r\r\r\r
| Cash and cash equivalents | \r\r | $ | \r64,196 | \r|
| Accounts receivable | \r\r | \r | 5,362 | \r|
| Inventory | \r\r | \r | 519,750 | \r|
| Goodwill | \r\r | \r | 2,662,669 | \r|
| Accounts payable | \r\r | \r | (777 | \r) |
| Total value of MediTaurus | \r\r | \r | 3,251,200 | \r|
| Noncontrolling interests in MediTaurus | \r\r | \r | (975,360 | \r) |
| Total fair value of consideration | \r\r | $ | \r2,275,840 | \r
The following table summarizes the allocation\rof the purchase price to the fair value of the assets acquired and liabilities assumed on the acquisition date:
\r\r\r\r
| Cash and cash equivalents | \r\r | $ | \r443,980 | \r|
| Inventory | \r\r | \r | 113,825 | \r|
| Intangibles | \r\r | \r | 2,067,727 | \r|
| Minority interests | \r\r | \r | 138,356 | \r|
| Accounts payable | \r\r | \r | (642,033 | \r) |
| Accrued expenses | \r\r | \r | (186,005 | \r) |
| Due to third parties | \r\r | \r | (1,020,850 | \r) |
| Total fair value of consideration | \r\r | $ | \r915,000 | \r
At December 31, 2019 and 2018, the following\rtable reflects amounts that were advanced by the Company to its cannabis-licensed clients primarily for working capital purposes,\rand the carrying amount of such advances after write-offs:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Kind Therapeutics USA Inc. (Maryland licensee) | \r\r | $ | \r1,475,675 | \r\r | \r | $ | \r2,679,496 | \r|
| Harvest Foundation LLC (Nevada licensee) | \r\r | \r | 1,938,787 | \r\r | \r | \r | 248,796 | \r|
| KPG of Anna LLC (Illinois licensee acquired Oct. 2019) | \r\r | \r | - | \r\r | \r | \r | 482,700 | \r|
| KPG of Harrisburg LLC (Illinois licensee acquired Oct. 2019) | \r\r | \r | - | \r\r | \r | \r | 449,385 | \r|
| Total working capital advances to third parties | \r\r | \r | 3,414,462 | \r\r | \r | \r | 3,860,377 | \r|
| Reserves against working capital advances | \r\r | \r | (3,414,462 | \r) | \r\r | \r | - | \r|
| Due from third parties, net | \r\r | $ | \r- | \r\r | \r | $ | \r3,860,377 | \r
At December 31, 2019 and 2018, notes\rreceivable were comprised of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| First State Compassion Center | \r\r | $ | \r527,261 | \r\r | \r | $ | \r578,722 | \r|
| Healer LLC | \r\r | \r | 846,985 | \r\r | \r | \r | 307,429 | \r|
| Atalo Holdings Inc. | \r\r | \r | - | \r\r | \r | \r | - | \r|
| Maryland Health & Wellness Center Inc. | \r\r | \r | 323,526 | \r\r | \r | \r | - | \r|
| High Fidelity Inc. | \r\r | \r | 252,873 | \r\r | \r | \r | - | \r|
| Chooze Corp. | \r\r | \r | - | \r\r | \r | \r | 257,687 | \r|
| Total notes receivable | \r\r | \r | 1,950,645 | \r\r | \r | \r | 1,143,838 | \r|
| Notes receivable, current portion | \r\r | \r | 311,149 | \r\r | \r | \r | 51,462 | \r|
| Notes receivable, less current portion | \r\r | $ | \r1,639,496 | \r\r | \r | $ | \r1,092,376 | \r
NOTE 5 – DEFERRED RENTS RECEIVABLE
\r\r\r\r
The Company is the lessor under several operating\rleases which contain rent holidays, escalating rents over time, options to renew, requirements to pay property taxes, insurance\rand/or maintenance costs, and contingent rental payments based on a percentage of monthly tenant revenues. The Company is not the\rlessor under any finance leases.
\r\r\r\r
The Company recognizes fixed rental receipts\rfrom such lease agreements on a straight-line basis over the expected lease term. Differences between amounts received and amounts\rrecognized are recorded under Deferred Rents Receivable on the balance sheet. Contingent rentals are recognized\ronly after tenants’ revenues are finalized and if such revenues exceed certain minimum levels.
\r\r\r\r
The Company leases the following owned properties:
\r\r\r\r
| \r | ● | \rDelaware – a 45,000 square foot facility purchased in September 2016 and developed into a cannabis cultivation, processing, and dispensary facility which is leased to a cannabis-licensed client occupying 100% of the space under a triple net lease that commenced in 2017 and expires in 2035. |
| \r | \r | |
| \r | ● | \rMaryland – a 180,000 square foot former manufacturing facility purchased in January 2017 and developed by the Company into a cultivation and processing facility which is leased to a licensed cannabis client under a triple net lease that commenced 2018 and expires in 2037. |
| \r | \r | |
| \r | ● | \rMassachusetts – a 138,000 square foot industrial property of which approximately half of the available square footage is leased to a non-cannabis manufacturing company under a lease that commenced in 2017 and expires in 2022. |
| \r | \r | |
| \r | ● | \rIllinois – two 3,400 square foot free-standing retail dispensaries in the cities of Anna and Harrisburg and leased to the KPGs, each under a 20-year lease that commenced in 2018. With the acquisition of the KPGs as disclosed in Note 3 – Acquisitions, this lease was eliminated upon the consolidation of the KPGs in October 2019. Accordingly, the rental receipts on such leases have been removed from the table of future minimum rental receipts below. |
\r\r
The Company subleases the following property:
\r\r\r\r
| \r | ● | \rDelaware – 4,000 square feet of retail space in a multi-use building space which the Company developed into a cannabis dispensary which is subleased to its cannabis-licensed client under a under a triple net lease expiring in 2021 with a five-year option to extend. |
\r\r
As of December 31, 2019 and 2018,\rcumulative fixed rental receipts under such leases approximated $9.5 million and $5.4 million, respectively, compared\rto revenue recognized on a straight-line basis of approximately $11.3 million and $7.5 million. Accordingly, the deferred\rrents receivable balances at December 31, 2019 and 2018 approximated $1.8 million and $2.1 million, respectively.
\r\r\r\r
Future minimum rental receipts for non-cancelable\rleases and subleases as of December 31, 2019 were:
\r\r\r\r
| 2020 | \r\r | $ | \r3,896,550 | \r|
| 2021 | \r\r | \r | 4,036,550 | \r|
| 2022 | \r\r | \r | 3,959,709 | \r|
| 2023 | \r\r | \r | 3,661,821 | \r|
| 2024 | \r\r | \r | 3,717,080 | \r|
| Thereafter | \r\r | \r | 40,404,470 | \r|
| Total | \r\r | $ | \r59,676,179 | \r
At December 31, 2019 and 2018, the\rCompany’s investments were comprised of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Current investments: | \r\r | \r | \r | \r | \r | \r | \r | |
| Terrace Inc. | \r\r | $ | \r1,449,144 | \r\r | \r | $ | \r- | \r|
| Total current investments | \r\r | $ | \r1,449,144 | \r\r | \r | $ | \r- | \r|
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Non-current investments: | \r\r | \r | \r | \r | \r | \r | \r | |
| GenCanna Global Inc. | \r\r | \r | - | \r\r | \r | \r | - | \r|
| CVP Worldwide LLC | \r\r | \r | 1,066,975 | \r\r | \r | \r | 1,172,163 | \r|
| Iconic Ventures Inc. | \r\r | \r | - | \r\r | \r | \r | 500,000 | \r|
| Chooze Corp. | \r\r | \r | 257,686 | \r\r | \r | \r | - | \r|
| Total non-current investments | \r\r | \r | 1,324,661 | \r\r | \r | \r | 1,672,163 | \r|
| Total investments | \r\r | $ | \r2,773,805 | \r\r | \r | $ | \r1,672,163 | \r
NOTE 9 – DEBENTURES RECEIVABLE
\r\r\r\r
As detailed in Note 4 – Investments,\rthe Company converted the GC Debentures into a 33.5% ownership interest in GenCanna in February 2019. Prior to conversion, the\rGC Debentures bore interest at a rate of 9% per annum and had an original maturity date of three years from issuance. For the\ryear ended December 31, 2018, the Company earned and received interest income of approximately $502,000 on the GC Debentures.
"}]},{"name":"rpt:f-294","factDimensions":{"xbrl:concept":"us-gaap:LeaseCostTableTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rThe components of lease expense for the year\rended December 31, 2019 were as follows:
\r\r\r\r
| Operating lease cost | \r\r | $ | \r832,403 | \r|
| Finance lease cost: | \r\r | \r | \r | |
| Amortization of right-of-use assets | \r\r | $ | \r23,085 | \r|
| Interest on lease liabilities | \r\r | \r | 6,414 | \r|
| Total finance lease cost | \r\r | $ | \r29,499 | \r
NOTE 14 – STOCK OPTIONS
\r\r\r\r
During 2019, the Company granted options to\rpurchase 2,565,000 shares of common stock, expiring four and five years from their grant dates, at exercise\rprices ranging from $0.42 to $1.95 per share. The fair value of these option grants of approximately $1,502,000\ris being amortized over their respective vesting periods, of which approximately $544,000 was amortized in 2019.
\r\r\r\r
During 2018, the Company granted options to\rpurchase 4,720,000 shares of common stock, expiring four and five years from their grant dates, at exercise\rprices ranging from $0.14 to $3.72 per share. The fair value of these option grants of approximately $5,897,000\ris being amortized over their respective vesting periods, of which approximately $3,339,000 and $1,534,000 was amortized in 2019\rand 2018, respectively.
\r\r\r\r
During 2019, options to purchase 3,667,499 shares\rof common stock were exercised at prices ranging from $0.08 to $0.77 per share. Of these exercised options, 2,167,499 were\rexercised on a cashless basis with the exercise prices paid via the surrender of 405,691 shares of common stock.
\r\r\r\r
During 2018, options to purchase 760,000 shares\rof common stock were exercised at prices ranging from $0.08 to $0.63 per share. Of these exercised options exercised\rin 2018, 460,000 were exercised on a cashless basis with the exercise price paid via the surrender of 105,398 shares\rof common stock.
\r\r\r\r
During 2019, options to purchase 117,501\rshares of common stock expired, and options to purchase 818,750 shares of common stock were forfeited, resulting in an aggregate\rreduction of amortization expense of approximately $432,000 in 2019. During 2018, options to purchase 200,000 shares\rof common stock expired, and options to purchase 250,000 shares of common stock were forfeited, resulting in an aggregate reduction\rof amortization expense of approximately $71,000 in 2018.
\r\r\r\r
Stock options outstanding and exercisable as\rof December 31, 2019 were:
\r\r\r\r
| Exercise Price | \r\r | \r | Shares Under Option | \r\r | \r | Remaining | \r||||||||
| per Share | \r\r | \r | Outstanding | \r\r | \r | Exercisable | \r\r | \r | Life in Years | \r|||||
| $ | \r0.130 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 0.50 | \r|
| $ | \r0.140 | \r\r | \r | \r | 550,000 | \r\r | \r | \r | 550,000 | \r\r | \r | \r | 1.00 | \r|
| $ | \r0.330 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 1.19 | \r|
| $ | \r0.417 | \r\r | \r | \r | 900,000 | \r\r | \r | \r | - | \r\r | \r | \r | 4.99 | \r|
| $ | \r0.450 | \r\r | \r | \r | 125,000 | \r\r | \r | \r | 125,000 | \r\r | \r | \r | 1.76 | \r|
| $ | \r0.590 | \r\r | \r | \r | 15,000 | \r\r | \r | \r | - | \r\r | \r | \r | 4.94 | \r|
| $ | \r0.630 | \r\r | \r | \r | 300,000 | \r\r | \r | \r | 300,000 | \r\r | \r | \r | 2.00 | \r|
| $ | \r0.770 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 3.00 | \r|
| $ | \r0.900 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 3.37 | \r|
| $ | \r0.910 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 2.81 | \r|
| $ | \r0.950 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 30,000 | \r\r | \r | \r | 3.00 | \r|
| $ | \r0.992 | \r\r | \r | \r | 300,000 | \r\r | \r | \r | - | \r\r | \r | \r | 4.74 | \r|
| $ | \r1.000 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 15,000 | \r\r | \r | \r | 4.84 | \r|
| $ | \r1.350 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | - | \r\r | \r | \r | 3.58 | \r|
| $ | \r1.950 | \r\r | \r | \r | 500,000 | \r\r | \r | \r | 125,000 | \r\r | \r | \r | 3.50 | \r|
| $ | \r2.320 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 3.70 | \r|
| $ | \r2.450 | \r\r | \r | \r | 2,000,000 | \r\r | \r | \r | 2,000,000 | \r\r | \r | \r | 2.98 | \r|
| $ | \r2.500 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 3.66 | \r|
| $ | \r2.650 | \r\r | \r | \r | 200,000 | \r\r | \r | \r | 150,000 | \r\r | \r | \r | 3.73 | \r|
| $ | \r2.850 | \r\r | \r | \r | 56,250 | \r\r | \r | \r | 37,500 | \r\r | \r | \r | 2.95 | \r|
| $ | \r2.850 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 50,000 | \r\r | \r | \r | 3.95 | \r|
| $ | \r3.000 | \r\r | \r | \r | 25,000 | \r\r | \r | \r | 12,500 | \r\r | \r | \r | 3.96 | \r|
| $ | \r3.725 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 100,000 | \r\r | \r | \r | 3.94 | \r|
| \r | \r | \r | \r | \r | 6,271,250 | \r\r | \r | \r | 4,207,500 | \r\r | \r | \r | \r |
NOTE 15 – WARRANTS
\r\r\r\r
In conjunction with the issuance\rof the $20M Debentures previously disclosed in Note 12 – Debentures Payable, in 2019 and 2018, the\rCompany issued three-year warrants to purchase 850,000 and 324,675 shares of its common stock, respectively, at\rexercise prices of $3.00 to $5.00 per share and $3.50 to $5.50 per share, respectively. The fair value of these\rwarrants at issuance approximated $1,148,000 in 2019 and $1,058,000 in 2018, with approximately $1,298,000 amortized\rto interest expense in 2019, approximately $91,000 in 2018, and the balance to be amortized over the remaining\rdurations of the $20M Debentures.
\r\r\r\r
As part of the $10M Note transaction previously\rdisclosed in Note 11 – Debt, in 2019, the Company issued three-year warrants to purchase 375,000 shares\rof common stock at an exercise price of $4.50 per share. The fair value of these warrants at issuance approximated $601,000, with\rapproximately $523,000 of this amount amortized to interest expense during the year, and the balance to\rbe amortized by the initial January 2020 maturity date of the $10M Note.
\r\r\r\r
In connection with $3M Note transaction previously\rdisclosed in Note 11 – Debt, in 2018, the Company issued three-year warrants to purchase 750,000 shares of the\rCompany’s common stock at an exercise price of $1.80 per share. The fair value of these warrants at issuance approximated\r$1,511,000, with approximately $882,000 amortized to interest expense during 2018, and the remaining $629,000 amortized during\r2019.
\r\r\r\r
In addition to the above warrants issued with\rthe $20M Debentures, $10M Note, and $3M Note, in connection with promissory notes issued to individuals in 2019 and 2018, the Company\rissued warrants to purchase 10,000 and 237,500 shares of common stock, respectively, at an exercise price of $0.75 and $0.55 per\rshare, respectively, expiring four years and three years, respectively, from issuance. The fair value of these warrants at issuance\rof approximately $5,000 in 2019 and $198,000 in 2018 were fully amortized to interest expense in the year of issuance.
\r\r\r\r
In 2018, alongside the sale of common stock,\rthe Company issued three-year and five-year warrants to purchase 6,098,962 shares of common stock at exercise prices ranging from\r$1.75 to 4.30 per share. The fair value of these warrants at issuance of approximately $11,146,000 was treated as a reduction to\rthe value of the common stock and charged to Additional Paid-In Capital on the balance sheet. No warrants were\rissued alongside sales of common stock in 2019.
\r\r\r\r
In 2019 and 2018, the Company issued stand-alone\rwarrants to purchase 1,250,000 and 625,000 shares of common stock, respectively, at exercise prices of $0.80 to 1.71 per share\rin 2019, and $0.20 to $2.45 per share in 2018. The 2019 warrants expire three years from issuance and the 2018 options expire three\rand five years from issuance. The fair value of the warrant issuances of approximately $392,000 in 2019 and $1,815,000 in 2018\rwere charged to expense in the year of issuance.
\r\r\r\r
During 2019 and 2018, warrants to purchase\r686,104 and 2,300,237 shares of common stock, respectively, were exercised at exercise prices ranging from $0.12 to $1.75\rper share in 2019 and $0.10 to $0.75 per share in 2018.
\r\r\r\r
At December 31, 2019 and 2018, warrants\rto purchase 11,780,107 and 10,606,211 shares of common stock, respectively, were outstanding with exercise\rprices ranging from $0.15 to $5.50 per share in 2019 and $0.12 to $5.50 per share in 2018.
"}]},{"name":"rpt:f-337","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 16 – REVENUES
\r\r\r\r
For the years ended December 31, 2019\rand 2018, the Company’s revenues were comprised of the following major categories:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Real estate | \r\r | $ | \r6,836,316 | \r\r | \r | $ | \r6,441,160 | \r|
| Management | \r\r | \r | 2,798,738 | \r\r | \r | \r | 1,581,548 | \r|
| Supply procurement | \r\r | \r | 3,555,555 | \r\r | \r | \r | 3,015,745 | \r|
| Licensing | \r\r | \r | 1,794,161 | \r\r | \r | \r | 700,173 | \r|
| Product sales | \r\r | \r | 1,542,037 | \r\r | \r | \r | - | \r|
| Product sales to related party | \r\r | \r | 29,029,249 | \r\r | \r | \r | - | \r|
| Other | \r\r | \r | 48,589 | \r\r | \r | \r | 113,289 | \r|
| Total revenues | \r\r | $ | \r45,604,644 | \r\r | \r | $ | \r11,851,915 | \r
\r\r
For the year ended December 31, 2019,\rrevenue from three clients represented 92% of total revenues. One of these clients was GenCanna, a related party, with\rwhom the Company conducted the seed sale transactions previously disclosed in Note 1 – Organization and Description\rof Business. The total revenue from these transactions with GenCanna are reflected under Product Sales To\rRelated Party in the table above.
\r\r\r\r
Excluding the revenues from GenCanna, two\rclients represented 78% and 73% of revenues for the years ended December 31, 2019 and 2018, respectively.
"}]},{"name":"rpt:f-338","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 20 – COMMITMENTS\rAND CONTINGENCIES
\r\r\r\r
Lease Commitments
\r\r\r\r
The Company is the lessee under five operating\rleases and four finance leases. These leases contain rent holidays and customary escalations of lease payments for the type of\rfacilities being leased. The Company recognizes rent expense on a straight-line basis over the expected lease term, including cancelable\roption periods which the Company fully expects to exercise. Certain leases require the payment of property taxes, insurance and/or\rmaintenance costs in addition to the rent payments.
\r\r\r\r
The details of the Company’s operating\rlease agreements are as follows:
\r\r\r\r
| \r | ● | \rDelaware – 4,000 square feet of retail space in a multi-use building under a five-year lease that commenced in October 2016 and contains a five-year option to extend the term. The Company developed the space into a cannabis dispensary which is subleased to its cannabis-licensed client. |
| \r | \r | |
| \r | ● | \rDelaware – a 100,000 square foot warehouse leased in March 2019 that the Company is developing into a cultivation and processing facility to be subleased to the same Delaware client. The lease term is 10 years, with an option to extend the term for three additional five-year periods. |
| \r | \r | |
| \r | ● | \rNevada – 10,000 square feet of an industrial building that the Company has built-out into a cannabis cultivation facility and plans to rent to its cannabis-licensed client under a sub-lease which will be coterminous with this lease expiring in 2024. |
| \r | \r | |
| \r | ● | \rMassachusetts – 10,000 square feet of office space which the Company utilizes as its corporate offices under a 10-year lease with a related party expiring in 2028, with an option to extend the term for an additional five-year period. |
| \r | \r | |
| \r | ● | \rMaryland – a 2,700 square foot 2-unit apartment under a lease that expires in July 2020 with an option to renew for a two-year term. |
\r\r
The Company leases machinery and office equipment\runder finance leases that expire in February 2022 through June 2024 with such terms being a major part of the economic useful life\rof the leased property.
\r\r\r\r
The components of lease expense for the year\rended December 31, 2019 were as follows:
\r\r\r\r
| Operating lease cost | \r\r | $ | \r832,403 | \r|
| Finance lease cost: | \r\r | \r | \r | |
| Amortization of right-of-use assets | \r\r | $ | \r23,085 | \r|
| Interest on lease liabilities | \r\r | \r | 6,414 | \r|
| Total finance lease cost | \r\r | $ | \r29,499 | \r
\r\r
The weighted average remaining lease term for\roperating leases is 9.3 years, and for the finance lease is 3.6 years. The weighted average discount rate used to determine the\rright-of-use assets and lease liabilities was 7.5% for all leases.
\r\r\r\r
Future minimum lease payments as of December\r31, 2019 under all non-cancelable leases having an initial or remaining term of more than one year were:
\r\r\r\r
| \r | \r | \r Operating \rLeases | \r \r | \r | \r Finance \rLease | \r |||
| 2020 | \r\r | $ | \r917,444 | \r\r | \r | $ | \r38,412 | \r|
| 2021 | \r\r | \r | 1,008,227 | \r\r | \r | \r | 38,412 | \r|
| 2022 | \r\r | \r | 949,535 | \r\r | \r | \r | 27,123 | \r|
| 2023 | \r\r | \r | 910,166 | \r\r | \r | \r | 23,201 | \r|
| 2024 | \r\r | \r | 835,411 | \r\r | \r | \r | 3,229 | \r|
| Thereafter | \r\r | \r | 4,304,441 | \r\r | \r | \r | - | \r|
| Total lease payments | \r\r | \r | 8,925,223 | \r\r | \r | $ | \r130,377 | \r|
| Less: imputed interest | \r\r | \r | (2,608,366 | \r) | \r\r | \r | (16,552 | \r) |
| \r | \r | $ | \r6,316,857 | \r\r | \r | $ | \r113,825 | \r
\r\r
Terminated Employment Agreement
\r\r\r\r
An employment agreement which commenced in\r2012 with Thomas Kidrin, the former CEO of the Company, that provided Mr. Kidrin with salary, car allowances, stock options, life\rinsurance, and other employee benefits, was terminated by the Company in 2017. At December 31, 2019 and 2018, the Company maintained\ran accrual of approximately $1,043,000 for any amounts that may be owed under this agreement, although the Company contends that\rsuch agreement is not valid and no amount is due.
\r\r\r\r
In July 2019, Mr. Kidrin, also a former director\rof the Company, filed a complaint in the Massachusetts Superior Court, that alleges the Company failed to pay all wages owed to\rhim and breached the employment agreement, and requests multiple damages, attorney fees, costs, and interest. The Company has moved\rto dismiss certain counts of the complaint and has asserted counterclaims against Mr. Kidrin alleging breach of contract, breach\rof fiduciary duty, money had and received, and unjust enrichment. The Company believes that the allegations in the complaint are\rwithout merit and intends to vigorously defend this matter and prosecute its counterclaims.
\r\r\r\r
Maryland Acquisition
\r\r\r\r
As previously disclosed in Note 3 –\rAcquisitions, the sellers of Kind have attempted to renegotiate the terms of the MOU, alleging that the MOU is not an enforceable\ragreement, despite the MOU containing all the definitive material terms with respect to the acquisition transaction and confirming\rthe management and lease agreements. The Company engaged with the sellers in a good faith attempt to reach updated terms acceptable\rto both parties, but the non-reciprocation of the sellers resulted in an impasse and both parties commenced legal proceedings.
\r\r\r\r
On November 13, 2019, Kind commenced an action\rin the Circuit Court for Washington County, MD against the Company alleging, inter alia, breach of contract, breach of fiduciary\rduty and unjust enrichment, and seeking a declaratory judgment, injunctive relief, an accounting and damages in excess of $75,000.\rOn November 15, 2019, the Company filed counterclaims against Kind and, as plaintiffs, the Company commenced an action against\rthe Kind sellers alleging breach of contract with respect to the MOU and the management agreement, unjust enrichment, promissory\restoppel/detrimental reliance, and fraud in the inducement. The Company seeks a declaratory judgement that the MOU is an enforceable\rcontract, specific performance of such contact, and the establishment of a constructive trust for the Company’s benefit.
\r\r\r\r
Both parties brought motions for a temporary\rrestraining order and a preliminary injunction. On November 21, 2019, the Court denied both parties’ motion for a temporary\rrestraining order. In its opinion, the Court specifically noted that, contrary to Kind’s allegations, the management agreement\rand lease “appear to be independent, valid and enforceable contracts.” Currently, each party’s preliminary injunction\rmotion is pending before the Court. The Company believes that its claims for breach of contract with respect to the MOU and the\rmanagement agreement, unjust enrichment, promissory estoppel/detrimental reliance, and fraud in the inducement are meritorious\rand that Kind’s claims against the Company are without merit. The Company intends to aggressively prosecute and defend the\raction.
"}]},{"name":"rpt:f-339","factDimensions":{"xbrl:concept":"us-gaap:SubsequentEventsTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 21 – SUBSEQUENT EVENTS
\r\r\r\r
GenCanna Bankruptcy Filing
\r\r\r\r
In February 2020, GenCanna filed for voluntary\rreorganization under Chapter 11 of the Bankruptcy Code with the U.S. Bankruptcy Court for the Eastern District of Kentucky. The\rfiling is intended to permit GenCanna to operate its business while working through a reorganization plan that could include refinancing\rof its existing indebtedness, or an alternative restructuring transaction such as a sale.
\r\r\r\r
Consequently, as of December 31, 2019, the\rCompany wrote off the outstanding receivable balance from GenCanna of approximately $29.0 million and the related balance of unearned\rrevenue of approximately $4.2 million as previously discussed in Note 1 – Organization and Description of Business.
\r\r\r\r
Additionally, the Company recorded a charge\rto net income of approximately $30.2 million, classified under Loss on Equity Investments on the statement of operations\rfor the year ended December 31, 2019, which reduced to zero the carrying value of the Company’s previous investment in GenCanna\ras previously discussed in Note 4 – Investments.
\r\r\r\r
Exchange Agreement
\r\r\r\r
In February 2020,\rthe Company entered into an exchange agreement with two institutional shareholders (the “TIS”) whereby the TIS loaned\rthe Company an aggregate of $4,417,500. In return for the loans, and the Company (i) issued promissory notes to the TIS for the\raggregate amount, bearing interest at 16.5% per annum and maturing in August 2021, with a right to extend the maturity date through\rFebruary 2022 upon payment of an extension fee. and (ii) exchanged 4,903,333 shares of the Company’s common stock previously\racquired by the TIS, for an equal number of shares of newly designated Series B convertible preferred stock.
\r\r\r\r
In connection with the exchange agreement,\rthe Company filed (i) a certificate of designation to designate the rights and preferences of the Series B convertible preferred\rstock, and (ii) a certificate of elimination to return all shares of the Series A convertible preferred stock, of which no shares\rwere issued or outstanding at the time of filing, to the status of authorized and unissued shares of undesignated preferred stock.
\r\r\r\r
Issuance of Additional Debenture
\r\r\r\r
In February 2020, the Company sold to the Holder\rof the $20M Debentures an additional convertible debenture in the principal amount of $1,000,000 bearing interest at a rate of\r6.5% per annum that matures one year from issuance, with a 6.5% issuance discount, resulting in net proceeds to the Company of\r$935,000 (the “$1M Debenture”).
\r\r\r\r
The terms of the $1M Debenture are consistent\rwith the terms of the $20M Debentures. The SPA, registration rights agreement, and addendum to the SPA were all amended and restated\rto incorporate the $1M Debenture. As part of issuance of the $1M Debenture, the Company issued three-year warrants to the Holder\rto purchase 180,000 shares of common stock at an exercise prices of $0.75 per share.
\r\r\r\r
Promissory Note Extensions
\r\r\r\r
As previously discussed in Note 11 –\rDebt, the Company and MariMed Hemp issued the $11.5M Note in February 2020 which amended and restated the previously issued\r$10M Note. The $11.5M Note bears interest at a rate of 15% per annum and matures on June 15, 2020, with monthly interest payments\rand minimum amortization payments of $3,000,000 in the aggregate due on or before April 30, 2020, of which the Company has already\rpaid $2.3 million. The $11.5M Note is secured by a first priority security interest in the assets of certain of the Company’s\rsubsidiaries and brands, and a pledge of the Company’s ownership interest in certain of its subsidiaries. The $11.5M Note\rimposes certain covenants on the borrowers effective on the date of the amendment agreement.
\r\r\r\r
The Company also extended\rthe maturity dates of another $9.4 million of promissory notes, and is in the process of finalizing the paperwork to extend another\r$3.0 million of promissory notes, as a result of which the Company will not be in default on any of its debt servicing payments.
\r\r\r\r
Loan Commitment
\r\r\r\r
In February, the Company received a commitment\rfrom an accredited investor for a $12.0 million loan, secured by the Company’s real estate, at a rate of 10% per annum with\ra one-year term, and an option to extend for an additional year. The loan contains an origination fee of four points and a prepayment\rpenalty of two months interest. This transactions is expected to close upon the lender’s completion of its due diligence,\rwhich is in its final stages, although there is no assurance that it will close in the foreseeable future or at all.
\r\r\r\r
Conversion of Debentures Payable
\r\r\r\r
In January 2020, the holder of the $20M Debentures\rconverted $1,000,000 of principal and approximately $205,000 of accrued interest into 3,555,859 shares of common stock at a conversion\rprice of $0.34 per share.
\r\r\r\r
Promissory Note Paydown
\r\r\r\r
In February, the Company paid cash to retire\ra promissory note in the principal amount of $100,000 which matured during that month.
\r\r\r\r
Equity Transactions
\r\r\r\r
In the first quarter of 2020, the Company\rissued 3,236,857 shares of common stock associated with the subscriptions on common stock outstanding at December 31, 2019 and\rpreviously disclosed in Note 13 – Equity. These subscriptions were comprised of (i) 32,726 shares in connection with\rcommon stock granted in 2019; (ii) 3,004,131 shares with respect to the December 2019 conversion of a portion of the $20M Debentures,\rand (iii) 200,000 shares associated with exercise of stock options by the Company’s CEO.
"}]},{"name":"rpt:f-340","factDimensions":{"xbrl:concept":"us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 1 – ORGANIZATION AND DESCRIPTION\rOF BUSINESS
\r\r\r\r
MariMed Inc. (the “Company”) is\ra leader in the emerging cannabis industry. The Company is an expert in the development, operation, management and optimization\rof facilities for the cultivation, production and dispensing of medicinal and recreational cannabis and cannabis-infused products.\rTo date, the Company has developed in excess of 300,000 square feet of state-of-the-art, regulatory-compliant facilities in five\rstates – Delaware, Illinois, Maryland, Massachusetts, and Nevada.
\r\r\r\r
At the outset of the Company’s entrance\rinto the cannabis industry, the Company provided advisory services and assistance to its clients in the procurement of state-issued\rcannabis licenses, leased its aforementioned cannabis facilities to these newly-licensed clients, and provided industry-leading\rexpertise and oversight in all aspects of their cannabis operations, as well as ongoing regulatory, accounting, human resources,\rand administrative services. During this time, the Company successfully secured, on behalf of its clients, 13 cannabis licenses\racross six states – two in Delaware, three in Illinois, one in Nevada, one in Rhode Island, three in Maryland, and three\rin Massachusetts.
\r\r\r\r
Since entering the cannabis industry, the Company\rhas demonstrated an excellent track record developing and operating licensed cannabis facilities, implementing its proprietary\roperating procedures, and industry best practices. In 2018, the Company commenced a strategic plan to transition from an advisory\rfirm that provides cannabis licensing, operational consulting and real estate services, to a direct owner of cannabis licenses\rand operator of seed-to-sale operations, dedicated to the improvement of health and wellness through the use of cannabinoids and\rcannabis products.
\r\r\r\r
The Company’s strategic plan consists\rof the acquisition of its cannabis-licensed clients who currently lease the Company’s facilities, and the consolidation of\rthese entities under the MariMed banner. The Company has played a key role in the successes of these entities, from the securing\rof their cannabis licenses, to the development of facilities that are models of excellence, to providing operational and corporate\rguidance. Accordingly, the Company believes it is well suited to own these facilities and manage the continuing growth of their\roperations.
\r\r\r\r
A goal in completing this transition is to\rpresent a simpler, more transparent financial picture to the investor community. Once the consolidation is complete, the Company’s\rfinancial statements will provide a clearer representation of the revenues, earnings, and other financial metrics that the Company\ris generating, rather than a fee-for-service revenue model that reports only consulting and management fees, and does not reflect\rthe full breadth of the Company’s overall business.
\r\r\r\r
To date, acquisitions of the licensed businesses\rin Massachusetts and Illinois have been state-approved and completed, with the remaining entities located in Maryland, Nevada,\rand Rhode Island at various stages of completion and state approvals as further discussed below. When implemented, all of the Company’s\rcannabis-licensed clients will be fully consolidated into the Company, establishing it as a fully integrated seed-to-sale multistate\roperator of licensed cannabis businesses.
\r\r\r\r
Each of the remaining potential acquisitions\ris subject to the respective state’s approval under its laws governing the ownership and transfer of cannabis licenses. The\rcompletion of the entire plan requires a modification of current cannabis license ownership laws in in Delaware and Rhode Island,\rand therefore there is no assurance that the Company will be successful in fully implementing its plan. However, the Company continues\rto develop additional revenue and business in the states in which it operates and plans to leverage its success in these markets\rto expand into other states where cannabis is and becomes legal.
\r\r\r\r
The Company has also created its own brands\rof precision-dosed, cannabis-infused products designed to treat specific health conditions, alleviate medical symptoms, or achieve\ra certain effect. These products are developed by the Company in cooperation with state-licensed facilities and operators who meet\rthe Company’s strict standards, including all natural—not artificial or synthetic—ingredients. The Company licenses\rits product formulations only to knowledgeable manufacturing professionals who agree to adhere to the Company’s precise scientific\rformulations using its trademarked product recipes.
\r\r\r\r
The Company’s branded products are licensed\runder brand names including Kalm Fusion™, Nature’s Heritage™, and Betty’s Eddies™, and are distributed\rin the form of dissolvable strips, tablets, powders, microwaveable popcorn, fruit chews, and with more varieties in development.\rThe Company also has exclusive sublicensing rights in certain states to distribute DabTabs™ vaporization tablets infused\rwith cannabis concentrates, the Binske® line of cannabis products made from premium artisan ingredients, and the clinically\rtested medicinal cannabis strains developed in Israel by Tikun Olam™. The Company intends to continue licensing and distributing\rits brands as well as other top brands in the Company’s current markets and in partnerships in other states markets across\rthe country where product sale is legal.
\r\r\r\r
In anticipation of the growing demand for hemp-derived\rcannabidiol (“CBD”), in 2018, the Company invested $30.0 million in GenCanna Global Inc. (“GenCanna”),\ra Kentucky-based cultivator, producer, and distributor of hemp and GMP-quality CBD oils and isolates. Concurrent with this investment,\rthe Company acquired MediTaurus LLC (“MediTaurus”), a company operating in the United States and Europe that has developed\rproprietary CBD formulations under its Florance™ brand.
\r\r\r\r
The transactions with GenCanna and MediTaurus,\ralong with the Company’s cannabis platform and product experience, enabled the Company to expand into the emerging global\rCBD market just as the U.S Farm Bill was adopted in late 2018 which descheduled industrial hemp and hemp-derived CBD as controlled\rsubstances and classified them as agricultural commodities. This new law enabled a new emerging industry of CBD oils, isolates,\rand infused products within the United States. In early 2019, the Company established a wholly owned subsidiary, MariMed Hemp Inc.\r(“MariMed Hemp”) to market and distribute hemp-derived CBD products across several vertical markets.
\r\r\r\r
The Company’s stock is quoted on the\rOTCQX market under the ticker symbol MRMD.
\r\r\r\r
The Company was incorporated in Delaware in\rJanuary 2011 under the name Worlds Online Inc. Initially, the Company developed and managed online virtual worlds. By early 2014,\rthis line of business effectively ceased operating and the Company pivoted into the legal cannabis industry.
\r\r\r\r
Significant Transactions in the Current\rPeriod
\r\r\r\r
During 2019, the Company, through its MariMed\rHemp subsidiary, entered into several hemp seed sale transactions with GenCanna whereby the Company acquired large quantities of\rtop-grade feminized hemp seeds with proven genetics at volume discounts that it sold to GenCanna at market rates. The seeds met\rthe U.S. government’s definition of federally legal industrial hemp, which was descheduled as a controlled substance and\rclassified as an agricultural commodity upon the signing of the 2018 U.S. Farm Bill.
\r\r\r\r
The Company purchased $20.75 million of hemp\rseed inventory which it sold and delivered to GenCanna for $33.2 million. The Company provided GenCanna with extended payment terms\rthrough December 2019, to coincide with the completion of the seeds’ harvest, although the payment by GenCanna was not contingent\rupon the success of such harvest or its yield. To partially fund the seed purchases, the Company raised $17.0 million in debt financings\rwhich is reflected in Notes Payable on the balance sheet and further discussed in Note 11 – Debt.
\r\r\r\r
By the end of 2019, GenCanna had not paid the\ramount it owed the Company for its seed purchases due to several challenges it faced late in the year, including a fire at its\rmain processing and lab facility, the domestic decline of CBD selling prices, and the contraction of the cannabis capital markets.\rIn February 2020, GenCanna filed for voluntary reorganization under Chapter 11 with the U.S. Bankruptcy Court in the Eastern District\rof Kentucky. The filing is intended to permit GenCanna to operate its business while working through a reorganization plan that\rcould include refinancing of its existing indebtedness, or an alternative restructuring transaction such as a sale.
\r\r\r\r
As required by the relevant accounting guidance,\rthe Company initially recorded the $33.2 million due from GenCanna as a related party receivable, with approximately $29.0 million\rrecognized as related party revenue, and approximately $4.2 million classified as unearned revenue (such amount representing the\rCompany’s 33.5% ownership portion of the profit on these transactions, which was to have been recognized as revenue upon\rpayment by GenCanna). As a result of GenCanna’s Chapter 11 filing, the Company wrote off the receivable balance of approximately\r$29.0 million and the entire unearned revenue balance of approximately $4.2 million. Additionally, the Company recorded a charge\rto net income of approximately $30.2 million, which reduced to zero the carrying value of the Company’s investment in GenCanna.
\r\r\r\r
In addition to the foregoing adjustments, the\rCompany recorded bad debt reserves in 2019 against the receivable and working capital balances due from (i) Kind of approximately\r$11.2 million in the aggregate, in light of the ongoing litigation between the Company and Kind, and (ii) Harvest of approximately\r$2.2 million in the aggregate, due to the anticipated effect on Harvest’s operations from a weakened local economy due to\rthe coronavirus pandemic. These charges are further described in Note 6 – Due From Third Parties and Note 17 –\rBad Debts.
\r\r\r\r
The Company expects the coronavirus pandemic\rto likewise have a negative impact on the operations of certain entities in which the Company has invested and to whom the Company\rhas extended loans. For that reason, the Company also wrote off (i) three notes receivable balances of approximately $1.6 million\rin the aggregate, (ii) goodwill of approximately 2.7 million associated with the Company’s acquisition of MediTaurus, and\r(iii) the carrying value of a $500,000 investment. These items are further described in Note 3 – Acquisitions, Note\r4 – Investments, and Note 7 – Notes Receivable.
"}]},{"name":"rpt:f-341","factDimensions":{"xbrl:concept":"us-gaap:SignificantAccountingPoliciesTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING\rPOLICIES
\r\r\r\r
Basis of Presentation
\r\r\r\r
The accompanying financial statements have\rbeen prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
\r\r\r\r
Certain reclassifications have been made to\rprior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income\r(losses) or cash flows.
\r\r\r\r
Going Concern
\r\r\r\r
In connection with\rthe preparation of its financial statements for the year ended December 31, 2019, the Company’s management evaluated the\rCompany’s ability to continue as a going concern in accordance with the ASU 2014-15, Presentation of Financial Statements–Going\rConcern (Subtopic 205-40), which requires an assessment of relevant conditions or events, considered in the aggregate, that\rare known or reasonably knowable by management on the issuance dates of the financial statements which indicated the probable likelihood\rthat the Company will be unable to meet its obligations as they become due within one year after the issuance date of the financial\rstatements.
\r\r\r\r
As part of its evaluation,\rmanagement assessed known events, trends, commitments, and uncertainties, which at the time included the status of its consolidation\rplan, the GenCanna bankruptcy, the amount of capital raised by the Company during the past two calendar years, the recent level\rof cannabis industry investment activity, the stock price movement of public cannabis companies, the actions and/or results of\rcertain bellwether cannabis companies, the measure of cannabis investor confidence, and the changes to state laws with respect\rto adult-use recreational and medical cannabis use.
\r\r\r\r
At December 31, 2019,\rthe Company had negative working capital of approximately $31.0 million, and for the year then ended, incurred negative cash flow\rfrom operations of approximately $24.8 million. For further discussion on these metrics and the Company’s liquidity and capital\rresources, please refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations\rof the Company’s Form 10-K for the fiscal year ended December 31, 2019.
\r\r\r\r
In early 2020, the\rCompany raised approximately $4.4 million as part of an exchange agreement with two institutional stockholders, and $935,000 from\rthe issuance of convertible debentures. Additionally, the Company has extended the maturity dates of approximately $19.4 million\rof promissory notes, and is in the process of finalizing the documentation to extend another $3.0 million of promissory notes.\rThese transactions are further disclosed in Note 21 – Subsequent Events.
\r\r\r\r
Moreover, as of the\rfiling date of this report, the Company has obtained a commitment from an accredited investor for a $12.0 million loan, secured\rby the Company’s real estate, at a rate of 10% per annum with a one-year term, and an option to extend for an additional\ryear. This transactions is expected to close upon the lender’s completion of its due diligence, which is in its final stages,\ralthough there is no assurance that it will close in the foreseeable future or at all. Also as of the filing date of this report,\rthe Company is in discussions with financial institutions to consider generating liquidity from the Company’s unencumbered\rreal property through mortgage-backed financings, the refinancing of certain outstanding mortgage loans, the sales-leaseback of\rcertain properties, and/or a combination thereof. Based on preliminary discussions, such financings could potentially generate\rupwards of $17.0 million from such transactions, however the Company has not signed any commitments it has received to date and\rthere are no assurances that it will.
\r\r\r\r
In addition to the\raforementioned financing transactions that have been consummated and that are in progress, the operations of the Company’s\rrecently acquired entities in Illinois and Massachusetts are expected to generate considerable liquidity and working capital for\rthe Company. The state of Illinois legalized adult-use cannabis in January 2020, which was added to the Company’s two existing\rcannabis licenses, thereby increasing the Company’s operations in this state to service both medical and recreational cannabis\rconsumers. In Massachusetts, the cultivation and production facility acquired by the Company will soon complete its first harvest\rand commence full scale selling operations in this state’s robust cannabis market.
\r\r\r\r
The Company believes that it will close incremental\rdebt financings in the foreseeable future, and it projects that its operating profit will organically support its day-to-day operations\rby the latter part of 2020. However, since there are no assurances that another financing transaction will be consummated, or that\rthe Company will meet or exceed its projections in light of the unknown current state of the global economy, there are similarly\rno assurances that the Company will be able to meet all of its obligations as they become due within one year after the issuance\rdate of these financial statements
\r\r\r\r
Principles of Consolidation
\r\r\r\r
The accompanying condensed consolidated financial\rstatements include the accounts of MariMed Inc. and the following majority-owned subsidiaries:
\r\r\r\r
| Subsidiary: | \r\r | Percentage \rOwned | \r ||
| MariMed Advisors Inc. | \r\r | \r | 100.0 | \r% |
| Mia Development LLC | \r\r | \r | 89.5 | \r% |
| Mari Holdings IL LLC | \r\r | \r | 100.0 | \r% |
| Mari Holdings MD LLC | \r\r | \r | 97.4 | \r% |
| Mari Holdings NV LLC | \r\r | \r | 100.0 | \r% |
| Hartwell Realty Holdings LLC | \r\r | \r | 100.0 | \r% |
| iRollie LLC | \r\r | \r | 100.0 | \r% |
| ARL Healthcare Inc. | \r\r | \r | 100.0 | \r% |
| KPG of Anna LLC | \r\r | \r | 100.0 | \r% |
| KPG of Harrisburg LLC | \r\r | \r | 100.0 | \r% |
| MariMed Hemp Inc. | \r\r | \r | 100.0 | \r% |
| MediTaurus LLC | \r\r | \r | 70.0 | \r% |
\r\r
Intercompany accounts and transactions have\rbeen eliminated.
\r\r\r\r
Use of Estimates
\r\r\r\r
The preparation of financial statements in\rconformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial\rstatements and disclosures thereof. Actual results could differ from these estimates or assumptions.
\r\r\r\r
Cash Equivalents
\r\r\r\r
The Company considers all highly liquid investments\rwith a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying\rvalues.
\r\r\r\r
The Company’s cash and cash equivalents\rare maintained with recognized financial institutions located in the United States. In the normal course of business, the Company\rmay carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses\ron balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard.
\r\r\r\r
Accounts Receivable
\r\r\r\r
Accounts receivable consist of trade receivables\rand are carried at their estimated collectible amounts.
\r\r\r\r
The Company provides credit to its clients\rin the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining\ra reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding\rbalances with consideration towards such client’s historical collection experience, as well as prevailing economic and market\rconditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $10.7 million and $150,000\rat December 31, 2019 and 2018, respectively. The 2019 reserve primarily consisted of reserves against the accounts receivable balances\rof Kind of approximately $9.7 million and Harvest of approximately $239,000, as further disclosed in Note 17 – Bad Debts.
\r\r\r\r
Inventory
\r\r\r\r
Inventory is carried at the lower of cost or\rnet realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage\rof overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria.\rThe Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of the date of\rthis report, no reserve was deemed necessary.
\r\r\r\r
Investments
\r\r\r\r
Investments are comprised of equity holding\rof private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes\rto fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are\rdeemed to have occurred.
\r\r\r\r
Revenue Recognition
\r\r\r\r
On January 1, 2018, the Company adopted the\rFinancial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract\rwith Customers, as amended by subsequently issued Accounting Standards Updates. This revenue standard requires an entity to\rrecognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it\rexpects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the following\rconsecutive steps:
\r\r\r\r
| \r | ● | \rIdentify the contract(s) with a customer; |
| \r | ● | \rIdentify the performance obligations in the contract(s); |
| \r | ● | \rDetermine the transaction price; |
| \r | ● | \rAllocate the transaction price to the performance obligations in the contract(s); and |
| \r | ● | \rRecognize revenue as the performance obligation is satisfied. |
\r\r
Additionally, when another party is involved\rin providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other\rparty—is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging for goods\ror services to be provided by the other party.
\r\r\r\r
The Company is typically considered the principal\rif it controls the specified good or service before such good or service is transferred to its client. The Company may also be\rdeemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf,\rprovided the Company (i) takes on certain responsibilities, obligations and risks, (ii) possesses certain abilities and discretion,\ror (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance\robligations it does not satisfy.
\r\r\r\r
The adoption of this standard did not have\ra significant impact on the Company’s consolidated operating results, and accordingly no restatement has been made to prior\rperiod reported amounts.
\r\r\r\r
The Company’s main sources of revenue\rare comprised of the following:
\r\r\r\r
| \r | ● | \rReal Estate – rental income and additional rental fees from leasing of the Company’s regulatory-compliant cannabis facilities to its clients, which are cannabis-licensed operating companies. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed a specified amount. |
| \r | \r | |
| \r | ● | \rManagement – fees for providing the Company’s cannabis clients with corporate services and operational oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue, and are recognized after services have been performed. |
| \r | \r | |
| \r | ● | \rSupply Procurement – the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies, and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser. |
| \r | \r | |
| \r | ● | \rLicensing – revenue from the sale of precision-dosed, cannabis-infused products, such as Kalm Fusion™ and Betty’s Eddies™, to legal dispensaries throughout the United States. The recognition of this revenue occurs when the products are delivered. |
| \r | \r | |
| \r | ● | \rConsulting – fees from third-parties where the Company provides assistance in securing cannabis licenses, and advisory services in the areas of facility design and development, and cultivation and dispensing best practices. These fees are recognized as the services are performed. |
| \r | \r | |
| \r | ● | \rProduct Sales – direct sales of cannabis, hemp, and products derived from these plants. During 2019, such revenue was generated from (i) the post-acquisition dispensary operations of both ARL in Massachusetts and the KPGs in Illinois, and (ii) the sales of hemp and CBD products by MariMed Hemp and MediTaurus. This revenue is recognized when products are delivered or at retail points-of-sale. |
\r\r
Research and Development Costs
\r\r\r\r
Research and development costs are charged\rto operations as incurred.
\r\r\r\r
Property and Equipment
\r\r\r\r
Property and equipment are stated at cost less\raccumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of\rthe asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed\rfrom the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in\rthe period incurred.
\r\r\r\r
The estimated useful lives of property and\requipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining\rduration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.
\r\r\r\r
The Company’s property and equipment\rare individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset\rmay not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment\rloss is measured by the excess of the asset’s carrying amount over its estimated fair value.
\r\r\r\r
Impairment analyses are based on management’s\rcurrent plans, asset holding periods, and currently available market information. If these criteria change, the Company’s\revaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.
\r\r\r\r
For the years ended December 31, 2019 and 2018,\rbased on the results of management’s impairment analyses, there were no impairment losses.
\r\r\r\r
Leases
\r\r\r\r
The consolidated financial\rstatements reflect the Company’s adoption of ASC 842, Leases, as amended by subsequent accounting standards updates,\rutilizing the modified retrospective transition approach which calls for applying the new standard to all of the Company’s\rleases effective January 1, 2019, which is the effective date of adoption.
\r\r\r\r
ASC 842 is intended to improve financial reporting\rof leasing transactions. The most prominent change from previous accounting guidance is the requirement to recognize right-of-use\rassets and lease liabilities on the consolidated balance sheet representing the rights and obligations created by operating leases\rthat extend more than twelve months in which the Company is the lessee. The Company elected the package of practical expedients\rpermitted under ASC 842. Accordingly, the Company accounted for its existing operating leases that commenced before the effective\rdate as operating leases under the new guidance without reassessing (i) whether the contracts contain a lease, (ii) the classification\rof the leases (iii) the accounting for indirect costs as defined in ASC 842.
\r\r\r\r
The Company determines if an arrangement is\ra lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and\rlease liabilities represent the Company’s obligation to make lease payments arising from the lease. Non-lease components\rwithin lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date\rbased on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The\rCompany’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company\rwill exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
\r\r\r\r
Impairment of Long-Lived Assets
\r\r\r\r
The Company evaluates the recoverability of\rits fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment\rof long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the\rassets are written down to fair value, which is determined based on discounted future cash flows or appraised values.
\r\r\r\r
Fair Value of Financial Instruments
\r\r\r\r
The Company follows the provisions of ASC 820,\rFair Value Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for\rdisclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements\rand related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to\rmeasure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in\ractive markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value\rhierarchy defined by ASC 820 are:
\r\r\r\r
| Level 1 | \rQuoted market prices available in active markets for identical assets or liabilities as of the reporting date. |
| \r | |
| Level 2 | \rPricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. |
| \r | |
| Level 3 | \rPricing inputs that are generally observable inputs and not corroborated by market data. |
\r\r
The carrying amounts of the Company’s\rfinancial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of\rthese instruments.
\r\r\r\r
The fair value of option and warrant issuances\rare determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the\rexercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock\ron issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by\rthe Company during the prior two fiscal years:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Life of instrument | \r\r | \r | 1.5 to 4.0 years | \r\r | \r | \r | 0.5 to 5.0 years | \r|
| Volatility factors | \r\r | \r | 1.039 to 1.106 | \r\r | \r | \r | 1.019 to 2.086 | \r|
| Risk-free interest rates | \r\r | \r | 1.42% to 2.28% | \r\r | \r | \r | 1.65% to 3.07% | \r|
| Dividend yield | \r\r | \r | 0% | \r\r | \r | \r | 0% | \r
\r\r
The expected life of an instrument is calculated\rusing the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment, which allows for using\rthe mid-point between the vesting date and expiration date. The volatility factors are based on the historical two-year movement\rof the Company’s common stock prior to an instrument’s issuance date. The risk-free interest rate is based on U.S.\rTreasury rates with maturity periods similar to the expected instruments life on the issuance date.
\r\r\r\r
The Company amortizes the fair value of option\rand warrant issuances on a straight-line basis over the requisite service period of each instrument.
\r\r\r\r
Extinguishment of Liabilities
\r\r\r\r
The Company accounts for extinguishment of\rliabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions for extinguishment are met,\rthe liabilities are written down to zero and a gain or loss is recognized.
\r\r\r\r
Stock-Based Compensation
\r\r\r\r
The Company accounts for stock-based compensation\rusing the fair value method as set forth in ASC 718, Compensation—Stock Compensation, which requires a public entity\rto measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant\rdate, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide\rservice in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees\rdo not render the requisite service.
\r\r\r\r
Income Taxes
\r\r\r\r
The Company accounts for income taxes in accordance\rwith ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between the\rfinancial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be\rin effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent\rmanagement concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities\rof a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.
\r\r\r\r
ASC 740 prescribes a comprehensive model for\rhow companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected\rto be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income\rtax liabilities or benefits for the years ended December 31, 2019 and 2018.
\r\r\r\r
Related Party Transactions
\r\r\r\r
The Company follows ASC 850, Related Party\rDisclosures, for the identification of related parties and disclosure of related party transactions.
\r\r\r\r
In accordance with ASC 850, the Company’s\rfinancial statements include disclosures of material related party transactions, other than compensation arrangements, expense\rallowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation\rof financial statements.
\r\r\r\r
Comprehensive Income
\r\r\r\r
The Company reports comprehensive income and\rits components following guidance set forth by ASC 220, Comprehensive Income, which establishes standards for the reporting\rand display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive\rincome applicable to the Company during the period covered in the financial statements.
\r\r\r\r
Earnings Per Share
\r\r\r\r
Earnings per common share is computed pursuant\rto ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average number\rof shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the\rsum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive\rsecurities during the period.
\r\r\r\r
As of December 31, 2019 and 2018, there were\r18,051,357 and 18,916,211, respectively, of potentially dilutive securities in the form of outstanding options and warrants. Also\ras of such dates, there were (i) $10.0 million and $8.6 million, respectively, of outstanding convertible debentures payable, and\r(ii) $350,000 of outstanding convertible promissory notes in both years, that were potentially dilutive, whose conversion into\rcommon stock is based on a discount to the market value of common stock on or about the future conversion date.
\r\r\r\r
For the years ended December 31, 2019 and 2018,\rall potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded\rfrom the diluted net income per share calculations, resulting in identical basic and fully diluted net income per share for these\rperiods. The potentially dilutive securities may dilute earnings per share in the future.
\r\r\r\r
Commitments and Contingencies
\r\r\r\r
The Company follows ASC 450, Contingencies,\rwhich requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or\rmore future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from\rlegal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief\rsought or expected to be sought.
\r\r\r\r
If the assessment of a contingency indicates\rthat it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated\rliability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material\rloss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent\rliability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies\rconsidered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.
\r\r\r\r
While not assured, management does not believe,\rbased upon information available at this time, that a loss contingency will have material adverse effect on the Company’s\rfinancial position, results of operations or cash flows.
\r\r\r\r
Beneficial Conversion Features on Convertible\rDebt
\r\r\r\r
Convertible instruments\rthat are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging, and not accounted for as a separate\requity component under the cash conversion guidance are evaluated to determine whether their conversion prices create an embedded\rbeneficial conversion feature at inception, or may become beneficial in the future due to potential adjustments.
\r\r\r\r
A beneficial conversion feature is a nondetachable\rconversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic\rvalue of the option, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it\ris attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full\ror partial conversions of the debt.
\r\r\r\r
Risk and Uncertainties
\r\r\r\r
The Company is subject to risks common to companies\roperating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations\rand jurisdictional laws.
\r\r\r\r
Noncontrolling Interests
\r\r\r\r
Noncontrolling interests represent third-party\rminority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown\rin the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a\rcomponent of equity within the balance sheets.
\r\r\r\r
Off Balance Sheet Arrangements
\r\r\r\r
The Company does not have any off-balance sheet\rarrangements.
\r\r\r\r
Recent Accounting Pronouncements
\r\r\r\r
In January\r2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) which simplifies goodwill impairment testing\rby requiring that such periodic testing be performed by comparing the fair value of a reporting unit with its carrying amount and\rrecognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. The\rCompany is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures, which\ris effective for fiscal years, including interim periods, beginning after December 15, 2019.
\r\r\r\r
In addition to the above, the Company has\rreviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption\rof any such pronouncements will have a material impact on its financial condition or the results of its operations.
"}]},{"name":"rpt:f-342","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4235469","decimals":0}]},{"name":"rpt:f-343","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"5569908","decimals":0}]},{"name":"rpt:f-344","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5569908","decimals":0}]},{"name":"rpt:f-345","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"}},{"name":"rpt:f-346","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"}},{"name":"rpt:f-347","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"4235469","decimals":0}]},{"name":"rpt:f-348","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:RetainedEarningsMember"}},{"name":"rpt:f-349","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:NoncontrollingInterestMember"}},{"name":"rpt:f-350","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNoteMember"},"factValues":[{"value":"7590000","decimals":0}]},{"name":"rpt:f-351","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNoteMember"},"factValues":[{"value":"1047000","decimals":0}]},{"name":"rpt:f-352","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities","xbrl:period":"2019-05-01T00:00:00/2019-06-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:TerraceIncMember"},"factValues":[{"value":"1590000","decimals":0}]},{"name":"rpt:f-353","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNoteMember"},"factValues":[{"value":"3827373"}]},{"name":"rpt:f-354","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNoteMember"},"factValues":[{"value":"2435116"}]},{"name":"rpt:f-355","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities","xbrl:period":"2019-05-01T00:00:00/2019-06-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:TerraceIncMember"},"factValues":[{"value":"500000"}]},{"name":"rpt:f-356","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromNotesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"19760000","decimals":0}]},{"name":"rpt:f-357","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromNotesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3206338","decimals":0}]},{"name":"rpt:f-358","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromNotesPayable","xbrl:period":"2019-06-02T00:00:00/2019-07-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SecuredPromissoryNotesMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember","us-gaap:TypeOfArrangementAxis":"MRMD:TenMillionNoteMember"},"factValues":[{"value":"10000000","decimals":0}]},{"name":"rpt:f-359","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromNotesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","srt:TitleOfIndividualAxis":"MRMD:IndividualsAndAccreditedInvestorsMember"},"factValues":[{"value":"2760000","decimals":0}]},{"name":"rpt:f-360","factDimensions":{"xbrl:concept":"MRMD:DebtCollectibleReserve","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:ConcentrationRiskByBenchmarkAxis":"us-gaap:AccountsReceivableMember"},"factValues":[{"value":"150000","decimals":0}]},{"name":"rpt:f-361","factDimensions":{"xbrl:concept":"MRMD:DebtCollectibleReserve","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:ConcentrationRiskByBenchmarkAxis":"us-gaap:AccountsReceivableMember"},"factValues":[{"value":"10700000","decimals":0}]},{"name":"rpt:f-362","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentUsefulLife","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:BuildingAndBuildingImprovementsMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"P7Y"}]},{"name":"rpt:f-363","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentUsefulLife","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"MRMD:BuildingsandBuildingImprovementsMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"P39Y"}]},{"name":"rpt:f-364","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentUsefulLife","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:FurnitureAndFixturesMember"},"factValues":[{"value":"P7Y"}]},{"name":"rpt:f-365","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentUsefulLife","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:MachineryAndEquipmentMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"P5Y"}]},{"name":"rpt:f-366","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentUsefulLife","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"us-gaap:MachineryAndEquipmentMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"P10Y"}]},{"name":"rpt:f-367","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"MRMD:TenantImprovementsMember"},"factValues":[{"value":"The remaining duration of the related lease."}]},{"name":"rpt:f-368","factDimensions":{"xbrl:concept":"us-gaap:AssetImpairmentCharges","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-369","factDimensions":{"xbrl:concept":"us-gaap:AssetImpairmentCharges","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-370","factDimensions":{"xbrl:concept":"us-gaap:UnrecognizedTaxBenefits","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-371","factDimensions":{"xbrl:concept":"us-gaap:UnrecognizedTaxBenefits","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-372","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:OptionsAndWarrantsMember"},"factValues":[{"value":"18916211"}]},{"name":"rpt:f-373","factDimensions":{"xbrl:concept":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis":"MRMD:OptionsAndWarrantsMember"},"factValues":[{"value":"18051357"}]},{"name":"rpt:f-374","factDimensions":{"xbrl:concept":"MRMD:PotentiallyDilutiveSecuritiesAmount","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ConvertiblePromissoryNotesMember"},"factValues":[{"value":"350000","decimals":0}]},{"name":"rpt:f-375","factDimensions":{"xbrl:concept":"MRMD:PotentiallyDilutiveSecuritiesAmount","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ConvertibleDebenturesPayableMember"},"factValues":[{"value":"8600000","decimals":0}]},{"name":"rpt:f-376","factDimensions":{"xbrl:concept":"MRMD:PotentiallyDilutiveSecuritiesAmount","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ConvertiblePromissoryNotesMember"},"factValues":[{"value":"350000","decimals":0}]},{"name":"rpt:f-377","factDimensions":{"xbrl:concept":"MRMD:PotentiallyDilutiveSecuritiesAmount","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ConvertibleDebenturesPayableMember"},"factValues":[{"value":"10000000","decimals":0}]},{"name":"rpt:f-378","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"760000"}]},{"name":"rpt:f-379","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:ThreeIndependentBoardMembersMember"},"factValues":[{"value":"100000"}]},{"name":"rpt:f-380","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.08"}]},{"name":"rpt:f-381","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"0.63"}]},{"name":"rpt:f-382","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.08"}]},{"name":"rpt:f-383","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"0.77"}]},{"name":"rpt:f-384","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:OwnershipAxis":"MRMD:IconicVenturesIncMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"0.10"}]},{"name":"rpt:f-385","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2018-09-01T00:00:00","xbrl:entity":"cik:0001522767","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"0.23"}]},{"name":"rpt:f-386","factDimensions":{"xbrl:concept":"us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2662669","decimals":0}]},{"name":"rpt:f-387","factDimensions":{"xbrl:concept":"us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit","xbrl:period":"2018-11-29T00:00:00/2018-12-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"732000","decimals":0}]},{"name":"rpt:f-388","factDimensions":{"xbrl:concept":"us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1331785","decimals":0}]},{"name":"rpt:f-389","factDimensions":{"xbrl:concept":"us-gaap:IntangibleAssetsNetExcludingGoodwill","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember","us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis":"MRMD:CannabisLicensesMember"},"factValues":[{"value":"138000","decimals":0}]},{"name":"rpt:f-390","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued","xbrl:period":"2018-04-01T00:00:00/2018-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:IRollieLLCMember","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember"},"factValues":[{"value":"264317"}]},{"name":"rpt:f-391","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"520000"}]},{"name":"rpt:f-392","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued","xbrl:period":"2018-04-01T00:00:00/2018-05-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:IRollieLLCMember"},"factValues":[{"value":"264317"}]},{"name":"rpt:f-393","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGOfAnnaLLCAndMariHoldingsMDLLCMember"},"factValues":[{"value":"1000000"}]},{"name":"rpt:f-394","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable","xbrl:period":"2018-12-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:IRollieLLCMember"},"factValues":[{"value":"280000","decimals":0}]},{"name":"rpt:f-395","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2018-08-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:AgriMedIndustriesOfPALLCMember","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember"},"factValues":[{"value":"1.00"}]},{"name":"rpt:f-396","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2018-12-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:TheHarvestFoundationLLCMember"},"factValues":[{"value":"1.00"}]},{"name":"rpt:f-397","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2018-11-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember"},"factValues":[{"value":"1.00"}]},{"name":"rpt:f-398","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2019-06-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:TerraceIncMember"},"factValues":[{"value":"0.0895"}]},{"name":"rpt:f-399","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2019-06-02T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"0.70"}]},{"name":"rpt:f-400","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2020-06-02T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:PurchaseAgreementMember","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"0.30"}]},{"name":"rpt:f-401","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2019-10-03T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember"},"factValues":[{"value":"1.00"}]},{"name":"rpt:f-402","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:AtaloHoldingsIncMember"},"factValues":[{"value":"0.25"}]},{"name":"rpt:f-403","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"519750","decimals":0}]},{"name":"rpt:f-404","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember"},"factValues":[{"value":"113825","decimals":0}]},{"name":"rpt:f-405","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"21000","decimals":0}]},{"name":"rpt:f-406","factDimensions":{"xbrl:concept":"us-gaap:Goodwill","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:IRollieLLCMember"},"factValues":[{"value":"266682","decimals":0}]},{"name":"rpt:f-407","factDimensions":{"xbrl:concept":"us-gaap:Goodwill","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"731902","decimals":0}]},{"name":"rpt:f-408","factDimensions":{"xbrl:concept":"us-gaap:Goodwill","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"2662669","decimals":0}]},{"name":"rpt:f-409","factDimensions":{"xbrl:concept":"us-gaap:Goodwill","xbrl:period":"2019-06-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"2700000","decimals":0}]},{"name":"rpt:f-410","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:IRollieLLCMember"},"factValues":[{"value":"13494","decimals":0}]},{"name":"rpt:f-411","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"64196","decimals":0}]},{"name":"rpt:f-412","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember"},"factValues":[{"value":"443980","decimals":0}]},{"name":"rpt:f-413","factDimensions":{"xbrl:concept":"MRMD:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLicenses","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"185000","decimals":0}]},{"name":"rpt:f-414","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"120689","decimals":0}]},{"name":"rpt:f-415","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"777","decimals":0}]},{"name":"rpt:f-416","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember"},"factValues":[{"value":"642033","decimals":0}]},{"name":"rpt:f-417","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"92765","decimals":0}]},{"name":"rpt:f-418","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember"},"factValues":[{"value":"1020850","decimals":0}]},{"name":"rpt:f-419","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"7454","decimals":0}]},{"name":"rpt:f-420","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:IRollieLLCMember"},"factValues":[{"value":"280176","decimals":0}]},{"name":"rpt:f-421","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:ARLHealthcareIncMember"},"factValues":[{"value":"724448","decimals":0}]},{"name":"rpt:f-422","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"3251200","decimals":0}]},{"name":"rpt:f-423","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"1568","decimals":0}]},{"name":"rpt:f-424","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"1092748","decimals":0}]},{"name":"rpt:f-425","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1904316","decimals":0}]},{"name":"rpt:f-426","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2019-02-01T00:00:00/2019-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:GenCannaGlobalIncMember"},"factValues":[{"value":"229000","decimals":0}]},{"name":"rpt:f-427","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember"}},{"name":"rpt:f-428","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2018-12-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember"},"factValues":[{"value":"1075000","decimals":0}]},{"name":"rpt:f-429","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember"},"factValues":[{"value":"2500000","decimals":0}]},{"name":"rpt:f-430","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentAmount1","xbrl:period":"2020-01-01T00:00:00/2020-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:DebtInstrumentAxis":"MRMD:TwentyMillionDebenturesMember"},"factValues":[{"value":"1000000","decimals":0}]},{"name":"rpt:f-431","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestments","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"43000","decimals":0}]},{"name":"rpt:f-432","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentQuotedMarketValue","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"1172000","decimals":0}]},{"name":"rpt:f-433","factDimensions":{"xbrl:concept":"us-gaap:EquityMethodInvestmentQuotedMarketValue","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"1067000","decimals":0}]},{"name":"rpt:f-434","factDimensions":{"xbrl:concept":"MRMD:NumberOfSharesPurchasedDuringPeriod","xbrl:period":"2018-12-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:BusinessAcquisitionAxis":"MRMD:IconicVenturesIncMember"},"factValues":[{"value":"2500000"}]},{"name":"rpt:f-435","factDimensions":{"xbrl:concept":"us-gaap:AccountsAndNotesReceivableNet","xbrl:period":"2019-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:ChoozeCorpMember"},"factValues":[{"value":"258000","decimals":0}]},{"name":"rpt:f-436","factDimensions":{"xbrl:concept":"MRMD:ImpairmentChargesOnInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:ChoozeCorpMember"}},{"name":"rpt:f-437","factDimensions":{"xbrl:concept":"MRMD:NonRefundablePayment","xbrl:period":"2018-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:VitiprintsMember","us-gaap:TypeOfArrangementAxis":"MRMD:LicensingAgreementMember"},"factValues":[{"value":"250000","decimals":0}]},{"name":"rpt:f-438","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"stpr:NV"},"factValues":[{"value":"Expiring in 2024."}]},{"name":"rpt:f-439","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MA","srt:ProductOrServiceAxis":"MRMD:NonCannabisMember"},"factValues":[{"value":"Expires in 2022"}]},{"name":"rpt:f-440","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MD","MRMD:LeaseContractualTermAxis":"MRMD:OperatingLeaseCommitmentsMember"},"factValues":[{"value":"Expires in July 2020 with an option to renew for a two-year term."}]},{"name":"rpt:f-441","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:DE"},"factValues":[{"value":"Expires in 2035"}]},{"name":"rpt:f-442","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MD"},"factValues":[{"value":"Expires in 2037"}]},{"name":"rpt:f-443","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","MRMD:LeaseContractualTermAxis":"MRMD:FinanceLeaseCommitmentsMember","us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis":"MRMD:MachineryMember"},"factValues":[{"value":"Expire in February 2022 through June 2024"}]},{"name":"rpt:f-444","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-03-30T00:00:00/2019-04-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:DE"},"factValues":[{"value":"The lease term is 10 years, with an option to extend the term for three additional five-year periods."}]},{"name":"rpt:f-445","factDimensions":{"xbrl:concept":"MRMD:LeaseExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MA"},"factValues":[{"value":"Expiring in 2028"}]},{"name":"rpt:f-446","factDimensions":{"xbrl:concept":"us-gaap:ContractWithCustomerLiabilityRevenueRecognized","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"11300000","decimals":0}]},{"name":"rpt:f-447","factDimensions":{"xbrl:concept":"us-gaap:ContractWithCustomerLiabilityRevenueRecognized","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7500000","decimals":0}]},{"name":"rpt:f-448","factDimensions":{"xbrl:concept":"us-gaap:LoansAndLeasesReceivableDeferredIncome","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2100000","decimals":0}]},{"name":"rpt:f-449","factDimensions":{"xbrl:concept":"us-gaap:LoansAndLeasesReceivableDeferredIncome","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1800000","decimals":0}]},{"name":"rpt:f-450","factDimensions":{"xbrl:concept":"MRMD:PaymentForPurchaseOfInventory","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"20750000","decimals":0}]},{"name":"rpt:f-451","factDimensions":{"xbrl:concept":"MRMD:PaymentForPurchaseOfInventory","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember"},"factValues":[{"value":"21600000","decimals":0}]},{"name":"rpt:f-452","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"686104"}]},{"name":"rpt:f-453","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2018-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"750000"}]},{"name":"rpt:f-454","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantOneMember"},"factValues":[{"value":"10606211"}]},{"name":"rpt:f-455","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:WarrantMember"},"factValues":[{"value":"2300237"}]},{"name":"rpt:f-456","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:WarrantOneMember"},"factValues":[{"value":"11780107"}]},{"name":"rpt:f-457","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ConvertibleDebenturesMember","srt:TitleOfIndividualAxis":"MRMD:AdditionalTenMillionHolderMember"},"factValues":[{"value":"550000"}]},{"name":"rpt:f-458","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2018-12-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:TwoOwnersMember","us-gaap:BusinessAcquisitionAxis":"MRMD:TheHarvestFoundationLLCMember"},"factValues":[{"value":"400000"}]},{"name":"rpt:f-459","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:SecuredPromissoryNotesMember","dei:LegalEntityAxis":"MRMD:MariMedHempIncMember","us-gaap:TypeOfArrangementAxis":"MRMD:TenMillionNoteMember"},"factValues":[{"value":"375000"}]},{"name":"rpt:f-460","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ConvertibleDebenturesMember","srt:TitleOfIndividualAxis":"MRMD:AdditionalTenMillionHolderMember","us-gaap:StatementEquityComponentsAxis":"MRMD:AdditionalWarrantsMember"},"factValues":[{"value":"300000"}]},{"name":"rpt:f-461","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TenMillionNoteMember"},"factValues":[{"value":"375000"}]},{"name":"rpt:f-462","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TwentyMillionDebenturesMember"},"factValues":[{"value":"850000"}]},{"name":"rpt:f-463","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TwentyMillionDebenturesMember"},"factValues":[{"value":"324675"}]},{"name":"rpt:f-464","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ThreeMillionNoteMember"},"factValues":[{"value":"750000"}]},{"name":"rpt:f-465","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TwentyMillionDebenturesTenMillionNoteAndThreeMillionNoteMember","us-gaap:ShortTermDebtTypeAxis":"MRMD:PromissoryNoteMember"},"factValues":[{"value":"10000"}]},{"name":"rpt:f-466","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:TwentyMillionDebenturesTenMillionNoteAndThreeMillionNoteMember","us-gaap:ShortTermDebtTypeAxis":"MRMD:PromissoryNoteMember"},"factValues":[{"value":"237500"}]},{"name":"rpt:f-467","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:ThreeYearAndFiveYearWarrantsMember"},"factValues":[{"value":"6098962"}]},{"name":"rpt:f-468","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:StandAloneWarrantsWarrantsMember"},"factValues":[{"value":"1250000"}]},{"name":"rpt:f-469","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"MRMD:StandAloneWarrantsWarrantsMember"},"factValues":[{"value":"625000"}]},{"name":"rpt:f-470","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:SecuritiesPurchaseAgreementMember","us-gaap:DebtInstrumentAxis":"MRMD:TwentyMillionDebenturesMember"},"factValues":[{"value":"180000"}]},{"name":"rpt:f-471","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMeasurementInput","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"MRMD:Integer","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputExpectedDividendRateMember"},"factValues":[{"value":"0.00"}]},{"name":"rpt:f-472","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentMeasurementInput","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputExpectedDividendRateMember"},"factValues":[{"value":"0.00"}]},{"name":"rpt:f-473","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesIssued","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"}},{"name":"rpt:f-474","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesIssued","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"}},{"name":"rpt:f-475","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesOutstanding","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"}},{"name":"rpt:f-476","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesOutstanding","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares"}},{"name":"rpt:f-477","factDimensions":{"xbrl:concept":"MRMD:PercentageOfSpaceOccupied","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:DE"},"factValues":[{"value":"1.00"}]},{"name":"rpt:f-478","factDimensions":{"xbrl:concept":"MRMD:ContractedCashInvestment","xbrl:period":"2018-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-479","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2019-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:HighFidelityIncMember"},"factValues":[{"value":"250000","decimals":0}]},{"name":"rpt:f-480","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2019-02-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:MarylandHealthAndWellnessCenterIncMember","us-gaap:ShortTermDebtTypeAxis":"MRMD:ConstructionLoanMember"},"factValues":[{"value":"300000","decimals":0}]},{"name":"rpt:f-481","factDimensions":{"xbrl:concept":"us-gaap:DueToRelatedPartiesCurrentAndNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:AtaloHoldingsIncMember"},"factValues":[{"value":"980000","decimals":0}]},{"name":"rpt:f-482","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDebtTableTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rAt December 31, 2019 and 2018, mortgage\rbalances, including accrued but unpaid interest, were comprised of the following:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Bank of New England – Massachusetts property | \r\r | $ | \r4,825,226 | \r\r | \r | $ | \r4,895,000 | \r|
| Bank of New England – Delaware property | \r\r | \r | 1,682,275 | \r\r | \r | \r | 1,791,736 | \r|
| DuQuoin State Bank – Illinois properties | \r\r | \r | 829,229 | \r\r | \r | \r | 850,076 | \r|
| Total mortgages payable | \r\r | \r | 7,336,730 | \r\r | \r | \r | 7,536,812 | \r|
| Mortgages payable, current portion | \r\r | \r | (223,889 | \r) | \r\r | \r | (188,231 | \r) |
| Mortgages payable, less current portion | \r\r | $ | \r7,112,842 | \r\r | \r | $ | \r7,348,581 | \r
Future minimum lease payments as of December\r31, 2019 under all non-cancelable leases having an initial or remaining term of more than one year were:
\r\r\r\r
| \r | \r | \r Operating \rLeases | \r \r | \r | \r Finance \rLease | \r |||
| 2020 | \r\r | $ | \r917,444 | \r\r | \r | $ | \r38,412 | \r|
| 2021 | \r\r | \r | 1,008,227 | \r\r | \r | \r | 38,412 | \r|
| 2022 | \r\r | \r | 949,535 | \r\r | \r | \r | 27,123 | \r|
| 2023 | \r\r | \r | 910,166 | \r\r | \r | \r | 23,201 | \r|
| 2024 | \r\r | \r | 835,411 | \r\r | \r | \r | 3,229 | \r|
| Thereafter | \r\r | \r | 4,304,441 | \r\r | \r | \r | - | \r|
| Total lease payments | \r\r | \r | 8,925,223 | \r\r | \r | $ | \r130,377 | \r|
| Less: imputed interest | \r\r | \r | (2,608,366 | \r) | \r\r | \r | (16,552 | \r) |
| \r | \r | $ | \r6,316,857 | \r\r | \r | $ | \r113,825 | \r
Future minimum rental receipts for non-cancelable\rleases and subleases as of December 31, 2019 were:
\r\r\r\r
| 2020 | \r\r | $ | \r3,896,550 | \r|
| 2021 | \r\r | \r | 4,036,550 | \r|
| 2022 | \r\r | \r | 3,959,709 | \r|
| 2023 | \r\r | \r | 3,661,821 | \r|
| 2024 | \r\r | \r | 3,717,080 | \r|
| Thereafter | \r\r | \r | 40,404,470 | \r|
| Total | \r\r | $ | \r59,676,179 | \r
Basis of Presentation
\r\r\r\r
The accompanying financial statements have\rbeen prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
\r\r\r\r
Certain reclassifications have been made to\rprior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income\r(losses) or cash flows.
\r\r\r\r"}]},{"name":"rpt:f-1044","factDimensions":{"xbrl:concept":"us-gaap:ConsolidationPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rPrinciples of Consolidation
\r\r\r\r
The accompanying condensed consolidated financial\rstatements include the accounts of MariMed Inc. and the following majority-owned subsidiaries:
\r\r\r\r
| Subsidiary: | \r\r | Percentage \rOwned | \r ||
| MariMed Advisors Inc. | \r\r | \r | 100.0 | \r% |
| Mia Development LLC | \r\r | \r | 89.5 | \r% |
| Mari Holdings IL LLC | \r\r | \r | 100.0 | \r% |
| Mari Holdings MD LLC | \r\r | \r | 97.4 | \r% |
| Mari Holdings NV LLC | \r\r | \r | 100.0 | \r% |
| Hartwell Realty Holdings LLC | \r\r | \r | 100.0 | \r% |
| iRollie LLC | \r\r | \r | 100.0 | \r% |
| ARL Healthcare Inc. | \r\r | \r | 100.0 | \r% |
| KPG of Anna LLC | \r\r | \r | 100.0 | \r% |
| KPG of Harrisburg LLC | \r\r | \r | 100.0 | \r% |
| MariMed Hemp Inc. | \r\r | \r | 100.0 | \r% |
| MediTaurus LLC | \r\r | \r | 70.0 | \r% |
\r\r
Intercompany accounts and transactions have\rbeen eliminated.
"}]},{"name":"rpt:f-1045","factDimensions":{"xbrl:concept":"us-gaap:UseOfEstimates","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rUse of Estimates
\r\r\r\r
The preparation of financial statements in\rconformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial\rstatements and disclosures thereof. Actual results could differ from these estimates or assumptions.
"}]},{"name":"rpt:f-1046","factDimensions":{"xbrl:concept":"us-gaap:CashAndCashEquivalentsPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rCash Equivalents
\r\r\r\r
The Company considers all highly liquid investments\rwith a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying\rvalues.
\r\r\r\r
The Company’s cash and cash equivalents\rare maintained with recognized financial institutions located in the United States. In the normal course of business, the Company\rmay carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses\ron balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard.
"}]},{"name":"rpt:f-1047","factDimensions":{"xbrl:concept":"us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rAccounts Receivable
\r\r\r\r
Accounts receivable consist of trade receivables\rand are carried at their estimated collectible amounts.
\r\r\r\r
The Company provides credit to its clients\rin the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining\ra reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding\rbalances with consideration towards such client’s historical collection experience, as well as prevailing economic and market\rconditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $10.7 million and $150,000\rat December 31, 2019 and 2018, respectively. The 2019 reserve primarily consisted of reserves against the accounts receivable\rbalances of Kind of approximately $9.7 million and Harvest of approximately $239,000, as further disclosed in Note 17 –\rBad Debts.
"}]},{"name":"rpt:f-1048","factDimensions":{"xbrl:concept":"us-gaap:InventoryPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rInventory
\r\r\r\r
Inventory is carried at the lower of cost\ror net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain\rpercentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard\rcriteria. The Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of\rthe date of this report, no reserve was deemed necessary.
"}]},{"name":"rpt:f-1049","factDimensions":{"xbrl:concept":"us-gaap:InvestmentPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rInvestments
\r\r\r\r
Investments are comprised of equity holding\rof private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes\rto fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments\rare deemed to have occurred.
"}]},{"name":"rpt:f-1050","factDimensions":{"xbrl:concept":"us-gaap:RevenueFromContractWithCustomerPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rRevenue Recognition
\r\r\r\r
On January 1, 2018, the Company adopted the\rFinancial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract\rwith Customers, as amended by subsequently issued Accounting Standards Updates. This revenue standard requires an entity\rto recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that\rit expects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the\rfollowing consecutive steps:
\r\r\r\r
| \r | ● | \rIdentify the contract(s) with a customer; |
| \r | ● | \rIdentify the performance obligations in the contract(s); |
| \r | ● | \rDetermine the transaction price; |
| \r | ● | \rAllocate the transaction price to the performance obligations in the contract(s); and |
| \r | ● | \rRecognize revenue as the performance obligation is satisfied. |
\r\r
Additionally, when another party is involved\rin providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other\rparty—is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging for goods\ror services to be provided by the other party.
\r\r\r\r
The Company is typically considered the principal\rif it controls the specified good or service before such good or service is transferred to its client. The Company may also be\rdeemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf,\rprovided the Company (i) takes on certain responsibilities, obligations and risks, (ii) possesses certain abilities and discretion,\ror (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance\robligations it does not satisfy.
\r\r\r\r
The adoption of this standard did not have\ra significant impact on the Company’s consolidated operating results, and accordingly no restatement has been made to prior\rperiod reported amounts.
\r\r\r\r
The Company’s main sources of revenue\rare comprised of the following:
\r\r\r\r
| \r | ● | \rReal Estate – rental income and additional rental fees from leasing of the Company’s regulatory-compliant cannabis facilities to its clients, which are cannabis-licensed operating companies. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed a specified amount. |
| \r | \r | |
| \r | ● | \rManagement – fees for providing the Company’s cannabis clients with corporate services and operational oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue, and are recognized after services have been performed. |
| \r | \r | |
| \r | ● | \rSupply Procurement – the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies, and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser. |
| \r | \r | |
| \r | ● | \rLicensing – revenue from the sale of precision-dosed, cannabis-infused products, such as Kalm Fusion™ and Betty’s Eddies™, to legal dispensaries throughout the United States. The recognition of this revenue occurs when the products are delivered. |
| \r | \r | |
| \r | ● | \rConsulting – fees from third-parties where the Company provides assistance in securing cannabis licenses, and advisory services in the areas of facility design and development, and cultivation and dispensing best practices. These fees are recognized as the services are performed. |
| \r | \r | |
| \r | ● | \rProduct Sales – direct sales of cannabis, hemp, and products derived from these plants. During 2019, such revenue was generated from (i) the post-acquisition dispensary operations of both ARL in Massachusetts and the KPGs in Illinois, and (ii) the sales of hemp and CBD products by MariMed Hemp and MediTaurus. This revenue is recognized when products are delivered or at retail points-of-sale. |
Research and Development Costs
\r\r\r\r
Research and development costs are charged\rto operations as incurred.
"}]},{"name":"rpt:f-1052","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rProperty and Equipment
\r\r\r\r
Property and equipment are stated at cost less\raccumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of\rthe asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed\rfrom the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in\rthe period incurred.
\r\r\r\r
The estimated useful lives of property and\requipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining\rduration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.
\r\r\r\r
The Company’s property and equipment\rare individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset\rmay not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment\rloss is measured by the excess of the asset’s carrying amount over its estimated fair value.
\r\r\r\r
Impairment analyses are based on management’s\rcurrent plans, asset holding periods, and currently available market information. If these criteria change, the Company’s\revaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.
\r\r\r\r
For the years ended December 31, 2019\rand 2018, based on the results of management’s impairment analyses, there were no impairment losses.
"}]},{"name":"rpt:f-1053","factDimensions":{"xbrl:concept":"us-gaap:LesseeLeasesPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rLeases
\r\r\r\r
The consolidated financial\rstatements reflect the Company’s adoption of ASC 842, Leases, as amended by subsequent accounting standards updates,\rutilizing the modified retrospective transition approach which calls for applying the new standard to all of the Company’s\rleases effective January 1, 2019, which is the effective date of adoption.
\r\r\r\r
ASC 842 is intended to improve financial reporting\rof leasing transactions. The most prominent change from previous accounting guidance is the requirement to recognize right-of-use\rassets and lease liabilities on the consolidated balance sheet representing the rights and obligations created by operating leases\rthat extend more than twelve months in which the Company is the lessee. The Company elected the package of practical expedients\rpermitted under ASC 842. Accordingly, the Company accounted for its existing operating leases that commenced before the effective\rdate as operating leases under the new guidance without reassessing (i) whether the contracts contain a lease, (ii) the classification\rof the leases (iii) the accounting for indirect costs as defined in ASC 842.
\r\r\r\r
The Company determines if an arrangement is\ra lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and\rlease liabilities represent the Company’s obligation to make lease payments arising from the lease. Non-lease components\rwithin lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date\rbased on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The\rCompany’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company\rwill exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
"}]},{"name":"rpt:f-1054","factDimensions":{"xbrl:concept":"us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rImpairment of Long-Lived Assets
\r\r\r\r
The Company evaluates the recoverability of\rits fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment\rof long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the\rassets are written down to fair value, which is determined based on discounted future cash flows or appraised values.
"}]},{"name":"rpt:f-1055","factDimensions":{"xbrl:concept":"us-gaap:FairValueOfFinancialInstrumentsPolicy","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rFair Value of Financial Instruments
\r\r\r\r
The Company follows the provisions of ASC 820, Fair\rValue Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for\rdisclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements\rand related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to\rmeasure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in\ractive markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value\rhierarchy defined by ASC 820 are:
\r\r\r\r
| Level 1 | \rQuoted market prices available in active markets for identical assets or liabilities as of the reporting date. |
| \r | |
| Level 2 | \rPricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. |
| \r | |
| Level 3 | \rPricing inputs that are generally observable inputs and not corroborated by market data. |
\r\r
The carrying amounts of the Company’s\rfinancial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of\rthese instruments.
\r\r\r\r
The fair value of option and warrant issuances\rare determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the\rexercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock\ron issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by\rthe Company during the prior two fiscal years:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Life of instrument | \r\r | \r | 1.5 to 4.0 years | \r\r | \r | \r | 0.5 to 5.0 years | \r|
| Volatility factors | \r\r | \r | 1.039 to 1.106 | \r\r | \r | \r | 1.019 to 2.086 | \r|
| Risk-free interest rates | \r\r | \r | 1.42% to 2.28% | \r\r | \r | \r | 1.65% to 3.07% | \r|
| Dividend yield | \r\r | \r | 0% | \r\r | \r | \r | 0% | \r
\r\r
The expected life of an instrument is calculated\rusing the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment, which allows for using\rthe mid-point between the vesting date and expiration date. The volatility factors are based on the historical two-year movement\rof the Company’s common stock prior to an instrument’s issuance date. The risk-free interest rate is based on U.S.\rTreasury rates with maturity periods similar to the expected instruments life on the issuance date.
\r\r\r\r
The Company amortizes the fair value of option\rand warrant issuances on a straight-line basis over the requisite service period of each instrument.
"}]},{"name":"rpt:f-1056","factDimensions":{"xbrl:concept":"MRMD:ExtinguishmentOfLiabilitiesPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rExtinguishment of Liabilities
\r\r\r\r
The Company accounts for extinguishment of\rliabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions for extinguishment\rare met, the liabilities are written down to zero and a gain or loss is recognized.
"}]},{"name":"rpt:f-1057","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rStock-Based Compensation
\r\r\r\r
The Company accounts for stock-based compensation\rusing the fair value method as set forth in ASC 718, Compensation—Stock Compensation, which requires a\rpublic entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the\raward on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee\ris required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity\rawards for which employees do not render the requisite service.
"}]},{"name":"rpt:f-1058","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rIncome Taxes
\r\r\r\r
The Company accounts for income taxes in accordance\rwith ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between\rthe financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will\rbe in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent\rmanagement concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities\rof a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.
\r\r\r\r
ASC 740 prescribes a comprehensive model for\rhow companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or\rexpected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized\rincome tax liabilities or benefits for the years ended December 31, 2019 and 2018.
"}]},{"name":"rpt:f-1059","factDimensions":{"xbrl:concept":"MRMD:RelatedPartyTransactionsPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rRelated Party Transactions
\r\r\r\r
The Company follows ASC 850, Related\rParty Disclosures, for the identification of related parties and disclosure of related party transactions.
\r\r\r\r
In accordance with ASC 850, the Company’s\rfinancial statements include disclosures of material related party transactions, other than compensation arrangements, expense\rallowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation\rof financial statements.
"}]},{"name":"rpt:f-1060","factDimensions":{"xbrl:concept":"us-gaap:ComprehensiveIncomePolicyPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rComprehensive Income
\r\r\r\r
The Company reports comprehensive income and\rits components following guidance set forth by ASC 220, Comprehensive Income, which establishes standards for the\rreporting and display of comprehensive income and its components in the consolidated financial statements. There were no items\rof comprehensive income applicable to the Company during the period covered in the financial statements.
"}]},{"name":"rpt:f-1061","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rEarnings Per Share
\r\r\r\r
Earnings per common share is computed pursuant\rto ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average\rnumber of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income\rby the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially\rdilutive securities during the period.
\r\r\r\r
As of December 31, 2019 and 2018,\rthere were 18,051,357 and 18,916,211, respectively, of potentially dilutive securities in the form of outstanding\roptions and warrants. Also as of such dates, there were (i) $10.0 million and $8.6 million, respectively, of outstanding convertible\rdebentures payable, and (ii) $350,000 of outstanding convertible promissory notes in both years, that were potentially\rdilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future\rconversion date.
\r\r\r\r
For the years ended December\r31, 2019 and 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance\rwith ASC 260, were excluded from the diluted net income per share calculations, resulting in identical basic and fully diluted\rnet income per share for these periods. The potentially dilutive securities may dilute earnings per share in the future.
"}]},{"name":"rpt:f-1062","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rCommitments and Contingencies
\r\r\r\r
The Company follows ASC 450, Contingencies,\rwhich requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or\rmore future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from\rlegal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief\rsought or expected to be sought.
\r\r\r\r
If the assessment of a contingency indicates\rthat it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated\rliability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material\rloss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent\rliability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies\rconsidered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.
\r\r\r\r
While not assured, management does not believe,\rbased upon information available at this time, that a loss contingency will have material adverse effect on the Company’s\rfinancial position, results of operations or cash flows.
"}]},{"name":"rpt:f-1063","factDimensions":{"xbrl:concept":"us-gaap:DebtPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rBeneficial Conversion Features on Convertible\rDebt
\r\r\r\r
Convertible instruments\rthat are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging, and not accounted for as a separate\requity component under the cash conversion guidance are evaluated to determine whether their conversion prices create an embedded\rbeneficial conversion feature at inception, or may become beneficial in the future due to potential adjustments.
\r\r\r\r
A beneficial conversion feature is a nondetachable\rconversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic\rvalue of the option, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it\ris attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full\ror partial conversions of the debt.
"}]},{"name":"rpt:f-1064","factDimensions":{"xbrl:concept":"us-gaap:ConcentrationRiskCreditRisk","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rRisk and Uncertainties
\r\r\r\r
The Company is subject to risks common to\rcompanies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government\rregulations and jurisdictional laws.
"}]},{"name":"rpt:f-1065","factDimensions":{"xbrl:concept":"MRMD:NoncontrollingInterestsPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNoncontrolling Interests
\r\r\r\r
Noncontrolling interests represent third-party\rminority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown\rin the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a\rcomponent of equity within the balance sheets.
"}]},{"name":"rpt:f-1066","factDimensions":{"xbrl:concept":"us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rOff Balance Sheet Arrangements
\r\r\r\r
The Company does not have any off-balance\rsheet arrangements.
"}]},{"name":"rpt:f-1067","factDimensions":{"xbrl:concept":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rRecent Accounting Pronouncements
\r\r\r\r
In January\r2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) which simplifies goodwill impairment\rtesting by requiring that such periodic testing be performed by comparing the fair value of a reporting unit with its carrying\ramount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair\rvalue. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures,\rwhich is effective for fiscal years, including interim periods, beginning after December 15, 2019.
\r\r\r\r
In addition to the above, the Company has\rreviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption\rof any such pronouncements will have a material impact on its financial condition or the results of its operations.
"}]},{"name":"rpt:f-1068","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"1.805"}]},{"name":"rpt:f-1069","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"}},{"name":"rpt:f-1070","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.42"}]},{"name":"rpt:f-1071","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"1.95"}]},{"name":"rpt:f-1072","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MinimumMember"},"factValues":[{"value":"0.14"}]},{"name":"rpt:f-1073","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"3.72"}]},{"name":"rpt:f-1074","factDimensions":{"xbrl:concept":"us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:ThreeIndependentBoardMembersMember"},"factValues":[{"value":"189000","decimals":0}]},{"name":"rpt:f-1075","factDimensions":{"xbrl:concept":"us-gaap:LossContingencyDamagesSoughtValue","xbrl:period":"2019-11-10T00:00:00/2019-11-14T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"75000","decimals":0}]},{"name":"rpt:f-1076","factDimensions":{"xbrl:concept":"us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"169123","decimals":0}]},{"name":"rpt:f-1077","factDimensions":{"xbrl:concept":"us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1168074","decimals":0}]},{"name":"rpt:f-1078","factDimensions":{"xbrl:concept":"dei:EntityPublicFloat","xbrl:period":"2019-06-29T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"264700000","decimals":0}]},{"name":"rpt:f-1079","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxDisclosureTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rNOTE\r18 – INCOME TAXES
\r\r\r\r
For the years ended December 31, 2019 and 2018,\rthe Company’s cumulative net operating losses were approximately $26.3 million and $11.6 million, respectively, and\raccordingly a tax provision was not required for the years then ended.
\r\r\r\r
The reconciliations between the Company’s\reffective tax rates and the statutory tax rate for the years ended December 31, 2019 and 2018 were as follows:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| U.S Federal taxes at the statutory rate | \r\r | \r | 21.0 | \r% | \r\r | \r | 21.0 | \r% |
| State taxes net of federal benefit | \r\r | \r | 6.3 | \r% | \r\r | \r | 6.3 | \r% |
| Valuation allowance | \r\r | \r | (27.3 | \r)% | \r\r | \r | (27.3 | \r)% |
| Total | \r\r | \r | 0.0 | \r% | \r\r | \r | 0.0 | \r% |
\r\r
The approximate income tax effect of each type\rof temporary difference and carryforward as of December 31, 2019 and 2018 is as follows:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Deferred tax assets: | \r\r | \r | \r | \r | \r | \r | \r | |
| Net operating loss carryforwards | \r\r | $ | \r26,291,878 | \r\r | \r | $ | \r11,559,576 | \r|
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Deferred tax liabilities: | \r\r | \r | \r | \r | \r | \r | \r | |
| Fixed assets | \r\r | \r | (5,421,341 | \r) | \r\r | \r | (3,529,167 | \r) |
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Net deferred tax asset | \r\r | \r | 20,870,537 | \r\r | \r | \r | 8,030,409 | \r|
| Valuation allowance | \r\r | \r | (20,870,537 | \r) | \r\r | \r | (8,030,409 | \r) |
| Total | \r\r | $ | \r- | \r\r | \r | $ | \r- | \r
\r\r
The Company uses the asset and liability method\rto account for income taxes in accordance with ASC 740, Income Taxes. Under this method, deferred income taxes are\rrecognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities\rat each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the period\rin which these differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce\rdeferred tax assets to the amounts expected to be realized.
\r\r\r\r
The Tax Cuts and Jobs Act (the “TCJA”)\rwas enacted on December 22, 2017. Among other things, the TCJA reduces the U.S. federal corporate tax rate from 35% to 21%, requires\rcompanies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates\rnew taxes on certain foreign sourced earnings.
\r\r\r\r
The one-time transition tax is based on the\rCompany’s total post-1986 earnings and profits (“E&P”) for which the Company has previously deferred from\rU.S. income taxes. As of December 31, 2018, the Company has completed its calculation of the total post-1986 foreign E&P for\rthese foreign subsidiaries. The Company has not recognized any adjustments in its income tax expense for its one-time transition\rtax liability.
\r\r\r\r
The Company has provided a valuation allowance\ragainst its net deferred tax assets at December 31, 2019 and 2018. Based upon the level of historical U.S. earnings and future\rprojections over the period in which the net deferred tax assets are deductible, at this time, management believes it is more likely\rthan not that the Company will not realize the benefits of these deductible differences.
\r\r\r\r
The federal net operating losses carryforward\rindefinitely, subject to an annual limitation of 80% of taxable income. The state net operating losses expire at various dates\rbeginning in 2031. These tax attributes are subject to an annual limitation from equity shifts, which constitute and change of\rownership as defined under IRC Section 382, which will limit their utilization. The Company has not completed a study through December\r31, 2019 to assess whether an ownership change under Section of 382 of the Code has occurred during 2019, due to the costs and\rcomplexities associated with such a study. The Company may have experienced various ownership changes, as defined by the code,\ras a result of financing transactions. Accordingly, the Company’s ability to utilize the aforementioned carryforwards may\rbe limited.
\r\r\r\r
Management assesses the available positive\rand negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets.\rA significant piece of objective negative evidence evaluated was the cumulative losses incurred through the period ended December\r31, 2019. Such objective evidence limits the ability to consider the subjective evidence, such as the Company’s projections\rfor future growth. On the basis of this evaluation, as of December 31, 2019, a valuation allowance has been recorded against all\rnet deferred tax assets as these assets are more likely than not to be unrealized. The amount of the deferred tax asset considered\rrealizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased\ror if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to the\rsubjective evidence such as the Company’s projections for growth.
\r\r\r\r
The Company previously adopted the provision\rfor uncertain tax positions under ASC 740. The adoption did not have an impact on the Company’s retained earnings balance.\rAt December 31, 2019 and 2018, the Company had no recorded liabilities for uncertain tax positions and had no accrued interest\ror penalties related to uncertain tax positions.
\r\r\r\r
The Company files income tax returns in the\rU.S. federal tax jurisdiction and various state jurisdictions. The Company is currently open to examination under the statute\rof limitations by the Internal Revenue Service and state jurisdictions for the tax years ended 2016 through 2019. Since the Company\ris in a U.S. loss carryforward position, carryforward tax attributes generated in prior years may still be adjusted upon future\rexamination if they have or will be used in a future period.
"}]},{"name":"rpt:f-1080","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rThe reconciliations between the Company’s\reffective tax rates and the statutory tax rate for the years ended December 31, 2019 and 2018 were as follows:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| U.S Federal taxes at the statutory rate | \r\r | \r | 21.0 | \r% | \r\r | \r | 21.0 | \r% |
| State taxes net of federal benefit | \r\r | \r | 6.3 | \r% | \r\r | \r | 6.3 | \r% |
| Valuation allowance | \r\r | \r | (27.3 | \r)% | \r\r | \r | (27.3 | \r)% |
| Total | \r\r | \r | 0.0 | \r% | \r\r | \r | 0.0 | \r% |
The approximate income tax effect of each type\rof temporary difference and carryforward as of December 31, 2019 and 2018 is as follows:
\r\r\r\r
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Deferred tax assets: | \r\r | \r | \r | \r | \r | \r | \r | |
| Net operating loss carryforwards | \r\r | $ | \r26,291,878 | \r\r | \r | $ | \r11,559,576 | \r|
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Deferred tax liabilities: | \r\r | \r | \r | \r | \r | \r | \r | |
| Fixed assets | \r\r | \r | (5,421,341 | \r) | \r\r | \r | (3,529,167 | \r) |
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Net deferred tax asset | \r\r | \r | 20,870,537 | \r\r | \r | \r | 8,030,409 | \r|
| Valuation allowance | \r\r | \r | (20,870,537 | \r) | \r\r | \r | (8,030,409 | \r) |
| Total | \r\r | $ | \r- | \r\r | \r | $ | \r- | \r
NOTE 8 – INVENTORY
\r\r\r\r
In 2019, the Company purchased\r$21.6 million of hemp seeds for its wholesale hemp distribution business and to develop hemp-derived CBD products. The seeds meet\rthe U.S. government’s definition of federally legal industrial hemp, which was descheduled as a controlled substance and\rclassified as an agricultural commodity upon the signing of the 2018 U.S. Farm Bill. As previously disclosed in Note 1 –\rOrganization and Description of Business, the Company sold a majority of these seeds to GenCanna, generating\ra related party receivable of $33.2 million which was written off as of December 31, 2019.
\r\r\r\r
At December 31, 2019, inventory\rwas comprised of approximately $226,000 of CBD isolate and hemp extract; approximately $476,000 of work-in-process; and approximately\r$518,000 of finished cannabis and CBD products. At December 31, 2018, inventory was comprised of product packaging and other\rcollateral.
"}]},{"name":"rpt:f-1241","factDimensions":{"xbrl:concept":"us-gaap:NetInvestmentIncome","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:TerraceIncMember"},"factValues":[{"value":"141000","decimals":0}]},{"name":"rpt:f-1242","factDimensions":{"xbrl:concept":"us-gaap:NetInvestmentIncome","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1243","factDimensions":{"xbrl:concept":"MRMD:InvestmentsCurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1244","factDimensions":{"xbrl:concept":"MRMD:InvestmentsCurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1449144","decimals":0}]},{"name":"rpt:f-1245","factDimensions":{"xbrl:concept":"MRMD:InvestmentsCurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:TerraceIncMember"},"factValues":[{"value":"1449144","decimals":0}]},{"name":"rpt:f-1246","factDimensions":{"xbrl:concept":"MRMD:InvestmentsCurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:TerraceIncMember"}},{"name":"rpt:f-1247","factDimensions":{"xbrl:concept":"MRMD:InvestmentsCurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:GenCannaGlobalIncMember"},"factValues":[{"value":"30000000","decimals":0}]},{"name":"rpt:f-1248","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1672163","decimals":0}]},{"name":"rpt:f-1249","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1324661","decimals":0}]},{"name":"rpt:f-1250","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"1172163","decimals":0}]},{"name":"rpt:f-1251","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:IconicVenturesIncMember"},"factValues":[{"value":"500000","decimals":0}]},{"name":"rpt:f-1252","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:GenCannaGlobalIncMember"}},{"name":"rpt:f-1253","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:ChoozeCorpMember"}},{"name":"rpt:f-1254","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:GenCannaGlobalIncMember"}},{"name":"rpt:f-1255","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:OwnershipAxis":"MRMD:CVPWorldwideLLCMember"},"factValues":[{"value":"1066975","decimals":0}]},{"name":"rpt:f-1256","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"MRMD:IconicVenturesIncMember"}},{"name":"rpt:f-1257","factDimensions":{"xbrl:concept":"MRMD:InvestmentsNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:ChoozeCorpMember"},"factValues":[{"value":"257687","decimals":0}]},{"name":"rpt:f-1258","factDimensions":{"xbrl:concept":"MRMD:LeaseCommencementDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MA","srt:ProductOrServiceAxis":"MRMD:NonCannabisMember"},"factValues":[{"value":"Commenced in 2017"}]},{"name":"rpt:f-1259","factDimensions":{"xbrl:concept":"MRMD:LeaseCommencementDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:DE"},"factValues":[{"value":"Commenced in 2017"}]},{"name":"rpt:f-1260","factDimensions":{"xbrl:concept":"MRMD:LeaseCommencementDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:IL"},"factValues":[{"value":"Commenced in 2018"}]},{"name":"rpt:f-1261","factDimensions":{"xbrl:concept":"MRMD:LeaseCommencementDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","srt:StatementGeographicalAxis":"country:MD"},"factValues":[{"value":"Commenced 2018"}]},{"name":"rpt:f-1262","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:KPGOfAnnaLLCMember"},"factValues":[{"value":"2019-10-31"}]},{"name":"rpt:f-1263","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:KPGofHarrisburgLLCMember"},"factValues":[{"value":"2019-10-31"}]},{"name":"rpt:f-1264","factDimensions":{"xbrl:concept":"us-gaap:NetIncomeLossAttributableToNoncontrollingInterest","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-696206","decimals":0}]},{"name":"rpt:f-1265","factDimensions":{"xbrl:concept":"us-gaap:NetIncomeLossAttributableToNoncontrollingInterest","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"295395","decimals":0}]},{"name":"rpt:f-1266","factDimensions":{"xbrl:concept":"us-gaap:NetIncomeLoss","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-81184719","decimals":0}]},{"name":"rpt:f-1267","factDimensions":{"xbrl:concept":"us-gaap:NetIncomeLoss","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-13604068","decimals":0}]},{"name":"rpt:f-1268","factDimensions":{"xbrl:concept":"us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"320702","decimals":0}]},{"name":"rpt:f-1269","factDimensions":{"xbrl:concept":"MRMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValue","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementClassOfStockAxis":"MRMD:CommonStockIssuanceObligationsMember"},"factValues":[{"value":"29000","decimals":0}]},{"name":"rpt:f-1270","factDimensions":{"xbrl:concept":"MRMD:ExchangeOfMembershipPercentageForShares","xbrl:period":"2018-08-01T00:00:00/2018-09-01T00:00:00","xbrl:entity":"cik:0001522767","dei:LegalEntityAxis":"MRMD:MariHoldingsMDLLCMember"},"factValues":[{"value":"0.005"}]},{"name":"rpt:f-1271","factDimensions":{"xbrl:concept":"MRMD:NumberOfSharesReceivedForExchangeOnMembershipInterest","xbrl:period":"2018-08-01T00:00:00/2018-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","dei:LegalEntityAxis":"MRMD:MariHoldingsMDLLCMember"},"factValues":[{"value":"222222"}]},{"name":"rpt:f-1272","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteSubscriptionsReceivable","xbrl:period":"2018-09-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","dei:LegalEntityAxis":"MRMD:MariHoldingsMDLLCMember"},"factValues":[{"value":"25000","decimals":0}]},{"name":"rpt:f-1273","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"200000"}]},{"name":"rpt:f-1274","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"117501"}]},{"name":"rpt:f-1275","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","srt:TitleOfIndividualAxis":"MRMD:BoardMemberMember"},"factValues":[{"value":"1450000"}]},{"name":"rpt:f-1276","factDimensions":{"xbrl:concept":"us-gaap:DueFromOtherRelatedParties","xbrl:period":"2019-10-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:CEOandCFOMember"}},{"name":"rpt:f-1277","factDimensions":{"xbrl:concept":"us-gaap:GainLossOnSaleOfInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-30334503","decimals":0}]},{"name":"rpt:f-1278","factDimensions":{"xbrl:concept":"us-gaap:GainLossOnSaleOfInvestments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-43221","decimals":0}]},{"name":"rpt:f-1279","factDimensions":{"xbrl:concept":"us-gaap:InventoryWorkInProcess","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:ProductOrServiceAxis":"MRMD:CBDIsolateAndHempExtractMember"},"factValues":[{"value":"476000","decimals":0}]},{"name":"rpt:f-1280","factDimensions":{"xbrl:concept":"us-gaap:InventoryFinishedGoods","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:ProductOrServiceAxis":"MRMD:CBDIsolateAndHempExtractMember"},"factValues":[{"value":"518000","decimals":0}]},{"name":"rpt:f-1281","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentPaymentTerms","xbrl:period":"2017-11-01T00:00:00/2017-12-01T00:00:00","xbrl:entity":"cik:0001522767","us-gaap:TypeOfArrangementAxis":"MRMD:MortgageAgreementMember"},"factValues":[{"value":"This mortgage was personally guaranteed by the Company's CEO and CFO. From the mortgage date through May 2019, the Company was required to make monthly payments of interest-only at a rate equal to the prime rate plus 2%, with a floor of 6.25% per annum. From May 2019 to May 2024, the Company is required to make principal and interest payments at a rate equal to the prime rate on May 2, 2019 plus 2%, with a floor of 6.25% per annum. Principal and interest payments shall continue from May 2024 through the end of the lease at a rate equal to the prime rate on May 2, 2024 plus 2%, with a floor of 6.25% per annum. "}]},{"name":"rpt:f-1282","factDimensions":{"xbrl:concept":"MRMD:AdditionalInterestPayableCurrentAndNoncurrent","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ConvertibleDebenturesMember"},"factValues":[{"value":"98000","decimals":0}]},{"name":"rpt:f-1283","factDimensions":{"xbrl:concept":"MRMD:AdditionalInterestPayableCurrentAndNoncurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:ConvertibleDebenturesMember"},"factValues":[{"value":"513000","decimals":0}]},{"name":"rpt:f-1284","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExaminationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Among other things, the TCJA reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new taxes on certain foreign sourced earnings."}]},{"name":"rpt:f-1285","factDimensions":{"xbrl:concept":"MRMD:OperatingLossCarryforwardExpirationDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"Expire at various dates beginning in 2031"}]},{"name":"rpt:f-1286","factDimensions":{"xbrl:concept":"us-gaap:DeferredTaxAssetsOperatingLossCarryforwards","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"11559576","decimals":0}]},{"name":"rpt:f-1287","factDimensions":{"xbrl:concept":"us-gaap:DeferredTaxAssetsOperatingLossCarryforwards","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"26291878","decimals":0}]},{"name":"rpt:f-1288","factDimensions":{"xbrl:concept":"us-gaap:OperatingLossCarryforwards","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"11600000","decimals":0}]},{"name":"rpt:f-1289","factDimensions":{"xbrl:concept":"us-gaap:OperatingLossCarryforwards","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"26300000","decimals":0}]},{"name":"rpt:f-1290","factDimensions":{"xbrl:concept":"MRMD:AgreementTermDescription","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"An employment agreement which commenced in 2012 with Thomas Kidrin, the former CEO of the Company, that provided Mr. Kidrin with salary, car allowances, stock options, life insurance, and other employee benefits, was terminated by the Company in 2017. "}]},{"name":"rpt:f-1291","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"126044","decimals":0}]},{"name":"rpt:f-1292","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"},"factValues":[{"value":"74160","decimals":0}]},{"name":"rpt:f-1293","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"74160","decimals":0}]},{"name":"rpt:f-1294","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"173","decimals":0}]},{"name":"rpt:f-1295","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"}},{"name":"rpt:f-1296","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"125871","decimals":0}]},{"name":"rpt:f-1297","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:RetainedEarningsMember"}},{"name":"rpt:f-1298","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:NoncontrollingInterestMember"}},{"name":"rpt:f-1299","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligationsShares","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"},"factValues":[{"value":"18000"}]},{"name":"rpt:f-1300","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligationsShares","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"172663"}]},{"name":"rpt:f-1301","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"391932","decimals":0}]},{"name":"rpt:f-1302","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"1815219","decimals":0}]},{"name":"rpt:f-1303","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1815219","decimals":0}]},{"name":"rpt:f-1304","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"}},{"name":"rpt:f-1305","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"}},{"name":"rpt:f-1306","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"391932","decimals":0}]},{"name":"rpt:f-1307","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:RetainedEarningsMember"}},{"name":"rpt:f-1308","factDimensions":{"xbrl:concept":"MRMD:AdjustmentsToAdditionalPaidInCapitalAmortizationOfOptionAndWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:NoncontrollingInterestMember"}},{"name":"rpt:f-1309","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestmentsShares","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"500000"}]},{"name":"rpt:f-1310","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1590000","decimals":0}]},{"name":"rpt:f-1311","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"915006","decimals":0}]},{"name":"rpt:f-1312","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"500","decimals":0}]},{"name":"rpt:f-1313","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"}},{"name":"rpt:f-1314","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"1589500","decimals":0}]},{"name":"rpt:f-1315","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:RetainedEarningsMember"}},{"name":"rpt:f-1316","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:NoncontrollingInterestMember"}},{"name":"rpt:f-1317","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodGrantedShares","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"108820"}]},{"name":"rpt:f-1318","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodGrantedShares","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"},"factValues":[{"value":"32726"}]},{"name":"rpt:f-1319","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodStockGranted","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"223148","decimals":0}]},{"name":"rpt:f-1320","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodStockGranted","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:CommonStockMember"},"factValues":[{"value":"109","decimals":0}]},{"name":"rpt:f-1321","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodStockGranted","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"MRMD:CommonStockSubscribedButNotIssuedMember"},"factValues":[{"value":"29438","decimals":0}]},{"name":"rpt:f-1322","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodStockGranted","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"193601","decimals":0}]},{"name":"rpt:f-1323","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodStockGranted","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:RetainedEarningsMember"}},{"name":"rpt:f-1324","factDimensions":{"xbrl:concept":"MRMD:StockIssuedDuringPeriodStockGranted","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:StatementEquityComponentsAxis":"us-gaap:NoncontrollingInterestMember"}},{"name":"rpt:f-1325","factDimensions":{"xbrl:concept":"us-gaap:Depreciation","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"999106","decimals":0}]},{"name":"rpt:f-1326","factDimensions":{"xbrl:concept":"us-gaap:Depreciation","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"657854","decimals":0}]},{"name":"rpt:f-1327","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfBeneficialConversionFeature","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5242483","decimals":0}]},{"name":"rpt:f-1328","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfBeneficialConversionFeature","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1522107","decimals":0}]},{"name":"rpt:f-1329","factDimensions":{"xbrl:concept":"us-gaap:GoodwillImpairmentLoss","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2662669","decimals":0}]},{"name":"rpt:f-1330","factDimensions":{"xbrl:concept":"us-gaap:GoodwillImpairmentLoss","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1331785","decimals":0}]},{"name":"rpt:f-1331","factDimensions":{"xbrl:concept":"us-gaap:ProvisionForDoubtfulAccounts","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"44539820","decimals":0}]},{"name":"rpt:f-1332","factDimensions":{"xbrl:concept":"us-gaap:ProvisionForDoubtfulAccounts","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"150000","decimals":0}]},{"name":"rpt:f-1333","factDimensions":{"xbrl:concept":"us-gaap:ProvisionForDoubtfulAccounts","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:GenCannaGlobalIncMember"},"factValues":[{"value":"11200000","decimals":0}]},{"name":"rpt:f-1334","factDimensions":{"xbrl:concept":"us-gaap:ProvisionForDoubtfulAccounts","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:HarvestFoundationLLCMember"},"factValues":[{"value":"2200000","decimals":0}]},{"name":"rpt:f-1335","factDimensions":{"xbrl:concept":"us-gaap:ProvisionForDoubtfulAccounts","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:MeditaurusLLCMember"},"factValues":[{"value":"1600000","decimals":0}]},{"name":"rpt:f-1336","factDimensions":{"xbrl:concept":"us-gaap:ProvisionForDoubtfulAccounts","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:KindTherapeuticsUSALLCMember"},"factValues":[{"value":"1500000","decimals":0}]},{"name":"rpt:f-1337","factDimensions":{"xbrl:concept":"MRMD:LossOnPreferredStockConversions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1338","factDimensions":{"xbrl:concept":"MRMD:LossOnPreferredStockConversions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"34044","decimals":0}]},{"name":"rpt:f-1339","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInAccountsReceivable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"37701009","decimals":0}]},{"name":"rpt:f-1340","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInAccountsReceivable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4073482","decimals":0}]},{"name":"rpt:f-1341","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherReceivables","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-299559","decimals":0}]},{"name":"rpt:f-1342","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherReceivables","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1485595","decimals":0}]},{"name":"rpt:f-1343","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-1355746","decimals":0}]},{"name":"rpt:f-1344","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseDueFromOfficersAndStockholders","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3387906","decimals":0}]},{"name":"rpt:f-1345","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherCurrentAssets","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"63815","decimals":0}]},{"name":"rpt:f-1346","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherCurrentAssets","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-156547","decimals":0}]},{"name":"rpt:f-1347","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherOperatingAssets","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"92981","decimals":0}]},{"name":"rpt:f-1348","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherOperatingAssets","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-163462","decimals":0}]},{"name":"rpt:f-1349","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInAccountsPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"632471","decimals":0}]},{"name":"rpt:f-1350","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInAccountsPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3614087","decimals":0}]},{"name":"rpt:f-1351","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInAccruedLiabilities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3436024","decimals":0}]},{"name":"rpt:f-1352","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInAccruedLiabilities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"183032","decimals":0}]},{"name":"rpt:f-1353","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInDeferredLiabilities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-105901","decimals":0}]},{"name":"rpt:f-1354","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInDeferredLiabilities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"105901","decimals":0}]},{"name":"rpt:f-1355","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherOperatingLiabilities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-238000","decimals":0}]},{"name":"rpt:f-1356","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherOperatingLiabilities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"98187","decimals":0}]},{"name":"rpt:f-1357","factDimensions":{"xbrl:concept":"us-gaap:NetCashProvidedByUsedInOperatingActivities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-24138317","decimals":0}]},{"name":"rpt:f-1358","factDimensions":{"xbrl:concept":"us-gaap:NetCashProvidedByUsedInOperatingActivities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-2907857","decimals":0}]},{"name":"rpt:f-1359","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"9668521","decimals":0}]},{"name":"rpt:f-1360","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquirePropertyPlantAndEquipment","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"8924311","decimals":0}]},{"name":"rpt:f-1361","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1362","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireInvestments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"30000000","decimals":0}]},{"name":"rpt:f-1363","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireNotesReceivable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2680000","decimals":0}]},{"name":"rpt:f-1364","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireNotesReceivable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"550000","decimals":0}]},{"name":"rpt:f-1365","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromCollectionOfNotesReceivable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1366","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromCollectionOfNotesReceivable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"45553","decimals":0}]},{"name":"rpt:f-1367","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1368","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"145382","decimals":0}]},{"name":"rpt:f-1369","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"119781","decimals":0}]},{"name":"rpt:f-1370","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"15000","decimals":0}]},{"name":"rpt:f-1371","factDimensions":{"xbrl:concept":"us-gaap:NetCashProvidedByUsedInInvestingActivities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-12537389","decimals":0}]},{"name":"rpt:f-1372","factDimensions":{"xbrl:concept":"us-gaap:NetCashProvidedByUsedInInvestingActivities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-40069998","decimals":0}]},{"name":"rpt:f-1373","factDimensions":{"xbrl:concept":"MRMD:ProceedsFromIssuanceOfCommonStockSubscriptions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1374","factDimensions":{"xbrl:concept":"MRMD:ProceedsFromIssuanceOfCommonStockSubscriptions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"55620","decimals":0}]},{"name":"rpt:f-1375","factDimensions":{"xbrl:concept":"MRMD:ProceedsFromIssuanceOfInterestInSubsidiary","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1376","factDimensions":{"xbrl:concept":"MRMD:ProceedsFromIssuanceOfInterestInSubsidiary","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1377","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfDebt","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"9600000","decimals":0}]},{"name":"rpt:f-1378","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfDebt","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"10007094","decimals":0}]},{"name":"rpt:f-1379","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfSecuredDebt","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"200081","decimals":0}]},{"name":"rpt:f-1380","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfSecuredDebt","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"114141","decimals":0}]},{"name":"rpt:f-1381","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromStockOptionsExercised","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"97500","decimals":0}]},{"name":"rpt:f-1382","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromStockOptionsExercised","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"39000","decimals":0}]},{"name":"rpt:f-1383","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromWarrantExercises","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"612441","decimals":0}]},{"name":"rpt:f-1384","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromWarrantExercises","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"385395","decimals":0}]},{"name":"rpt:f-1385","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromRepaymentsOfShortTermDebt","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1178402","decimals":0}]},{"name":"rpt:f-1386","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromRepaymentsOfShortTermDebt","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-217451","decimals":0}]},{"name":"rpt:f-1387","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfCapitalDistribution","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"474229","decimals":0}]},{"name":"rpt:f-1388","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfCapitalDistribution","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"690917","decimals":0}]},{"name":"rpt:f-1389","factDimensions":{"xbrl:concept":"us-gaap:NetCashProvidedByUsedInFinancingActivities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"33310079","decimals":0}]},{"name":"rpt:f-1390","factDimensions":{"xbrl:concept":"us-gaap:NetCashProvidedByUsedInFinancingActivities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"45791939","decimals":0}]},{"name":"rpt:f-1391","factDimensions":{"xbrl:concept":"us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-3365627","decimals":0}]},{"name":"rpt:f-1392","factDimensions":{"xbrl:concept":"us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2814084","decimals":0}]},{"name":"rpt:f-1393","factDimensions":{"xbrl:concept":"us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4104315","decimals":0}]},{"name":"rpt:f-1394","factDimensions":{"xbrl:concept":"us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"738688","decimals":0}]},{"name":"rpt:f-1395","factDimensions":{"xbrl:concept":"us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations","xbrl:period":"2018-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1290231","decimals":0}]},{"name":"rpt:f-1396","factDimensions":{"xbrl:concept":"us-gaap:InterestPaidNet","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1294810","decimals":0}]},{"name":"rpt:f-1397","factDimensions":{"xbrl:concept":"us-gaap:InterestPaidNet","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1286007","decimals":0}]},{"name":"rpt:f-1398","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxesPaidNet","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1399","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxesPaidNet","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"12584","decimals":0}]},{"name":"rpt:f-1400","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfIntangibleAssets","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"197500","decimals":0}]},{"name":"rpt:f-1401","factDimensions":{"xbrl:concept":"us-gaap:AmortizationOfIntangibleAssets","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1402","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfStockGrants","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"223148","decimals":0}]},{"name":"rpt:f-1403","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfStockGrants","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1404","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfOptionGrants","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1457684","decimals":0}]},{"name":"rpt:f-1405","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfOptionGrants","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3945398","decimals":0}]},{"name":"rpt:f-1406","factDimensions":{"xbrl:concept":"MRMD:EquityIssuedToSettleObligations","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5180","decimals":0}]},{"name":"rpt:f-1407","factDimensions":{"xbrl:concept":"MRMD:EquityIssuedToSettleObligations","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1024117","decimals":0}]},{"name":"rpt:f-1408","factDimensions":{"xbrl:concept":"MRMD:ChangeInFairValueOfInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"640856","decimals":0}]},{"name":"rpt:f-1409","factDimensions":{"xbrl:concept":"MRMD:ChangeInFairValueOfInvestments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1410","factDimensions":{"xbrl:concept":"MRMD:IncreaseDecreaseInOperatingLeasePayments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"529434","decimals":0}]},{"name":"rpt:f-1411","factDimensions":{"xbrl:concept":"MRMD:IncreaseDecreaseInOperatingLeasePayments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1412","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherCurrentLiabilities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"858176","decimals":0}]},{"name":"rpt:f-1413","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInOtherCurrentLiabilities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1414","factDimensions":{"xbrl:concept":"MRMD:IncreaseDecreaseInUnearnedRevenue","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1415","factDimensions":{"xbrl:concept":"MRMD:IncreaseDecreaseInUnearnedRevenue","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1416","factDimensions":{"xbrl:concept":"MRMD:ConversionOfDebenturesReceivable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"30000000","decimals":0}]},{"name":"rpt:f-1417","factDimensions":{"xbrl:concept":"MRMD:ConversionOfDebenturesReceivable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1418","factDimensions":{"xbrl:concept":"MRMD:ConversionsOfDebenturesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"8975920","decimals":0}]},{"name":"rpt:f-1419","factDimensions":{"xbrl:concept":"MRMD:ConversionsOfDebenturesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1435506","decimals":0}]},{"name":"rpt:f-1420","factDimensions":{"xbrl:concept":"MRMD:BeneficialConversionFeatureOnDebenturesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4235469","decimals":0}]},{"name":"rpt:f-1421","factDimensions":{"xbrl:concept":"MRMD:BeneficialConversionFeatureOnDebenturesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5569908","decimals":0}]},{"name":"rpt:f-1422","factDimensions":{"xbrl:concept":"MRMD:DiscountOnDebenturesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1148056","decimals":0}]},{"name":"rpt:f-1423","factDimensions":{"xbrl:concept":"MRMD:DiscountOnDebenturesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1057833","decimals":0}]},{"name":"rpt:f-1424","factDimensions":{"xbrl:concept":"MRMD:DiscountOnPromissoryNotes","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"605780","decimals":0}]},{"name":"rpt:f-1425","factDimensions":{"xbrl:concept":"MRMD:DiscountOnPromissoryNotes","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1709595","decimals":0}]},{"name":"rpt:f-1426","factDimensions":{"xbrl:concept":"MRMD:IssuanceOfCommonStockAssociatedWithSubscriptions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"169123","decimals":0}]},{"name":"rpt:f-1427","factDimensions":{"xbrl:concept":"MRMD:IssuanceOfCommonStockAssociatedWithSubscriptions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"370000","decimals":0}]},{"name":"rpt:f-1428","factDimensions":{"xbrl:concept":"us-gaap:StockIssued1","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1047100","decimals":0}]},{"name":"rpt:f-1429","factDimensions":{"xbrl:concept":"us-gaap:StockIssued1","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7589788","decimals":0}]},{"name":"rpt:f-1430","factDimensions":{"xbrl:concept":"MRMD:OperatingLeaseRightofuseAssetsAndLiabilities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7251837","decimals":0}]},{"name":"rpt:f-1431","factDimensions":{"xbrl:concept":"MRMD:OperatingLeaseRightofuseAssetsAndLiabilities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1432","factDimensions":{"xbrl:concept":"MRMD:FinanceLeaseRightofuseAssetsAndLiabilities","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"172605","decimals":0}]},{"name":"rpt:f-1433","factDimensions":{"xbrl:concept":"MRMD:FinanceLeaseRightofuseAssetsAndLiabilities","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1434","factDimensions":{"xbrl:concept":"MRMD:PaymentsToBusinessAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1000","decimals":0}]},{"name":"rpt:f-1435","factDimensions":{"xbrl:concept":"MRMD:PaymentsToBusinessAcquisitions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1436","factDimensions":{"xbrl:concept":"MRMD:ConversionOfNotesReceivableToInvestment","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"257687","decimals":0}]},{"name":"rpt:f-1437","factDimensions":{"xbrl:concept":"MRMD:ConversionOfNotesReceivableToInvestment","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1438","factDimensions":{"xbrl:concept":"MRMD:ConversionOfAdvancesToNotesReceivable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"855913","decimals":0}]},{"name":"rpt:f-1439","factDimensions":{"xbrl:concept":"MRMD:ConversionOfAdvancesToNotesReceivable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1440","factDimensions":{"xbrl:concept":"MRMD:ExerciseOfOptionsViaReductionOfObligation","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"350000","decimals":0}]},{"name":"rpt:f-1441","factDimensions":{"xbrl:concept":"MRMD:ExerciseOfOptionsViaReductionOfObligation","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1442","factDimensions":{"xbrl:concept":"MRMD:CashlessExerciseOfStockOptions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1762","decimals":0}]},{"name":"rpt:f-1443","factDimensions":{"xbrl:concept":"MRMD:CashlessExerciseOfStockOptions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1444","factDimensions":{"xbrl:concept":"MRMD:ReclassOfAccruedInterestFromNotesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"127450","decimals":0}]},{"name":"rpt:f-1445","factDimensions":{"xbrl:concept":"MRMD:ReclassOfAccruedInterestFromNotesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1446","factDimensions":{"xbrl:concept":"MRMD:ReclassOfAccruedInterestFromDebenturesPayable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"62748","decimals":0}]},{"name":"rpt:f-1447","factDimensions":{"xbrl:concept":"MRMD:ReclassOfAccruedInterestFromDebenturesPayable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1448","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"9603","decimals":0}]},{"name":"rpt:f-1449","factDimensions":{"xbrl:concept":"MRMD:OutstandingReceivableBalance","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:CreditFacilityAxis":"MRMD:GenCannaBankruptcyFilingMember"},"factValues":[{"value":"29000000","decimals":0}]},{"name":"rpt:f-1450","factDimensions":{"xbrl:concept":"MRMD:UnearnedRevenue","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:CreditFacilityAxis":"MRMD:GenCannaBankruptcyFilingMember"},"factValues":[{"value":"4200000","decimals":0}]},{"name":"rpt:f-1451","factDimensions":{"xbrl:concept":"us-gaap:LoansPayable","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","srt:TitleOfIndividualAxis":"MRMD:TwoInstitutionalShareholdersMember"},"factValues":[{"value":"4417500","decimals":0}]},{"name":"rpt:f-1452","factDimensions":{"xbrl:concept":"us-gaap:LoansPayable","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","srt:TitleOfIndividualAxis":"MRMD:AccreditedInvestorMember"},"factValues":[{"value":"1200000","decimals":0}]},{"name":"rpt:f-1453","factDimensions":{"xbrl:concept":"MRMD:PaymentsToAcquireLicenses","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"308815","decimals":0}]},{"name":"rpt:f-1454","factDimensions":{"xbrl:concept":"MRMD:PaymentsToAcquireLicenses","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1455","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireOtherInvestments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1456","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireOtherInvestments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"800000","decimals":0}]},{"name":"rpt:f-1457","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfStandaloneWarrantIssuances","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"391932","decimals":0}]},{"name":"rpt:f-1458","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfStandaloneWarrantIssuances","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1815219","decimals":0}]},{"name":"rpt:f-1459","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfWarrantsAttachedToDebt","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2455964","decimals":0}]},{"name":"rpt:f-1460","factDimensions":{"xbrl:concept":"MRMD:AmortizationOfWarrantsAttachedToDebt","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1171330","decimals":0}]},{"name":"rpt:f-1461","factDimensions":{"xbrl:concept":"MRMD:ConversionsOfPromissoryNotes","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1462","factDimensions":{"xbrl:concept":"MRMD:ConversionsOfPromissoryNotes","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1075000","decimals":0}]},{"name":"rpt:f-1463","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligation","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"120864","decimals":0}]},{"name":"rpt:f-1464","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedToSettleObligation","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"18540","decimals":0}]},{"name":"rpt:f-1465","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForAcquisitions","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2470840","decimals":0}]},{"name":"rpt:f-1466","factDimensions":{"xbrl:concept":"MRMD:CommonStockIssuedForAcquisitions","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"266682","decimals":0}]},{"name":"rpt:f-1467","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeasePrincipalPayments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"13954","decimals":0}]},{"name":"rpt:f-1468","factDimensions":{"xbrl:concept":"us-gaap:FinanceLeasePrincipalPayments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1469","factDimensions":{"xbrl:concept":"us-gaap:DeferredFinanceCostsNet","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"17000000","decimals":0}]},{"name":"rpt:f-1470","factDimensions":{"xbrl:concept":"MRMD:WorkingCapitalDeficit","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-31000000","decimals":0}]},{"name":"rpt:f-1471","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromConvertibleDebt","xbrl:period":"2020-01-01T00:00:00/2020-03-29T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","srt:TitleOfIndividualAxis":"MRMD:TwoInstitutionalStockholdersMember"},"factValues":[{"value":"4400000","decimals":0}]},{"name":"rpt:f-1472","factDimensions":{"xbrl:concept":"MRMD:AddionallyIssuanceOfConvertibleDebt","xbrl:period":"2020-01-01T00:00:00/2020-03-29T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","srt:TitleOfIndividualAxis":"MRMD:TwoInstitutionalStockholdersMember"},"factValues":[{"value":"935000","decimals":0}]},{"name":"rpt:f-1473","factDimensions":{"xbrl:concept":"us-gaap:NotesPayable","xbrl:period":"2020-03-29T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","srt:TitleOfIndividualAxis":"MRMD:TwoInstitutionalStockholdersMember","us-gaap:AwardDateAxis":"MRMD:ExtendedMaturityDatesMember"},"factValues":[{"value":"194000000","decimals":0}]},{"name":"rpt:f-1474","factDimensions":{"xbrl:concept":"us-gaap:NotesPayable","xbrl:period":"2020-03-29T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:TypeOfArrangementAxis":"MRMD:ExchangeAgreementMember","srt:TitleOfIndividualAxis":"MRMD:TwoInstitutionalStockholdersMember","us-gaap:AwardDateAxis":"MRMD:ExtendedAnotherMaturityDatesMember"},"factValues":[{"value":"3000000","decimals":0}]},{"name":"rpt:f-1475","factDimensions":{"xbrl:concept":"us-gaap:NotesPayable","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:DebtInstrumentAxis":"MRMD:PromissoryNotesMember"},"factValues":[{"value":"9400000","decimals":0}]},{"name":"rpt:f-1476","factDimensions":{"xbrl:concept":"us-gaap:ShortTermBorrowings","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","srt:TitleOfIndividualAxis":"MRMD:AccreditedInvestorMember"},"factValues":[{"value":"120000000","decimals":0}]},{"name":"rpt:f-1477","factDimensions":{"xbrl:concept":"MRMD:TransactionCosts","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"17000000","decimals":0}]},{"name":"rpt:f-1478","factDimensions":{"xbrl:concept":"us-gaap:DueFromOfficersOrStockholders","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3860377","decimals":0}]},{"name":"rpt:f-1479","factDimensions":{"xbrl:concept":"us-gaap:DueFromOfficersOrStockholders","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1480","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentFeeAmount","xbrl:period":"2019-04-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"MRMD:SecuredPromissoryNotesMember","us-gaap:TypeOfArrangementAxis":"MRMD:SixMillionNoteMember"},"factValues":[{"value":"900000","decimals":0}]},{"name":"rpt:f-1481","factDimensions":{"xbrl:concept":"us-gaap:AccountsReceivableRelatedPartiesCurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:HarvestFoundationLLCMember"},"factValues":[{"value":"239000","decimals":0}]},{"name":"rpt:f-1482","factDimensions":{"xbrl:concept":"us-gaap:AccountsReceivableRelatedPartiesCurrent","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:GenCannaGlobalIncMember"},"factValues":[{"value":"9700000","decimals":0}]},{"name":"rpt:f-1483","factDimensions":{"xbrl:concept":"us-gaap:DueFromRelatedParties","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:HarvestFoundationLLCMember"},"factValues":[{"value":"1900000","decimals":0}]},{"name":"rpt:f-1484","factDimensions":{"xbrl:concept":"us-gaap:DueFromRelatedParties","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:RelatedPartyTransactionsByRelatedPartyAxis":"MRMD:GenCannaGlobalIncMember"},"factValues":[{"value":"1500000","decimals":0}]},{"name":"rpt:f-1485","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentAnnualPrincipalPayment","xbrl:period":"2020-03-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"100000","decimals":0}]},{"name":"rpt:f-1486","factDimensions":{"xbrl:concept":"MRMD:GoingConcernPolicyTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rGoing Concern
\r\r\r\r
In connection with\rthe preparation of its financial statements for the year ended December 31, 2019, the Company’s management evaluated the\rCompany’s ability to continue as a going concern in accordance with the ASU 2014-15, Presentation of Financial Statements–Going\rConcern (Subtopic 205-40), which requires an assessment of relevant conditions or events, considered in the aggregate, that\rare known or reasonably knowable by management on the issuance dates of the financial statements which indicated the probable likelihood\rthat the Company will be unable to meet its obligations as they become due within one year after the issuance date of the financial\rstatements.
\r\r\r\r
As part of its evaluation,\rmanagement assessed known events, trends, commitments, and uncertainties, which at the time included the status of its consolidation\rplan, the GenCanna bankruptcy, the amount of capital raised by the Company during the past two calendar years, the recent level\rof cannabis industry investment activity, the stock price movement of public cannabis companies, the actions and/or results of\rcertain bellwether cannabis companies, the measure of cannabis investor confidence, and the changes to state laws with respect\rto adult-use recreational and medical cannabis use.
\r\r\r\r
At December 31, 2019,\rthe Company had negative working capital of approximately $31.0 million, and for the year then ended, incurred negative cash flow\rfrom operations of approximately $24.8 million. For further discussion on these metrics and the Company’s liquidity and capital\rresources, please refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations\rof the Company’s Form 10-K for the fiscal year ended December 31, 2019.
\r\r\r\r
In early 2020, the\rCompany raised approximately $4.4 million as part of an exchange agreement with two institutional stockholders, and $935,000 from\rthe issuance of convertible debentures. Additionally, the Company has extended the maturity dates of approximately $19.4 million\rof promissory notes, and is in the process of finalizing the documentation to extend another $3.0 million of promissory notes.\rThese transactions are further disclosed in Note 21 – Subsequent Events.
\r\r\r\r
Moreover, as of the\rfiling date of this report, the Company has obtained a commitment from an accredited investor for a $12.0 million loan, secured\rby the Company’s real estate, at a rate of 10% per annum with a one-year term, and an option to extend for an additional\ryear. This transactions is expected to close upon the lender’s completion of its due diligence, which is in its final stages,\ralthough there is no assurance that it will close in the foreseeable future or at all. Also as of the filing date of this report,\rthe Company is in discussions with financial institutions to consider generating liquidity from the Company’s unencumbered\rreal property through mortgage-backed financings, the refinancing of certain outstanding mortgage loans, the sales-leaseback of\rcertain properties, and/or a combination thereof. Based on preliminary discussions, such financings could potentially generate\rupwards of $17.0 million from such transactions, however the Company has not signed any commitments it has received to date and\rthere are no assurances that it will.
\r\r\r\r
In addition to the\raforementioned financing transactions that have been consummated and that are in progress, the operations of the Company’s\rrecently acquired entities in Illinois and Massachusetts are expected to generate considerable liquidity and working capital for\rthe Company. The state of Illinois legalized adult-use cannabis in January 2020, which was added to the Company’s two existing\rcannabis licenses, thereby increasing the Company’s operations in this state to service both medical and recreational cannabis\rconsumers. In Massachusetts, the cultivation and production facility acquired by the Company will soon complete its first harvest\rand commence full scale selling operations in this state’s robust cannabis market.
\r\r\r\r
The Company believes that it will close incremental\rdebt financings in the foreseeable future, and it projects that its operating profit will organically support its day-to-day operations\rby the latter part of 2020. However, since there are no assurances that another financing transaction will be consummated, or\rthat the Company will meet or exceed its projections in light of the unknown current state of the global economy, there are similarly\rno assurances that the Company will be able to meet all of its obligations as they become due within one year after the issuance\rdate of these financial statements.
"}]},{"name":"rpt:f-1487","factDimensions":{"xbrl:concept":"us-gaap:BusinessAcquisitionProFormaInformationTextBlock","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767"},"factValues":[{"value":"\r\rConsolidated unaudited pro forma results of\roperations for the Company are presented below assuming this 2019 acquisition had occurred at January 1, 2018, the beginning of\rthe reporting period of these financial statements.
\r\r\r\r
| \r | \r | Year Ended December 31, | \r||||||
| \r | \r | 2019 | \r\r | \r | 2018 | \r|||
| Total revenues | \r\r | $ | \r48,444,052 | \r\r | \r | $ | \r14,417,923 | \r|
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Net income (loss) | \r\r | $ | \r(81,705,403 | \r) | \r\r | $ | \r(13,514,832 | \r) |
| \r | \r | \r | \r | \r | \r | \r | \r | |
| Net income (loss) per share | \r\r | $ | \r(0.39 | \r) | \r\r | $ | \r(0.07 | \r) |
NOTE\r17 – BAD DEBTS
\r\r\r\r
For the\ryears ended December 31, 2019 and 2018, the Company recorded bad debt expense of approximately $44.5 million and $150,000, respectively.\r
\r\r\r\r
The amount\rrecorded in 2019 included (i) the write off of the accounts receivable balance due from GenCanna of approximately $29.0\rmillion following GenCanna’s Chapter 11 filing, and (ii) the recording of bad debt reserves against the accounts receivable\rand working capital balances due from Kind of approximately $9.7 million and approximately $1.5 million, respectively, in light\rof the current litigation between the Company and Kind.
\r\r\r\r
Additionally, 2019 bad debt expense included\rthe following amounts that were based on the Company’s expectation of the negative impact of the coronavirus pandemic on\rthe operations of certain of the Company’s debtors, and therefore the collectibility thereof: (i) the recording of bad debt\rreserves against the accounts receivable and working capital balances due from Harvest of approximately $239,000 and $1.9 million,\rrespectively, and (ii) the write off of notes receivable and accrued interest balances due from Atalo of approximately $1.0 million\rand two other entities of approximately $650,000 in the aggregate.
"}]},{"name":"rpt:f-1509","factDimensions":{"xbrl:concept":"MRMD:ReserveAgainstWorkingCapitalAdvances","xbrl:period":"2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1510","factDimensions":{"xbrl:concept":"MRMD:ReserveAgainstWorkingCapitalAdvances","xbrl:period":"2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-3414462","decimals":0}]},{"name":"rpt:f-1511","factDimensions":{"xbrl:concept":"MRMD:PaymentsForProceedsFromSaleOfNotesReceivable","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-211989","decimals":0}]},{"name":"rpt:f-1512","factDimensions":{"xbrl:concept":"MRMD:PaymentsForProceedsFromSaleOfNotesReceivable","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"15116","decimals":0}]},{"name":"rpt:f-1513","factDimensions":{"xbrl:concept":"us-gaap:GainLossOnDispositionOfAssets1","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1514","factDimensions":{"xbrl:concept":"us-gaap:GainLossOnDispositionOfAssets1","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2858","decimals":0}]},{"name":"rpt:f-1515","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInInventories","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"495394","decimals":0}]},{"name":"rpt:f-1516","factDimensions":{"xbrl:concept":"us-gaap:IncreaseDecreaseInInventories","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}},{"name":"rpt:f-1517","factDimensions":{"xbrl:concept":"MRMD:IncreaseDereaseInFinanceLeaseInterestPayments","xbrl:period":"2019-01-01T00:00:00/2020-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"6414","decimals":0}]},{"name":"rpt:f-1518","factDimensions":{"xbrl:concept":"MRMD:IncreaseDereaseInFinanceLeaseInterestPayments","xbrl:period":"2018-01-01T00:00:00/2019-01-01T00:00:00","xbrl:entity":"cik:0001522767","xbrl:unit":"iso4217:USD"}}]}}